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Abstract

The resin glycoside, ipomoeassin F has been shown to be extremely potent against multiple
cancer lines (IC50 = 4.2-36 nM). However, the mechanism of action of this potent and complex
natural product is still not fully understood. The α,β-unsaturated esters of the glucosyl moiety
have been shown to be vital for the overall cytotoxicity of ipomoeassin F. Nevertheless, the
importance of the tigloyl ester of the glucosyl moiety is still largely unknown. This work aimed
to study the pharmacophore importance of the tigloyl ester by creating, an efficient, scalable, and
flexible synthesis route for various analogs. The 18-linear step synthesis utilized multiple regioselective and chemo-selective reactions, while not affecting the highly functionalized (1→2)-βdisaccharide moiety. The synthesis route modified the C-3 glucosyl position in the penultimate
step, making medicinal chemistry studies of the tigloyl moiety possible.

The late-stage

conformationally-controlled highly regio-selective esterification allowed for the completion of
ipomoeassin F and other tigloyl modified analogs. The in-house cytotoxicity data conveyed that
large aromatic modifications greatly reduced the cytotoxicity against multiple cancer cell lines.
The ipomoeassin F was submitted for NCI-60 cell line screening that showed good sensitivity
against breast, renal, and melanoma cell lines (GI50 = ⁓30 nM). To determine the importance of
α,β-methyl groups of tigloyl moiety, acrylic modifications were envisioned but were difficult to
obtain using the developed synthesis route. Therefore, we believe the α,β-unsaturated double bond
should be tri-substituted to effectively study the tigloyl moiety. This work advanced the scientific
knowledge of an underexplored natural product with an unknown mechanism of action and
unreached therapeutic potential.
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CHAPTER 1. BACKGROUND AND INTRODUCTION

1.1. Natural Products

Over the past century, the synthesis of complex natural products has been a challenging
yet rewarding task for organic chemists around the world. This field of study, called total
synthesis, has bettered the lives of billions of people around the world and made modern life
possible. From pharmaceuticals1 to pesticides2, fragrance 3-5 to food flavorings3, 6, 7, countless lives
have been positively affected by the synthesis of complex natural products. A natural product can
be defined as any chemical compound or substance isolated from a living thing. Historically, the
major factors inhibiting the developed of natural products has been structural complexity and
limited quantities. Often a natural product is difficult to isolated in pure form, produced in trace
amounts (<10 mg), or the biomass is limited (<0.01% by weight). So, total syntheses have been
developed to prepare larger quantities of a natural product for further studies (mg to gram scale).
There are many different classes of natural products from numerous sources like plants,8 bacteria,8,
9

and even microorganisms.10, 11 However the total syntheses of natural products are still far from

routine. In the following chapters we will look at a class of natural product called resin glycosides,
specially ipomoeassins, isolated from the morning glory flower.

1.2. Cancer
In 2015, the Worldwide Health Organization (WHO) reported cancer was responsible for
1 in 6 deaths worldwide and 8.8 million people have died to this currently, incurable disease. The
United States alone accounted for almost 1.7 million new cancer cases and over 600,000 cancer
deaths last year.12 Even though great advances have been made over the past few decades, such
as structure-based drug design,13-15 protein crystallography,16, 17 binding methods (surface plasmon

1

resonance, isothermal calorimetry, etc.), and the human genome project, cancer still remains a
seemingly never-ending battle.1, 18 The term “cancer” is said to go back to the Greek physician
Hippocrates (460-370 BC), who is considered by many as the “Father of Medicine.” He used the
Greek words carcinoma and carconis to explain the crab shaped tumors he observed on his
patients. Around 100 BC, the Roman physician Celsus translated the two Greek words to cancer,
from the Latin word for crab. Since this time, people have feared of the term cancer.19, 20

1.2.1. Natural Products and Cancer Research

Throughout history, cultures have turned to nature for their needs, and the treatment of
cancer is no different.21, 22 The WHO has estimated that between 65-70% of the world is reliant
on plant-derived medicines. These “traditional” or “crude” medicines can be very important in
underdeveloped countries, where modern health care options are not accessible. In 1983, Hartwell
reported over 3000 different plant species are used for the treatment of cancers.23 In 2000, more
than 350 plant species were added to Hartwell’s list. However, these numbers can be misleading
because the claims of efficacy generally apply to the treatment of a patient’s skin. So, many of
these treatments should be looked at with skepticism. That said, a few examples of plant-derived
anti-cancer agents have been directly or indirectly linked back to ethochemical uses.24 One
example of a direct relationship is the tree Podophyllum peltatum, odophylltoxin, and the clinically
anti-cancer agent etoposide. Commonly known as the Mayapple or the American mandrake, this
tree has a variety of medicinal uses, including the treatment of warts and skin cancers. These
traditional uses caused an investigation of the roots resulting in the isolation of podophyllotoxin,
the active agent.

Finally, a shortened synthesis was developed from the stereoisomers of

2

epipdophyllotoxin. Currently, etoposide is marketed clinically for the treatment of different skin
cancers.25-27

1.2.2. Problems with Drug Discovery and Cancer Research

Many factors have contributed to cancer becoming a major problem in modern society.
Some of the reasons range from the detection or treatment of the cancer,28 the social habits of the
patient, and the cost of treatment.29, 30 Researchers cannot control a patient’s social activities or
government funding, but scientists and physicians can identify better targets, prepare more
effective, less toxic drugs, and attempt to control the metastasis once the tumors have developed.
In this section some problems with drug discovery and cancer research will be examined in greater
detail.
The difficulty of finding “druggable” targets and target identification are problems in all
areas of drug discovery. In general, a “druggable” target is anything that can be modified or
inhibited by a drug (e.g. nucleic acid, peptide, or protein). Even with advances in the human
genome, the number of druggable targets remains very low.31, 32 In 2015, the FDA stated that only
a quarter of the newly approved drugs attack novel or previously un-druggable targets. Later the
same year, the FDA stated that ten target families accounted for more than three-fourths (78%) of
all FDA-approved new molecular entities (NME).9, 33-36 Research has shown potential target
classes like GPCRs, ion channels, and nuclear receptors remain largely unstudied. Kinhlberg et
al. stated that only 3000 out of the approximately 30000 genes in the human genome are related
to diseases. Less than half of these, 600-1500 genes, are considered targets for inhibition for
“traditional” small molecule drugs.37 So, there is a need and opportunity to increase the number
of therapeutic targets.31, 32 Many pharmaceutical companies only focus on druggable targets

3

because there is a higher chance for proof of concept (POC) and a greater percentage the NME
will proceed to phase 3 trials. One reason for the narrow focus is the large amount of literature
data on relatively few “druggable” targets. Chemical biologists and medical chemists have argued
and debated the terms “druggable” or “undruggable” target. Fortunately, there is not a single
answer for this difficult question. One clear conclusion is researchers in all areas of life sciences
(organic chemistry, chemical biology, etc.) must work together to expand the number “druggable”
targets for significant progress to be made against diseases such as cancer.

Although there is not a perfect target to inhibit a specific disease, including cancer, here
are a few rules that medicinal chemists need to consider (Table 1.1).38, 39 The most important
aspect is the availability of human data, whether it is basic research or preclinical data from tissue

Table 1.1. Some Characteristics of an “Ideal” Drug Target
1. Target is selectivity for the drug of interest (toxicity).
2. Can prove the target is being modified and the
pathophysiology of the disease is changing.
3. Modification of the target will not affect normal physiological
conditions or possible diseases.
4. Ability to forecast or predict possible side reactions from the
phenotype data (e. g. animal model or mutation databases)
5. The target is not evenly spread throughout the body.
6. Ability to obtain a 3-D structure conformational change during
the drug-target interaction.
7. Chemical Assays of the target are favorable for high
throughput screening.
8. Not many other drugs competing for the target (helps with
intellectual property situations and gives more freedom to
design drug).
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taken from an affected subject. Unwanted side effects will occur when any potential therapeutic
is introduced to a biological system, so being able to predict the unwanted side reactions is critical.
This can save the pharmaceutical company significant time and financial capital predicting side
effects that could happen in humans from a simpler model (mice or pig model, mutation databases,
etc.).38, 40 Similarly, the “undruggable” or “difficult-to-drug” targets have common characteristics.
The binding sites of these targets are generally devoid of functionality, either extremely lipophilic
or high polar, fluid, or flat.41, 42 Often, a lack of functionality refers to the limited opportunity for
hydrogen bonding. Interestingly, the inability to develop drugs with good oral bioavailability has
caused some potential targets to be abandoned and viewed as “undruggable.”37

Protein-protein interactions (PPI) offer an interesting opportunity to develop new
treatments for diseases like cancer. The human proteome is predicted to have between 100,000
and 1,000,000 PPI.17, 43 Even if only a small number of these PPI are found to be druggable for
diseases like cancer, it could be a great prospect for future chemotherapeutic agents. Another
interesting aspect in contemporary drug discovery is the often-naïve concept of “one drug-one
target.” Many clinical examples have been shown to exhibit polypharmacology by inhibiting
multiple targets.44, 45 This makes the number of potential targets almost limitless from the different
However, this “limitless space” for new

targets combination that could be utilized.

chemotherapeutic agents is met with a heightened cause for safety concerns.46, 47

1.2.3. Drug-Target Interaction and Validation

The other major obstacle in drug discovery, specifically cancer research, is target
validation.48, 49 It is very important for pharmaceutical companies to validate the drug-target
interaction before scaling-up a potential therapeutic agent. Many times target validation is aided
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by the development of a chemical probe molecule.50 The probe molecule is structurally similar to
the drug but has some key chemical and structural differences.48 Although the standards for a
chemical probe differ, the criteria for the probe should be more severe than the potential drug
because of the increased functionality (Table 1.2). This can sometimes lead to unwanted off-target
interactions. One key criteria in the chemical probe is the inactive chemical probe as a negative
control. The inactive probe is often an inactive enantiomer of the potential drug.48

The medicinal chemists Bunnage, Piatnitski, and Jones, from Pfizer, recently investigated
the failure of more than 40 drug programs and tried to determine the reasons for their inefficacy.51
This led them to coin the term “four pillars of cell-based target validation” (Figure 1.1). The first
pillar involves confirmation of cellular penetration and the validation of a chemical probe at the
active site of the target (Table 1.2). Pillar 1 confirms the on-target activity of the probe and makes
sure the response for the chemical probe is not due to off-target hits. Confirming the drug-target
interactions should be one of the first tests conducted, because false positives could lead to
misleading pharmacological (pillar 3) or phenotypic (pillar 4) results. Often, techniques like LC-

Figure 1.1. The four pillars of cell-based drug-target interaction and validation coined by
Pfizer.
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MS can be utilized to measure the in-cell concentrations of cell extractions. Sometimes, MS must
be combined with other techniques like sophisticated microscopic imaging or radiometric methods
because of changing local concentrations of specific subcellular compartments. Pillar 2 builds on
pillar 1 and involves selectivity studies and probe-engagement. When designing a chemical probe,
the chemist has to be thoughtful of the highly reactive functional groups.48 These groups can
potentially cause unwanted side-reactions, leading to misleading or even false conclusions. Pillar
2 is often found to be the most important, because it links pillar 1 (active site confirmation) to
pillars 3 (pharmacology) and 4 (phenotype). Unlike the studies to optimize the selectivity or
potency (pillar 1), the determination of a probe’s performance can be very challenging for in vivo
or live cell studies.

Table 1.2. Criteria for developing and
designing a functional chemical probe.
Similar activity to target molecule
Selective (>100 fold)
Potent in in biochemical assay (<100 nM)
Potent in cellular assay (<100 nM)
Aqueous solubility
Several active and chemical classes
Negative control (e.g. enantiomer)
Cell permeability (active/passive transport)
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Luckily, major developments have been made in the past decade with techniques like
activity-based protein profiling (ABPP) to determine the drug-target interaction. Pillar 3 involves
measuring the expression of pharmacology and creating assays to measure the pharmacological
effects of the chemical probe. Pillar 4 includes the development of assays to prove or disprove
phenotype perturbation in a human disease. The degree of “translatability” of these results from
patient to patient should always be considered. Lastly, the researchers should consider factors like
nonspecific cell death because this can lead to a waste of time and resources. The “four pillars of
cell-based target validation” can help with the target validation of a small molecule, but this is still
a risky endeavor.48 Scientific literature is full of examples of failed projects and un-bridled claims
of strong drug-target interactions.36, 38, 39 Medical chemists, chemical biologists, and biochemists
must work together to increase the number of “druggable” targets to make advancements in the
treatment of major diseases, such as cancer.

1.3. Organic Synthesis and Medical Chemistry to Advance Cancer Research

The problems with current anti-cancer chemotherapeutic agents range from their extremely
difficult syntheses,52 high cost,29,

53

and unwanted side-effects.36,

38, 39

Organic chemistry,

specifically medicinal chemistry tries to limit some of these problems by synthesizing biologically
active compounds.18

Organic chemists use diverse chemical transformations and cheap,

commercially available starting materials to construct a target molecule for a particular application.
An organic chemist may or may not know the application of the target molecule he/she is trying
to synthesize, often the challenge of constructing the molecule being the driving force for the
research. A medicinal chemist often already knows the application of his/her target molecule,
whether to inhibit a disease or upregulate a biological process.
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The importance of natural products in drug discovery and cancer research has been stated
by numerous reviewers.1, 24, 54, 55 In 2016, Newman and Cragg published a review on the NCEs
from 1981 to 2014.1 They stated that almost 60% of the 1500 NCEs were natural products, natural
products derivatives, or mimicked natural products. For anti-cancer drugs, 83% of the approved
chemotherapeutic agents (113 of 136) were natural products or directly derivative.56 Still, some
pharmaceutical companies have moved away from natural products, selling off the rights or
closing entire natural product departments. The reasons for the shift away from natural products
have been debated. Some of the commonly examined reasons include an inability to reproduce
spectroscopic evidence of the natural product during the synthesis, problems scaling-up or
producing enough NCEs for commercialization, and difficult to impossible chemical
transformations.52, 57, 58 Despite the problems, most major pharmaceutical companies believe
natural products and their derivatives will continue to play a major role in drug discovery and
cancer chemotherapy.

The reason for the high percentage of anti-cancer agents being based on natural products
has been debated (Table 1.3).56 One accepted reason is that the complex chemical structure of
most natural products can interact with a larger number of biological targets.1, 18 This may explain
why nature has been a leading source of compounds for drug development, when compared to
combinatorial libraries and small-molecules. Most natural products exhibit a trend when compared
to small molecule drugs.59 The last three points in limit off-target interactions between the natural
product and biological environment.49

Extreme toxicity is a major problem of cancer

chemotherapies and one of the leading causes for attrition during clinical trials.60
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Table 1.3. Common Characteristics of Natural Products Compared
to Small-Molecules or Combinatorial Libraries
1. More complex ring structure (bridged, fused, and spiro ring
fusions)
2. Less nitrogen, sulfurs, and halogens (helps with toxicity)
3. More H+ bonding (both donors and acceptors)
4. Less rotatable bond but more flexible overall structure
5. Larger number of heteroatoms (oxygen, less common nitrogen)
6. More hydrophilic than many small molecules (especially A.
compounds)
7. High percentage of sp3 carbons (more 3-D structure)
8. Morefew
chiral
centerscan
(Rbe
orfound
S configurations)
Unfortunately,
examples
of a directly isolated natural product being used
as the actual drug. Often, the natural product acts as a structural scaffold or lead compound for
the synthesis of a library of compounds or analogs. During this time, the organic chemists must
work very closely with computational chemists and chemical biologists to determine the
pharmacophoric “hot spots” and the moieties of the molecules that are vital to biological activity.24,
54, 59

Lipinski’s rule of five has acted as a guide for medicinal chemists to design potential

therapeutic agents with the correct physiological properties and low cytotoxicity.37,

60

The

development of SAR libraries takes significant time and patience to find a molecule with good
pharmacological properties. Through collaborative studies, an organic chemist can start to
determine the important SAR of a molecule and determine the best synthesis method.
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1.3.1. Total Synthesis

Total synthesis is the classic technique for the preparation of complex natural products.
Structural complexity and chemical challenges have driven groups from around the world to
construct natural products.1, 24, 54, 55 To begin the total synthesis procedure, a chemist starts from
a cheap, commercially available starting material. Then, he/she performs a series of chemical
transformations to add structural moieties. Due to the structural complexity, stereochemistry or
regio-chemistry may need to be considered for an intermediate with multiple reaction sites. To
limit this problem, organic chemists utilize protecting groups or functionalities that can be added
and removed without affecting the rest of the molecule. Finally, after a series of chemical
transformations, a complex intermediate is obtained, and all the protecting groups can be removed
to make the natural products. The total syntheses of natural products fall into two main categories:
linear and convergent.

For a linear synthesis, the target molecule is obtained from a series of straight-line reactions
from one starting material.61, 62 During a linear synthesis, a series of chemical transformations are
performed until the target compound is reached. Scheme 1.1 shows examples the linear syntheses
of anastrozole 10 and exemestane 12 from commercially available starting materials. These drugs
are used to treat different types of breast cancers thought an irreversibly binding of Type II

Scheme 1.1. Linear synthesis of Anastrozole 10 (Arimidex) and Exemestane 12 (Aromasin).
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aromatase inhibitor. A convergent synthesis utilizes two or more starting materials and the
different moieties of the natural product are synthesized independently. Then, a coupling reaction
between two separate moieties to form a more complex intermediate. This process along with
other chemical transformations are performed until the target natural product is completed.

A convergent synthesis offers specific advantages and benefits over a linear synthesis. One
of the main problems with a linear synthesis is the overall yield quickly drops with each chemical
transformation. This means most clinical drugs utilizing a linear synthesis are at the maximum 68 steps.1, 25, 54 A convergent synthesis limits this problem by separately synthesizing the different
moieties of the natural product. This gives the organic chemists more material to use to optimize
reaction conditions and test other factors. Another benefit is analogs can be synthesized for SAR
studies without greatly modifying the synthesis route.126 The amount of time to synthesize a
natural product can often be a major limiting factor in drug discovery. Designing a convergent
synthesis route can help lessen the time and material needed to prepare a complex natural product
because different moieties can prepare concurrently.

1.3.2. Diverted Total Synthesis

Sometimes during the total synthesis of a natural product, a pharmacophore of the natural
product can be recognized. The pharmacophore is the vital moiety, or moieties, of the natural
product that is necessary for biological activity. Biological information along with a good
synthetic approach allows for the removal of needless moieties of the natural product. In most
situations, the synthesis of the pharmacophore is easier than the natural product.24 In the mid2000s, Danishefsky et al. created the term “Diverted Total Synthesis” (DTS) to define this method
of synthesis.63 Danishefsky stated in the paper, he was definitely not the first chemist to use this
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method.64 DTS had been used by numerous groups in both industry and academia in the 1970s
and 1980s. Because the target molecule can be less complex, the synthesis is usually more
efficient, taking less time to make the biologically-active agent. Another benefit is the reduction
in cost of chemical reagents and human manpower. These advantages give the organic chemists
more time, financial capital, and materials to synthesize analogs with varying degrees of structural
complexity based on a simpler pharmacophore.

Prominent examples of the structurally simpler pharmacophores developed into anti-cancer
agents are shown in Figure 1.2. Halichondrin B 13 was isolated in the mid-1980s from the marine
sponge Halichondria genus and found to be cytotoxic against multiple cancer cell lines.65,

66

During the total synthesis, Kishi et al. found the left half of halichondrin B 13 (blue) was not vital
to the biological activity.67, 68 This led them to develop the analogue E7389 14 that retained all the
biological activity of halichondrin B 13.69 Besides making the synthesis easier, the analog 14
showed decreased toxicity and greater in vivo stability. E7389 14 was developed into Eribulin for
the treatment of multiple breast cancers.70-72

Figure 1.2. Simpler pharmacophores based on a natural product used as anti-cancer agents
in clinical medicine.
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Flavopiridol 16 was a molecule based on the natural product rohitukine 15 isolated in the
early 1990s. Rohitukine 15 was isolated from the Dysoxylum binectariferum and is used to treat
rheumatoid arthritis. Over 100 analogs were synthesized based on 15, only flavopiridol 16 was
found to inhibit cyclin-dependent kinases and be extremely active against numerous lung and
breast carcinoma cell lines.73 In the past decade, flavopiridol (Alvocidib) has moved into at least
nine clinical trials (phase 2 to phase 3) for the treatment of lymphomas, leukemias, and solid
tumors. Flavopiridol 16 has also been used in combination with other anticancer agents to increase
the potency. Often the isolated natural product is not the chemical entity developed into an anticancer agent. Dolastatin 10 17 is an example of a natural product that failed during clinical trials,
while the modified auristatin PE (TZT-1027) 18 is, currently, in clinical trials (Figure 1.3).24 The
removal of the thiazole in 18 caused increased tubulin polymerization, resulting in cell cycle arrest
and starting apoptosis. Auristatin PE is being delivered to specific epitopes by use of monoclonal
antibodies for the treatment of hematologic cancers.71,

74, 75

Eribulin 14, Alvocidib 16, and

Auristatin PE 18 are some examples of a structurally simple compound that contained the
biologically important pharmacophore for the treatment of various cancers.

Figure 1.3. The synthetic analog Auristatin PE (Soblidotin or TZT-1027) 18 based on the
natural product Dolastatin 10 17 that was terminated during clinical trials.
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1.3.3. Semisynthesis

Starting with a structurally-complex starting material is ideal for the synthesis of a natural
product.25, 54 This method is called the semisynthesis of a natural product. Since a limiting factor
in the study of a complex natural product is the amount of material, the development of a
semisynthesis can shorten the synthesis of the natural product or a biologically active
intermediate.76 Semisynthetic methods can be very valuable to produce numerous analogs quickly
and easily.71, 77 Often the source of the complex intermediate is from biomass like wood, alcohol
fuels, or crops, which are readily available, cheap, and the waste products of other industrial
processes. Enzymatic methods are another technique used to install functional groups during a
semisynthesis. Enzymes are a great alternative to conventional catalysts and chemical reagents,
because enzymes always give the correct product in high yield. Fermenting bacteria has been
shown to produce large amounts of complex intermediates or even complete natural product.76
Unfortunately, some functionalities are difficult to obtain through semisynthetic methods because
of functional group tolerance or incompatible reaction conditions. So, a semisynthesis is best
utilized for the preparation of the natural product or an already known biologically active
intermediate.

One of the best and well-known examples of the impact of a semisynthesis is of paclitaxel
23 (Taxol).19, 25 The natural product was isolated from the Pacific yew (Taxus brevifolia) in 1958
and found to have good therapeutic activity against multiple cancer cell lines (single digit nM).
However, paclitaxel 23 could not be commercially developed because of the unusual ring fusion
and large number of functional groups. Also, each mature Pacific yew tree (40 feet) would only
give approximately 0.5 g of paclitaxel 23, not allowing direct isolation of large qualities of the
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Scheme 1.2. Semi-Synthesis if Taxol from 10-Deacetylbaccatic III.

natural product. This limited the amount of paclitaxel 23 to study, until a semisynthesis was
developed from 10-deacetylbaccatin III 19 by Robert A. Holton at Florida State (Scheme 1.2). 78
The 10-deacetylbaccatin III 19 was readily available in large quantities from the needles of
multiple Taxus species giving a readily available, renewable resource.79-81

After slight

modification in the semisynthesis route, Holton et al. obtained a significant amount of 23 for
animal testing and commercial use.78

In the early 1990s, Bristol-Myers-Squibb (B-M-S)

purchased the rights to and developed Taxol 23 to treat many different cancers, including breast,
ovarian, and specific lung cancers.11 Taxol 23 has become the most popular chemotherapeutic
drug for numerous kinds of cancers and acts as a standard for new potential therapeutic agents.25,82
The development of Taxol 23 gives an example that shows the potential importance of
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semisynthesis for organic chemistry. As enzymic methods and the isolation techniques improve,
semisynthesis will become a more important part of natural product synthesis.

1.4. Resin Glycosides

1.4.1. History of Resin Glycosides

Resin glycosides isolated from the morning glory family (Convolvulaceae) have been used
as traditional medicines for the treatment of numerous diseases throughout history.83 The plant
species making up the Convolvulaceae family can be found worldwide, but more than 60% are
spread throughout Central America.84, 85 These secondary metabolites are commonly known as
glycolipids or lipo-oligosaccharides, a chemical entity special to the morning glory family. The
Convolvulaceae family name was derived from the Latin word convolvo, meaning wrapping or
interlaced vines wrapped around a support. All parts of the plant, including the bulbs, flowers,
and the stems have been exploited for different medicinal issues; however, the bulbs have been the
common part of the plants exploited (Figure 1.4).86

Figure 1.4. The vines and bulbs (seeds) of the morning glory flower. The botanical name,
Convolvulaceae, for the morning glory family was derived from the Latin word convolvo, meaning
interweaving vines. The bulbs or roots were valued for their laxative properties by new world
civilizations.
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Most of the Convolvulaceae species have been found to possess drastic purgative
properties. One of the first recorded uses of a Convolvulaceae species for a therapeutic effect was
in Meso-America. Where the Aztecs used multiple species of the tuber-shaped roots to exhibit a
diverse range of laxative and cathartic effects (Figure 1.4). More recent studies have shown the
roots of genus, Ipomoea (I. purga, I. orizabbensis, I. stans, and I. jalapa) were most commonly
used.87 During colonial expansion of the Americas a commercial enterprise developed, shipping
the roots from the Americas to Europe which continues to the present day. The roots would have
been ground to a fine powder and mixed with alcoholic extracts. Sometimes the ground resin
glycosides would have been taken alone or in concert with other ingredients to reduce unwanted
therapeutic effects. In parts of Mexico the plants were even ground down to a resin and used to
prevent invasive weeds during crop production. This ethnopharmacology relationship between
resin glycosides and a potential pesticides would be confirmed later in the 20th century.88 By the
end of the 19th century, reports started to be published on the phytochemical and chemical
properties of the resin glycosides. However, most of this published data has been recently found
to be non-conclusive and even scientifically un-reliable. It was not until the discovery of
techniques like HPLC, NMR, and MS that resin glycosides could start to be fully studied in greater
detail.89 Still today, several crude drugs with laxative properties isolated from the morning glory
can be found commercially. This shows the potential importance of Old World remedies and why
modern techniques should be used to study their potential before finalizing a conclusion.

1.4.2. Structural Diversity and Chemical Complexity

Currently more than 250 resin glycosides have been discovered and fully characterized.
The molecular weight of these molecules ranges from a few 100 g/mol to more than 2000 g/mol.58
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So, there are many resin glycoside congeners that can be observed for this class of natural
products.90 However, most of the resin glycosides have some common structural features in their
chemical make-ups (Figure 1.5).91-94 All resin glycosides are amphipathic secondary metabolites,
meaning they contain two distinct regions (hydrophobic and hydrophilic region).55 These regions
make the resin glycoside very interesting to study because they can exist in both a non-polar and
polar environment.

Figure 1.5. Resin glycosides containing different monosaccharides with and without a
macrolactone substructure.
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The hydrophilic or sugar moiety contains up to six hetero-polysaccharides connected by
O-glyosidic linkages.87,

95

However, most of the resin glycosides isolated to date contain a

disaccharide core structure (Cusctuic Resinoside A, 24). This moiety is often called the glycone
region of the resin glycoside. The structural diversity in the glycone region comes from two
factors, the diversity of the sugars and short-chain fatty acids. Most resin glycosides conatin sugars
that are a combination of epimers of pentoses (D-Fucp, D-Qui, L-Rha, and D-Xly) or D-Glcp.87
Few resin glycosides isolated have been found to contain D-Gal or other sugars. Differing fatty
acids are the second source of structural diversity in the glycone part of the resin glycoside. These
aliphatic acids range from just a few carbons; like acetic (Ac), butyric, 3-hydroxy-2-methylbutyric
acid, and propionic acids to longer saturated fatty acids; such as n-dodecanoic, n-hexanoic, and nhexadecanoic acids. The fatty acids (aglycone region) are always connected to the glycone core
of the natural product though a glyosidic bond.

The hydrophobic or aglycone moiety of resin glycosides is made-up of a long chain fatty
acid, either tetradecanoic (C14) or hexadecenoic (C16) acid.87 The structural diversity in the
aglycone region comes from the potential macrolactone formation, hydroxylation, or oxygenation.
Jalapinolic acid or (11S)-hydroxyhexadecanoic acid has been found to be the most common
aglycone for resin glycosides (Figure 1.2, green color).84, 88, 96 The aglycone is always connected
to glycone through a glyosidic bond. Often this bond forms a macrocycle or macrolactone across
two or more monosaccharides of the glycone region (orizbic acids 27-31 and soldanellic acid 32).
However, resin glycosides like, cuscutic acid A1-A2 25-26, contain an acyclic form of the aglycone.
For these resin glycosides, the C-11 hydroxyl does not form a glyosidic bond to the glycone ring.
The other difference is the hydroxylation of the resin glycosides. Most of the aglycone fatty acids
contain one hydroxyl group (11S) which connection the two moieties. However, some examples
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contain an aglycone made-up of dihydroxyl fatty acid.

The ipomoeassins family of resin

glycosides covered later in this section will show some examples of functionality in the aglycone
region.

1.5. Common Methods of the Synthesis of Resin Glycosides

1.5.1. Classical Resin Glycoside Syntheses
Despite the advancements in carbohydrate chemistry in the 20th century, only recently have
the syntheses of macrocyclic glycolipids and more specifically resin glycosides been successfully
completed. Numerous organic groups have made contributions to the resin glycoside field, like
Pereda-Miranda, Yang, Xu, and many others.97 Also, recent advancements have been made to
achieve specific glyosidic linkages between the aglycone and glycone moieties. The largest
contributions to the glycolipids field has been made by Alois Fürstner et al.98, 99 To date, the
preparation of bioactive glycoconjugates can be difficult and far from routine. Still, organic
chemists push forward synthesizing complex resin glycosides with interesting structural and
biological properties.

1.5.2. Calonyctin A1
Calonyctin A 33 was the first resin glycoside synthesized by Schmidt et al. in 1995.100, 101
Calonyctin A 33 (Scheme 1.3) was a tetrasaccharide that had been shown to inhibit the growth of
multiple crops such as beans, peanuts, and sweet potatoes. The tetrasaccharide 34 was constructed
through a series of glycosylation reactions using the trichloroacetimidate method. This kind of
donor was developed by Schmidt et al. in the early 1980s and has become the leading method to
make donors for glycosylation reactions.102-105 The racemic mixture resulted in the 1:1 mixture of
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Scheme 1.3. Final steps in Schmidt et al. synthesis of calonyctin A 33.
the glycosylated products that were then treated with KOH and separated to give the carboxylic
acid (CA) 36. At this point, the correct configuration of the aglycone moiety was determined.100,
101

To form the macrolide, an intramolecular coupling was performed under Mukaiyama-Corey

conditions with PySSPy 37 and TPP. The 2-pyridyl thioester intermediate 36 had to be heated at
reflux and in highly dilute conditions to give the 22-membered macrolactone 38. The AllOc was
isomerized with Wilkinson’s catalyst and deprotected by the HgO/HgCl2. Finally, hydrogenation
was performed to remove the benzyl protecting group and the total synthesis of calonyctin 33 was
achieved. Schmidt et al. synthesis of calonyctin A 33 may be inefficient when compared with
modern reactions and techniques, but this work opened organic synthesis to resin glycosides.
1.5.3. Tricolorin A and G
The tricolorins are the prototype members and class of the resin glycosides (Figure 1.6).
Tricolorins were isolated from the Ipomoea tricolor Cav in Mexico where the plant was ground
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into a powder and used as a crop protectant for sugar cane.106, 107 Tricolorin A 39 and G 40 were
first synthesized by Heathcock et al.

108, 109

in 1996 and by Fürstner et al. in 1998.98, 99

Figure 1.6. Structures of Tricolors A 39 and G 40.

In the synthesis by Heathcock et al., a macrolactonization reaction was performed using
Yamaguchi’s method to form the macrolactone 42 ring from jalapinolic acid (Scheme 1.4).109, 110
The macrolactonization method was satisfactory to synthesize the natural products but does not
permit a wide range of analogs.111-113 The resin glycoside contains a large number of free-hydroxyl
groups in the glycone region, potentially causing difficulty obtaining the correct regio-chemistry.

Fürstner et al. designed a route including ring closing metathesis (RCM) (Scheme 1.5)
reaction to form the macrolactone ring of tricolorin A 39 and G 40 (Figure 1.6). The RCM reaction
was developed by Grubbs and Hoveyda in the mid-1990s for the formation of new sp2-sp2 bonds.
This reaction has allowed for the synthesis of numerous resin glycoside and their analogs because
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Scheme 1.4. Heathcock’s macrolactonization for tricolorin A 39.

of the wide functional group compatibility.99 These homogenous transition metal catalysts are
stable at RT (solid powder) and readily accessible though many chemical companies. To perform
the glycosylation, Fürstner used the Schmidt donor 44 (red) as an effective and reliable way to
selectively form the glyosidic linkage.

The formation of a Schmidt donor114-117

(trichloroacetimidate donor) for glycosylation reactions and the RCM reaction have become
common synthetic methods for many amphiphilic glycoconjugates.118 The final few steps in the
synthesis of tricolorin G 40 involved the deprotection of benzoyl and isopropylidene protecting
groups. The Fürstner et al. synthesis of tricolorin A 39 and G 40 gave an example of RCM that
improved the flexibility of macrocycle syntheses, allowing for the preparation of analogs for SAR
studies. The most common catalysts 57-60 applicable for RCM reactions, are shown in Figure
1.7.
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Scheme 1.5. Fürstner et al. synthesis of tricolorin A 39 and G 40 using the RCM reaction.

Figure 1.7. Regularly used catalysts 57-60 for the RCM or RCAM reactions.

25

1.5.4. Sophorolipid Lactone

Another unusual family of resin glycosides are sophorolipids (SL) isolated from the yeast
Candida bombicola.118 These glycolipids are used as biodegradable emulsifiers in multiple
industries like cosmetic, food production, and pharmaceuticals. Interestingly, Candida bombicola
has been shown to be able to grow on pure hydrocarbons.119, 120 In 2017, SL were found to have
anti-proliferative effects against human cervical cancer cells.121 Native SL are made up of a
mixture of 14 different natural products with 61 being the most abundant shown in Figure 1.8.

Figure 1.8. The most abundant sorphorolipid 61 containing an unsaturated aglycone.

The glycone moiety of 61 is structurally simple with two glucose (Glcp) units making up
of a disaccharide backbone (Figure 1.8). However, the aglycone of 61 was not composed of
jalalpinolic acid, but a C-18 fatty acid with a cis double bond between C-9 and C-10 (red, Figure
1.8). As shown in the synthesis of tricolorins, RCM became the common method for synthesizing
the large, saturated FA of the aglycone region. The RCM reactions tend to give a higher ratio of
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the more stable (E)-double bond conformation. The resulting double bond can then be reduced
though hydrogenation conditions to give the saturated aglycone.98, 99 This offered an interesting
challenge for Fürstner et al. synthesis of SL 61 (Scheme 1.6).122 To give the essential (Z)-alkene
in SL 61, Fürstner et al. employed an innovative method called ring closing alkyne metathesis
(RCAM) developed in the late-1990s.123, 124 This transformation gave an internal alkyne instead
of the mixture of double bonds observed for the RCM reaction. The triple bond could be selectivity
reduced though a Birch reduction (trans formation) or Lindlar hydrogenation (cis formation).124
The RCAM reaction worked effectively well for Fürstner et al.’s first total synthesis of SL 61
(Scheme 1.6).118 Fürstner et al. observed the RCAM proceeding smoothly from 64 to 66 with the
Mo catalyst 65. Neither the glyosidic linkages or the acid-labile p-methyloxyphenyl (PMB) groups
were affected by this transformation. Afterwards, Lindar’s hydrogenation of 66 and the PMB-

Scheme 1.6. Fürstner et al. synthesis of SL 61 using RCAM method.
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ether protecting groups were deprotected in 67 with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
(DDQ) and the synthesis of SL 61 was completed.122

1.6. Ipomoeassins

The ipomoeassin family is a small class of six resin glycosides isolated in the mid-2000s
by Kingston et al. from the Suriname rainforest.125 Ipomoeassins are part of the larger family of
resin glycosides isolated from the Ipomoea sp., more commonly known as the morning glory
flower. The ipomoea family is made up of about 650 plant species worldwide with almost half of
the species located in Central and South America. Like other resin glycosides, many ancient
Central and South American cultures used a crude mixture from the morning glories for their
purgative and laxative properties. Recently, the biological applications of the ipomoeassins have
grown ranging from antifungal, antibacterial, and cytotoxicity.84, 86 However, the mode of action
(MOA) of these bioactive molecules is still not well understood. This small family of glycoresins
contain some interesting structural features, while exhibiting potent biological activity.
The ipomoeassins consist of a (1→2)-β-disaccharide core structure with different acylation
patterns connected by the hydroxylated fatty acid derivatives 68-73 (Figure 1.9). The disaccharide
or glycone moiety is made up of a Glcp and Fucp-derivative. The peripheral acylation of
cinnamate (cinn, C-4-Glcp) and tiglate (tig, C-3-Glcp) are rarely found in other resin glycosides.94,
126, 127

As seen in tricolorins or batatin VI (Figure 1.2), the saturated or hydrated forms (2-

methylbutyate or 3-hydroxy-2-methylburyic acid) are more often found.128, 129 The C-4-Fucp
moiety differs for some of the ipomoeassins with some natural products being acylated (A 68, C
70, D 71), while other are hydroxylated (B 69, E 72). The fatty acid or aglycone is made-up of a
C14 or C16 chain connected to the glycone moiety though glyosidic bonds (C-6-Glcp and C-1-
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Fucp). Like many resin glycosides, the (11S)-configuration is found to connect the aglycone back
to the glycone moiety.93 Unlike most resin glycosides, ipomoeassins contain an oxygenation at C4 of the aglycone.125, 130 Also, the aglycone of some ipomoeassins contain an unusual stereogenic
center at C-5. Ipomoeassins C 70, D 71, and E 72 contain either an acylated or free hydroxyl
group. This made some of the first syntheses of ipomoeassin E 72 more difficult than the syntheses
of A 68 and B 69. The absolute configuration of C-5 and C-11 stereogenic centers of the aglycone
were confirmed by the Mosher’s ester test.125
Table 1.4. Ipomoeassin A-F
n

R1

R2

68

Ipomo- A

2

H

Ac

69

Ipomo- B

2

H

H

70

Ipomo- C

2

OH

Ac

71

Ipomo- D

2

OAc

Ac

72

Ipomo- E

2

OAc

H

73

Ipomo- F

4

H

Ac

Figure 1.9. The Family of ipomoeassins 68-73.

Ipomoeassins offer an interesting case study for research of the potential importance of resin
glycosides for modern medicine (Table 1.1). In 2005, Kingston et al. found ipomoeassins A-E 6872 showed potent cytotoxicity against the A2780 ovarian cancer cell line, ranging from 35 to 1900
nM.125 The potential pharmacophore “hot spots” seemed to be the acylation patterns of the C-4Fucp and C-5 of the aglycone. Ipomoeassin D 71 only differed from ipomoeassin C 70 by the Ac
group at C-5 of the aglycone moiety, while being two-fold more active (35 nM to 2.9 µM).
Ipomoeassin E 72 varies from ipomoeassin D 71 at the C-4-Fucp moiety caused a 100-fold
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decrease in the cytotoxicity (35 nM to 3.3 µM). This showed small changes in the ipomoeassins
structure that could greatly affect the biological properties.

Table 1.5. Cell Growth Inhibitory Data for Ipomoeassin A, B, C, D, E, and F. IC50

68
69
70
71
72
73

Ipomo- A
Ipomo- B
Ipomo- C
Ipomo- D
Ipomo- E
Ipomo- F

n R1

R2

A2780

HT-29

2
2
2
2
2
4

Ac
H
Ac
Ac
H
Ac

0.5 µM
0.4 µM
2.9 µM
35 nM
3.3 µM
36 nM

46.1 nM
396 nM
‒
11.8 nM
393 nM
4.2 nM

H
H
OH
OAc
OAc
H

MDAMBA-435
42.6 nM
2700 nM
‒
19.9 nM
1633 nM
9.4 nM

H522-T1

U937

108.9 nM
1070nM
‒
23.2 nM
967 nM
12.9 nM

20.2 nM
134 nM
‒
7.9 nM
163 nM
2.6 nM

In 2007 a new glycoresin, ipomoeassin F 73, was isolated by Kingston et al.
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Ipomoeassin F 73 was shown to be structurally similar to ipomoeassin A 68 with the only
difference being the fatty acid tether (C16 vs. C14). This small change had a large effect on the
cytotoxicity of the natural products. The published data showed that the addition of two methylene
units could affect the lipophilicity of the aglycone of ipomoeassin F 73.132 The cell growth
inhibitory assays showed ipomoeassin F 73 to be significantly more potent than its congeners
against multiple cancer cell lines. Interestingly, ipomoeassin D 71 is only 2-3-fold less potent than
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ipomoeassin F 73. The only structural difference in the two compounds is the C-5 Ac group of
the aglycone moiety. This makes the synthesis of the aglycone for ipomoeassin D 71 considerably
more difficult than ipomoeassin F 73. The superior potency against multiple cell lines and easier
aglycone synthesis are the reasons ipomoeassin F 73 was studied.

1.6.1. Previous Syntheses of Ipomoeassins

Multiple syntheses of ipomoeassins have been performed over the past decade by Fürstner
132, 133

, Postema,134 and Shi.135-138 Fürstner et al. reported the first synthesis of ipomoeassins B 69

and E 72 in early 2007,133 while Postema et al. published the first synthesis of the ipomoeassin F
73 in 2009134 and shortly after Fürstner et al. synthesized ipomoeassin A, C, D, and F.132 Recently,
Shi et al. have published multiple papers on the synthesis of ipomoeassin F 73 and numerous
analogs based on the natural product.135-138 All the published syntheses utilized RCM (Figure 1.7)
to form the macrolactone ring because of the high flexibility and the favorable reactivity profile.118
The unsaturated ester groups (cinn C-4-Glcp and tig C-3-Glcp) have caused some difficulty
because common reduction methods are not selective enough to reduce just the cis/trans double
bond intermediate from the RCM reaction.

The key steps in Fürstner et al. synthesis of ipomoeassins A 68 and B 69 are shown in
Scheme 1.7.133 (S)-epichlorohydrin 75 has become a common starting material for resin glycosides
because it establishes the (S)-configuration at C-11 of the aglycone. The Fucp acceptor 77 was
synthesized in a few transformations from (S)-epichlorohydrin 75 and D-Fucp 74. The glucosyl
(Glcp) donor 76 was prepared from a previously published hemiketal. After the glycosylation of
76 and 77 to form the (1→2)-β-disaccharide and an acetyl de-protection, a regioselective
esterification installed the tig group 78. The reductive opening of substituted benzylidene gave
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the unexpected C-6-O-PMB ether 80, causing Fürstner et al. to change the envisioned
RCM/hydrogenation method. The (1→2)-β-disaccharide 78 was exposed to Yamaguchi conditions
to couple with cinn acid substitute 79. Fürstner et al. believed the C-silylated derived 79 could
survive the hydrogenation with Wilkinson’s catalyst because of its tri-substituted double bond.
Then, the dimethyl phenylsilyl group 79 could be removed later in the synthesis. The 4-oxo-8nonenic acid 81 was coupled with the (1→2)-β-disaccharide using Yamaguchi conditions to afford
the diene 82, followed by an RCM reaction to give the un-saturated macrocycle.139 The reduction
of the double bond with Wilkinson’s catalyst proceeded surprisingly well (81%). Finally, the
protecting groups were removed with diluted trifluoracetic acid (TFA) and trissulfonium
difluorotrimethylsilicate (TASF) to give ipomoeassin B 69. Interestingly, they reported other
acidic conditions or fluoride sources were not feasible for the removal of TBS and isopropylidene
groups. Finally, Ipomoeassin A 68 was afforded by an HOAc-induced orthoester rearrangement
to give the observed axial acetate.133

Scheme 1.7. Fürstner et al. synthesis of ipomoeassin A 68 and B 69 with the RCM reaction.
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Most of Fürstner et al. synthesis of ipomoeassins A 68 and E 72 could be extended to
ipomoeassin E 72. The main difference comes from the C-5 acetyl group on the aglycone moiety.
The synthesis of 5-acetyl-4-oxo-8-nonenoic acid 83 by Fürstner et al. is shown in Scheme 1.8.133
Sharpless-type kinetic resolution was performed on the alcohol 84.140, 141 Then, a ring expansion
with catalytic vandayl acetylacetonate (VO(acac)2), oxidation of the hemiacetal, and conjugate
reduction of the enone gave the lactone 85.142 The six-membered lactone 85 was opened by
trimethylsilyl ethanol (TMSEOH) and acid 83 formed by a fluoride-aided cleavage of the ester.143,
144

Yamaguchi conditions were used to couple the acid 83 with the (1→2)-β-disaccharide 80

(Scheme 1.8). The remaining four steps to ipomoeassin E 72 followed the route of ipomoeassin
A 68 (Scheme 1.7).133

Scheme 1.8. The scalable route to the 5-acetyl-4-oxonon-8-enoic acid 81 developed by
Fürstner for the synthesis of ipomoeassin E 72.
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The first synthesis of ipomoeassin F 73 by Postema et al. is shown in Scheme 1.9.134 Three
differences from the first synthesis by Fürstner et al. were the Glcp starting material 86 (glucal),
the late stage introduction of the peripheral α,β-unsaturated esters (cinn C-4-Glcp and tig C-3Glcp), and the RCM catalyst (H-G II, 60). Postema et al. chose to start with the commercially
available glucal 86 for the preparation of the Glcp donor 89. After a TBS protection of 87, a
dihydroxylation with osmium tetroxide (OsO4) was performed to give the mixture of anomers 88.
Studies have shown OsO4 to be extremely toxic, making this route not favorable for large synthesis
of ipomoeassin F 73.145, 146 Unlike Fürstner synthesis, Postema et al. chose to start with optically
pure 1,2-epoxyheptane and with the addition of a vinyl cuprate formed (4S)-nonenol 65. This
chemistry was adapted from the chiral epoxidation studies developed by Jacobsen et al. in the mid2000s.147

The Fucp acceptor 92 was made through a series of transformations after the

glycosylation of Fucp bromide 90 and (4S)-nonenol. The final two steps in the synthesis of the
Fucp acceptor 92 involved the Ac introduction to C-4-Fucp and the de-protection of TBS with a

Scheme 1.9. Postema et. al. first synthesis of ipomoeassin F 73 in 2009.
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weak acid (HCl, MeOH) to give the HO-2-Fucp (91→92). Like Fürstner et al. synthesis, a (1→2)β-disaccharide 93 was formed between the Schmidt donor 89 and Fucp acceptor 92 catalyzed by
BF3 ∙ OEt2. They also observed a significant amount of the isopropylidene (C-4-Glcp and C-6Glcp) removed to give the diol. After a CSA deprotection of the acetonide, the 4-oxo-8-noenoic
acid 81148 was regio-selectively introduced (Steglich method) to the C-6 hydroxyl of the Glcp
moiety. The RCM reaction was catalyzed by H-G II 60 catalyst and the mixture of cis-trans
isomers hydrogenated (H2, Pd/C). The simple hydrogenation conditions offered a big advantage
over Fürstner et al. synthesis, since they needed to use Wilkinson’s catalyst to not interfere with
the unsaturated esters (cinn and tig). Then, the HO-3-Fucp was protected with chloroacetylation
followed by Steglich esterification with cinn acid to give the intermediate 95. Expectedly, this
coupling reaction was very difficult because of the bulky OTBS group blocked the C-4-Glcp. The
esterification would only proceed if heated under solvent evaporation and replacement conditions.
Then, the C-3-Fucp TBS was removed with silicon tetrafluoride (SiF4) and HO-3-Glup coupling
reaction of tig acid (DCC, DMAP). Finally, the ipomoeassin F 73 was obtained after an excess of
DABCO removed the α-chloroacetates.

Later in 2009, Fürstner et al. synthesized ipomoeassin A- F 68-73 for the most complete
study of ipomoeassins at the time (Scheme 1.10).149 They chose to make the (S)-alcohols 49 a, b
through a series of Grignard reactions catalyzed by copper(I) cyanide (CuCN).

After a

glycosylation with a bromo Fucp, like Postema et al. synthesis (Scheme 1.8 90→91), they obtained
the C-3/C-4 protected Fucp acceptor 97 a, b in two steps. This is a benefit over Postema et al
synthesis that took five steps to achieve the Fucp acceptor 92 from the bromo-sugar 91 (Scheme
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Scheme 1.10. Key transformation in Fürstner’s synthesis of ipomoeassins.

1.9). The Schmidt donor 98 was prepared from a hemiketal published a previously reported
route.122 The glycosylation reaction of donor 98 and acceptor 97 a, b was catalyzed by the BF3 ∙
Et2O, then the C-2-Glcp and C-3-Glcp deacetylated with potassium methoxide (KOMe). The
increased nucleophilicity of the HO-3-Glcp was utilized to perform a regioselective esterification
to install the tig moiety giving 99 a, b. The benzylidene acetal was opened with NaBH3CN with
chlorotrimethylsilane (TMSCl), followed by Yamaguchi esterification with the C-silyated cinn
acid

79,

and

oxidative

cleavage

of

the

C-6-Glcp

PMB

using

2,3-dichloro-5,6-

dicyanobenzoquinone (DDQ) to give the lone free alcohol. Fürstner et al. believed trisubstituted
alkene 79 would not inhibit the RCM reaction and allow for simpler hydrogenation conditions
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from the alkene metathesis product. Then, the sacrificial protecting group was simultaneously
removed with the C-2-Fucp TBS at the end of the synthesis. The C-silyated cinn acid 79 was
derived from 3-phenyl-propargyl alcohol in four steps. A Yamaguchi esterification was performed
with 4-oxo-8-noenoic acid 81 to give the RCM precursor 101 a, b. The aglycone intermediates
that contained the C-5 stereocenter (aglycone) were prepared similarly to Scheme 1.8.110, 140, 150
The RCM reaction proceeded smoothly, and the corresponding double bond was reduced with
Wilkinson's catalyst. This choice of catalyst was interesting because they thought the C-silyated
group would not interfere with a hydrogenation reaction. Finally, ipomoeassin B 69 was attained
by removal of the silyl protecting group (C-3-Fucp and C-4-Glcp cinn) with TASF and the
isopropylidene acetal deprotected with dilute TFA. Ipomoeassin A 68 and F 73 were achieved by
an AA-promoted orthoester rearrangement to give the axial acetate.

Along with the natural product, Fürstner et al. prepared a small library of analogs 102-104
to confirm the importance of the oxygenation and acylation patterns (Figure 1.10).132 They
prepared the 4-deoxy-ipomoeassin B 102 in four steps from the esterification of intermediate 99a
with the commercially available 8-nonenoic acid. The deacetylated 103 and the regioisomer 104

Figure 1.10. First synthetized analogs of the ipomoeassins by Fürstner et al. in 2009.
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were accidently obtained during the final step, when high concentrations of TFA caused the Ac
cleavage and migration. Compared to ipomoeassin F 73, C-4-Fucp hydroxylated analog 103
showed slight loss in anti-tumor activity (two-fold loss). The 4-deoxy-ipomoeassin B 102 was the
most active, indicating the C-4 ketone is not important to biological activity. Interestingly, they
chose not to make 4-deoxy analog 102 based on ipomoeassin F 73. Later, Shi et al. synthesized
the 4-deoxy-ipomoeassin F analog that exhibited good cytotoxicity with a only a two-fold loss in
the cytotoxicity.136

Recently, Shi et al. has reported the total synthesis of the ipomoeassin F 73 and numerous
analogs based on the natural product.135-138 In 2015, they published a new synthesis route of
ipomoeassin F 73 and the unnatural 11 R-epimer (Scheme 1.11).135 Unlike Postema et al.
synthesis, Shi et al. wanted to design a synthetic route where the cinn group was introduced as late
as possible. They believe a late-stage introduction of the cinn moiety could situate important SAR

Scheme 1.11. Shi et al. synthesis of ipomoeassin F 73 and its 11R-epimer.
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studies at the C-4-Glcp, since unsaturated esters are rare for resin glycosides (Figure 1.5-1.8). The
reactivity HO-3-Fucp was exploited to regio-selectively install the silyl group for the Fucp
acceptor 105. Shi et al. chose to use D-Glcp, not glucal (Postema et al. Scheme 1.9) for the
preparation of the Glcp moiety. This was a benefit over Postema et al. synthesis, since Shi et al.
did not need to use toxic OsO4 to form the OH-2-Glcp and OH-3-Glcp.134 Similar to the previous
synthesis of ipomoeassins, the trichloroacetimidate donor 106 was designed because of the highly
effective transformation. Alloc was chosen as a transient protecting group for C-2-Glcp to assist
the formation of the β-(1→2)-disaccharide linkage though neighboring group participation. The
de-protection conditions and wide functional group tolerance made Alloc an attractive protecting
group.151

After the glycosylation catalyzed by trimethylsilyl trifluoromethanesulfonate

(TMSOTf), an acetylation was performed at C-4-Fucp, and the C-2-Glcp Alloc removed to give
the (1→2)-β-disaccharide 107. The free OH-2-Fucp was protected with TBS and the CSA
removed the isopropylidene to afford the diol 108. Unlike the previous syntheses of ipomoeassin,
Shi et al. took advantage of the nucleophilicity of the primary OH-6-Glcp and regio-selectively
added the 4-oxo-8-nonenoic acid 81 to afford the diene 109. The macrocycle formation was
catalyzed by H-G II 60 and the corresponding cis-trans double bond was reduced with H2. Then,
the cinn moiety could be introduced to the OH-4-Glcp 110 without the worry of any unwanted
regioisomers. The final step in the synthesis involved the removal of the TBS groups to give
ipomoeassin F 73. Since 1.6 g of intermediate 110 was synthesized, this route could be utilized in
the future to prepare grams scale quantities of ipomoeassin F.136
1.7. Statement of the Problem
By 2015, multiple syntheses have been developed for the resin glycoside, ipomoeassin F
(Scheme 1.7-1.11).133-135,

149

Through these syntheses numerous analogs were prepared to
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investigate the importance of different moieties of the natural product. In 2016, Shi et al.
synthetized a library of analogs for the most systematic study of ipomoeassin F 73 to date. They
found the C-4 ketone and the macrolactone ring were not vital to overall activity of the natural
product, while modification of the 3-O-Glp (tig) or 4-O-Glp (cinn) would remarkably spoil the
cytotoxicity (150-1000 loss in activity). Even subtle modification to the α,β-unsaturated esters
resulted in dramatic changes in the cytotoxicity of the analogs. These analogs caused Shi et al. to
postulate that the cinn group could be a pharmacophoric “hot spot” through π-π stacking
interaction with an aromatic AA. This finding caused Shi et al. to hypothesize that the α,βunsaturated esters could form a covalent bond with the target through a 1,4-Michael addition.135,136
1.7.1. Ipomoeassins… Novel Target?
More significant than SAR studies, was the information found through the NCI 60-cell line
screening of ipomoeassin A 68 (most abundant congener of the ipomoeassins family). This
screening showed ipomoeassin A 68 to have comparable potency and selective growth inhibition
to clinically anti-cancer agents against different cancer cells lines.58 Interestingly, ipomoeassin A
68 exhibited a pattern of activity evidently different from known anticancer agents.135, 136 This
pattern caused researchers to ask whether ipomoeassins could be inhibiting a novel or
“undruggable” target? Since known “druggable” targets make up only a small percentage of the
potential targets in the human genome (Table 1.3).38,

51, 152

This led researchers to ask if

ipomoeassins, specifically ipomoeassin F, act as a scaffold to develop a new class of antineoplastic
drugs?
One moiety of ipomoeassin F 73 that has not been well-studied is the 3-O-Glcp and the
role of the tig moiety. This position is interesting to explore for a few different reasons. The first
reason is the structural aspects of the α,β-unsaturated ester of tig acid. It is more common to find
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the reduced form of the short-chain aliphatic acid, such as mba or propionic, or saturated fatty
acids (Figure 1.5-1.8, n-decanoic or palmitic acids).87, 127 The second reason is similar to the first,
involving the α,β-unsaturated ester (tig moiety). Shi et al. comprehensive SAR study showed the
two Michael acceptor systems are very interesting.136 This combination is very uncommon and a
distinguishing trait of the ipomoeassins family. Even if one of the α,β-unsaturated esters forms a
covalent bond with the target, the identification of the target protein/proteins could be simplified.
However, the roles of the α-methyl and β-methyl group in tig were not known.

Figure 1.11. Design Synthesis route to examine of C-3-Glcp tig moiety to overall activity of
ipomoeassin F 73.
1.7.2. Designing a Synthesis Route
To examine the importance of the tig moiety and determine its importance for the
cytotoxicity of ipomoeassin F 73, a scalable and flexible synthesis route needed to be developed.
To design a successful synthesis route, late-stage modification to the 3-O-Glcp needed to be
performed. This would make the synthesis more efficient and lessen the need for valuable
intermediates. The total synthesis by Fürstner et al. could not be adapted because they added the
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tig moiety in the early stages, making medicinal chemistry studies of the C-3-Glcp inefficient
(Scheme 1.8 and 1.10).133 The synthesis of Postema et al. was better because they introduced the
tig in the penultimate step (Scheme 1.9). Unfortunately, their overall yield for the synthesis of
ipomoeassin F 73 was extremely low (<0.4 %).134 Since RCM had been found to be extremely
efficient for preparing macrocycles and their derivatives, this strategy was adopted. The cinn
moiety was also introduced in the later stage because of potential steric problems and the moiety’s
importance to the cytotoxicity of ipomoeassin F 73. The synthesis route is highlighted by multiple
regioselective esterification reactions, orthogonal protections and deprotections, and the formation
of the (1→2)-β-disaccharide through a glycosylation reaction.
The goal of this project was to design a successful synthesis route to examine the role of
the tig moiety (C-3-Glcp) of ipomoeassin F 73.

In the following sections the chemical

transformations used to achieve this goal will be presented in detail. These studies will provide
significant insight for future studies of ipomoeassins for anti-cancer drug development.
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CHAPTER 2. SYNTHESIS OF THE C-3 MODIFIED IPOMOEASSIN F ANALOGS

Even with the invention of modern technologies and good reaction profiles carbohydrate
synthesis continue to be a challenge task for organic chemists. Carbohydrates possess greater
structurally diversity than most other natural products (branching character, stereochemical issues,
different glyosidic bonds, etc.). Also, carbohydrates contain a significantly higher number of
heteroatoms and hydroxyl groups, when compared to other classes of natural products.1 This has
caused chemists to develop different protecting groups to ensure the correct glyosidic bonds and
ester linkages are obtained. Some chemists have started using enzymes to guarantee the correct
regio-selectivity and stereoselectivity, but this process is takes time and can be very expensive.2

Recently, natural products containing carbohydrates have become relevant because of their
potential anti-cancer applications.3,

4

One interesting class of natural products containing

carbohydrates is the family of ipomoeassins.5, 6 Since 2013, Shi et al. have been studying the
ipomoeassins, specifically ipomoeassin F 1, to gain a greater knowledge into the mechanism of
action (MOA) of these resin glycosides. One portion of ipomoeassin F 1 that had not been well
studied was the C-3-Glcp or the tigoyl (tig) moiety. Shi et al. knew from previous studies that the
C-3-Glcp tig moiety was vital to the cytotoxicity but did not know if modifications could be made
to extend ipomoeassins into new/advanced area of drug discovery.

2.1 Retro-Synthesis

To study the role of tig, an efficient and scalable synthesis route needed to be developed.
We envisioned a route that would introduce the C-4-Glcp cinnamoyl (cinn) and the C-3-Glcp tig
in the late-stage.7-9 Since, RCM reactions have been shown to be highly efficient and effective in
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constructing large macrocycles, this strategy was adopted like in the previous syntheses of
ipomoeassins.10, 11 The retro-synthetic scheme for making C-3-Glcp modified ipomoeassin F
analogs is shown in Scheme 2.1 (bond disconnections in red). A regioselective esterification could
be performed at the C-3-Glcp followed by a one-pot deprotection of the C-4 acetal and the -OTBS
at C-3-Fucp to achieve the final analogs from 2. We believed the final deprotection could happen
in one pot based on the previous studies of OSW-1 and other complex natural products.12, 13 The
OH-3-Glcp should be favored for the esterification over the OH-2-Glcp because of greater
nucleophilicity of the OH-3-Glcp. Also, Fürstner et al. showed that regioselective esterification

Scheme 2.1. Retrosynthesis of the C-3-Glcp modified ipomoeassin F 1 analogs.
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could be performed at the more nucleophilic C-3-Glcp site (9:1) in a ipomoeassins B and E
synthesis.10, 14 However, their substrate for the regio-selective esterification was significantly
simpler, since they had only constructed the non-cyclical (1→2)-β-disaccharide.8 Also, the -OTBS
at C-3-Fucp should help to block the OH-2-Fucp making the regioselective esterification of OH3-Glcp more favorable.

The diol intermediate 2 was the most important intermediate for the synthesis because
different modifications were regio-selectively introduced, as discussed above. The levulinoyl (lev)
group was chosen as the transient protecting group for the 2-O-Glcp and 3-O-Glcp for a few
different reasons. The lev groups can be orthogonally deprotected in the late-stage using hydrazine
acetate (3→2) (NH2NH2 ∙ AcOH). Moreover, the neighboring group participation effect of the lev
group helped to control the β-glycosylation formation found in ipomoeassin F 1 (glycone).
However, the C-4 ketone in the aglycone 5 had be protected to avoid hydrazination when the lev
groups were removed. The macrocycle 3 was obtained through an RCM and hydrazination
sequence from the diene 4. Another benefit for the late-stage introduction of the C-4-Glcp cinn
and the C-3-Glcp tig was that the cis/trans RCM intermediate could be effectively reduced through
strong hydrogenation conditions. In the previous syntheses of the ipomoeassins, the hydrogenation
of the cis/trans double bond intermediate caused Fürstner and Postema some diffcultlies.9, 15 The
diene 4 could be preparaed through a regioselctive esterification between the 4-acetal-8-nonenoic
acid 5 and the OH-6-Glcp diol 6. Mutliple esterification methods were tried with Mukaiyama
esterification conditions being favored due to a simpler work-up and purification process.

The diol 6 could be assembled though deprotection of the isopropylidene group and
acetylation of the OH-4-Fucose (Fucp). The (1→2)-β-disaccharide intermediate 7 could be readily
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made by a chemo-selective glycosylation of the glucosyl (Glcp) donor 8 and fucosyl (Fucp)
acceptor 9. The β-configuration could be achieved exclusively via neighboring group participation
at C-2-Glcp.2,

16-18

The Glcp donor 8 could be assembled through a series of chemical

transformations from the commercially available D-glucose (Glcp) 13. The fucosyl (Fucp)
acceptor 9 can be prepared from D-fucose (Fucp) 13 though a glycosylation of a Schmidt donor
and the (4S)-nonenol 10.

Like the glycosylation affording the (1→2)-β-disaccharide 7,

neighboring group participation could be utilized to obtain the β-configuration.2, 16-18 To establish
the (11S)-stereocenter of the aglycone in ipomoeassin F 1, the (4S)-nonenol 10 could be prepared
from commercially available (S)-epichlorohydrin 11. This synthesis route features multiple
glycosylation reactions, two regio-selective esterification, and an RCM reaction to form the
macrocycle, along with other chemical transformations. The work presented in the following
chapter presents an efficient and scalable synthesis route to study the role of the C-3-Glcp moiety
of ipomoeassin F 1.

2.2. Synthesis of the Aglycone of Ipomoeassin F

The aglycone moiety of ipomoeassin F 1 is highlighted in red and blue in Figure 2.1. RCM
reactions have been found to be efficient for the synthesis of large macrocycles, including

Figure 2.1. Parts of the aglycone moiety of ipomoeassin F 1.
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ipomoeassins. For this project ipomoeassin F 1 aglycone would be composed of the 4-oxo-8nonenoic acid 14 (left tether) and (4S)-nonenol 10 (right tether). So, a retro-synthetic scheme was
envisioned that would prepare the left and right tethers of the aglycone separately. Separately
preparing the two tethers and performing an RCM reaction would make the synthesis more
convergent than if a macrolactonization approach were developed. Also, we wanted to study the
importance of the aglycone for the cytotoxicity of ipomoeassin F 1. Thus, preparing each tether
of the aglycone separately allowed for flexible modifications without affecting the synthesis of
other fragments of ipomoeassin F 1. The tail of the aglycone (C-11–C-16) has been found to be
very important to the cytotoxicity of ipomoeassins.19-21 The cytotoxicity decreased by 5-100-fold,
when the length of the aglycone tail was decreased by 2 carbons (ipomo. F vs. ipomo. A). The
published data shows the addition of the two methylene units affects the lipophilicity of the
backbone of the ipomoeassins.22 The following section will cover in detail the synthesis of the
aglycone of ipomoeassin F 1.

2.2.1. Preparation of (4S)-nonen-4-ol

The (4S)-nonen-4-ol 10 can be prepared from commercially available (S)-epichlorohydrin
11 in three steps (Scheme 2.2). Using (S)-epichlorohydrin 11 may not be the most cost-effective
method for the synthesis of the aglycone; however, the starting material 11 does establish the (S)configuration of the ipomoeassin F 1 aglycone. The only stereogenic center (11S) on the aglycone
has proven to be of great importance to the cytotoxicity of ipomoeassin F 1.7 Also, the five carbon
tail seemed to be very important for the cytotoxicity of ipomoeassins.19-21 Butylmagnesium
bromide in the presence of copper (I) cyanide (CuCN) was used to open up the 1,2-exopide ring
of 11 to give the 1-chloro-3-heptanol 15. Since, this Grignard reaction was performed on a
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Scheme 2.2. Synthesis of the (4S)-nonenol 10 from (S)-epichlorohydrin 11.
relatively large scale (10-15 g), the formation of the Grignard reagent had to be controlled.23
Treating the α-chloro alcohol 15 with an excess of sodium hydroxide formed a 1,2-expoxide
intermediate 16 through an intramolecular SN2 reaction.24, 25 Lastly, another Grignard reaction
was performed with vinylmagnesium bromide to open-up the 1,2-expoxide ring 16 that give the
chiral alcohol 10.26, 27 These three reactions were performed in succession without any purification
until reaching the (4S)-nonen-4-ol 10. The overall yield from S-epichlorohydrin 11 to (4S)-nonen4-ol 10 was 61%.

2.2.2. Synthesis of 4-oxo-8-nonenoic acid

The synthesis of the 4-oxo-noenoic acid 14 was more tedious than the (4S)-nonen-4-ol 11.
In previous syntheses of the ipomoeassins, the 4-oxo-8-nonenoic acid 14 (Scheme 2.3) could be
prepared through a Grignard reaction in one step from succinic anhydride 44 and 4pentenylmagnesium bromide 45. However, the yield of 4-oxx-8-nonenoic acid 14 was low (20-
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Scheme 2.3. Original route for the preparation of the 4-oxo-8-nonenoic acid 14.

35%) even though literature examples showed the yield of similar Grignard reactions could be
increased to almost 60%. One of the main reasons for the low yield was any excess Grignard
reagent would react another at the C-4 ketone giving a tertiary alcohol. During the purification of
14, streaking was observed on the TLC and the column. This situation was resolved by adding a
few drops of acetic acid to the eluent system. Despite the drawback in in the Grignard reaction,
this method allowed for the preparation of 4-oxo-noenoic acid 14 in one step on a multi-gram
scale.

2.3. Preparation of the Fucosyl Acceptor

The synthesis of the Fucp acceptor 9 is more straight forward than the synthesis of the Glcp
donor 8. A route was envisioned to start from commercially available D-Fucp 13 and (4S)-nonenol
10 to make-up the left tether of the aglycone (Figure 2.2). After the formation of a Fucp Schmidt
donor, a glycosylation could be performed with (4S)-nonenol 10. Then, after a few chemical
transformations, a regioselective introduction of TBS was envigored based on the nucleophilicity
of HO-3-Fucp.7,

15

The increased activity of the HO-C-3 of monosaccharides has been well

established in the literature. It was believed this method would provide an efficient, scalable route
with the use of minimal protections for the preparation of the Fucp acceptor 9.
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Figure 2.2. The preparation of the Fucp acceptor 9 from D-Fucp 13.
During the scaling-up process of this project, the focus shifted from the methodology to
the scalability of each chemical transformation. Factors such as the design of experiment (DOE)
and principle cost analysis (PCA) had to be considered to perform the reaction on a multi-gram
scale. One of the biggest cost for an academic research laboratory is the cost of the chemicals and
personnel. As shown in the Figure 2.3 most of the starting materials of ipomoeassin F 1 are cheap
(< $1/ 1g). However, the price of the (S)-epichlorohydrin 11 and D-Fucp 13 are significantly

Figure 2.3. Scalability of the synthesis route for ipomoeassin F 1 and C-3-Glcp analogs.
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higher than the other starting materials of ipomoeassin F 1.

Using the enantiopure (S)-

epichlorohydrin 11 was justifiable because it established the (11S)-configuration of the overall
compound.

As, the (11S)-configuration has been found to be vital to the cytotoxicity of

ipomoeassins F. D-Fucp 13 was the most expensive starting material for this project (SigmaAldrich: $493.00/5g). This high price of D-Fucp 13 caused us to think, could a cheaper and more
commercially available starting material be used instead of D-Fucp 13? Then, through a series of
chemical transformations prepare the D-Fucp 13. By starting with a simpler monosaccharide, the
number of steps increased, but allowed for a cheaper monosaccharide for the multi-gram synthesis
of the Fucp acceptor 9.

Figure 2.4. The preparation of the Fucp acceptor 9 from D-Fucp 13.
2.3.1. Synthesis of D-Fucose

To prepare the Fucp acceptor 9 on a multi-gram scale, 1,2:3,4-di-isopropylidene-Dgatactose (Gal) 21 was chosen as a cheaper starting material. The 1,2:3,4-di-isopropylidene-Dgatactose (Gal) 21 was significantly cheaper than D-Fucp 13 ($11.64/ 1 g vs. $96.50/ 1g). The
synthesis route of 1,2:3,4-di-isopropylidene-D-Gal 21 to peracetylated-D-Fucp 24 is shown in
Scheme 2.4. The first step was a modified Appeal reaction of the alcohol group with iodine to
form 22 in 90%.28 The by-product in this reaction was triphenylphosphine oxide and easily
removed by filtration or column chromatography. Then a hydrogenation catalyzed by N,N-
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diisopropylethylamine (DIEA) was be performed to remove iodine and give the C-6 methyl group
23. Next, the two di-isopropylidene groups were removed by heating intermediate 23 to 70oC in
80% acetic acid to give the D-Fucp 13 (61% over three steps).29 Then D-Fucp 13 was globally

Scheme 2.4. The scalable route of from 1,2:3,4-di-isopropylidene-D-Gal 63 to D-Fucp 13.

acetylated to deliver 24 using acetic anhydride catalyzed by DMAP.30, 31 The overall yield from
1,2:3,4-di-isopropylidene-D-galactose 21 to intermediate 24 was 51% over four steps. Scheme
2.4 did make the synthesis of Fucp acceptor 9 longer (three steps) but gave a cheaper starting
material for scaling-up of the Fucp acceptor 9.

2.3.2. Preparation of the Fucosyl Acceptor from D-Fucose
The route to the β-Fucp acceptor 9 took five steps from peracetylated Fucp 24 (Scheme
2.5). Scheme 2.5 shows the route followed to achieve the C-3-OTBS β- Fucp acceptor 9. The
Fucp donor 25 was prepared from the peracetylated Fucp 66 through a de-protection of the
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anomeric acetyl group with benzylamine (BnNH2) and the formation of the Schmidt donor 25.29,
32

Then, a chemo-selective glycosylation was performed between the (4S)-nonenol 11 and the

trichloroacetimidate donor 25 catalyzed by TMSOTf.8 Only the β-product 26 was obtained
because of neighboring group participation of the C-2-Fucp. To obtain the triol intermediate 27,
the acetyl groups were de-protected with NaOMe in MeOH. The regioselective TBS-protection
proved to be the most difficult transformation to prepare the β- Fucp acceptor 9. We knew that in
the Gal configuration, the reactivity order of the secondary OH groups were 3-OH > 2-OH > 4OH.7, 15 So, a regioselective TBS introduction was performed on the OH-3-Fucp. The first method
involved the use of DMF as a solvent. Surprisingly, this method did not give a satisfactory yield
(<45%) or good selectivity. Along with the two undesired regioisomers, a significant amount of
the unreacted starting material 27 was also recovered (15-20%). Nevertheless, the protected βFucp acceptor 9 was synthesized on a gram scale. During the scaling-up of the Fucp acceptor 9,
this reaction was optimized. After modifying the different parameters (temperature, reaction time,

Scheme 2.5. Synthesis of the TBS Protected fucoside acceptor 9.
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and equivalents) the solvent was changed from DMF to DCM. This change in the solvent
increased the yield (almost 30%) and selectivity of the silyl protection. However, the main
advantage was the easier work-up and shorter reaction time (overnight vs. 1-2 hrs.). The
regioselectivity of the silyl protection was confirmed by both 1H and COSY NMR.

The

regioselective introduction of the TBS group to the C-3-Fuc improved the preparation of the Fucp
acceptor 9 over the previous synthesis of ipomoeassins.9, 15

2.4. Synthesis of the Glucosyl Donor

Finding a scalable route for the synthesis of the Glcp donor 8 proved to be a more difficult
than first envisioned (Figure 2.5). Based on previous syntheses of resin glycosides, especially the
ipomoeassins, a Schmidt donor provided a tried and efficient method for the construction of the
(1→2)-β-disaccharide intermediate 7. So, an efficient and scalable route was designed for the
construction of a Glcp donor 8.9, 33-35 To design a successful, scalable synthesis route for the
Schmidt donor 8 from D-Glcp 12 a few key criteria had to be satisfied (Figure 2.6). First, an acyl
group had to be installed at C-2-Glcp to facilitate the formation of the (1→2)-β-disaccharide
formation found in ipomoeassin F 1. This is well-known as neighboring group preparation or the
neighboring group effect (red). A 2-O-acyl group would block the α-face of the glucosyl donor

Figure 2.5. Preparation of the Glcp donor 8 from D-Glcp 12.
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during glycosylation, allowing the Fucp acceptor 9 to attack the β-face. Secondly, we believed
that a transient protecting group at C-3-Glcp could selectively be removed later in the synthesis.
This would allow for a more convergent synthesis route and later-stage modifications of the C-3Glcp moiety. Thirdly, another temporary group needed to be incorporated at C-4/C-6 to allow the
cinn moiety to be introduced late in the synthesis. We believed the best protection group for these
positions was an isopropylidene acetal because it is small and can be easily removed in the presents
of other functionalities (e.g. glyosidic bonds, esters, and silyl protections). For this work several
different Glcp were investigated with multiple different anomeric protections. The work to
develop a simple, effective synthesis to prepare the Glcp donor 8 in an efficient manner are
presented in detail in the following section.

Figure 2.6. Criteria and Parameters to design an efficient and scalable synthesis route for
the glucosyl donor 8 of C-3-Glcp ipomoeassin F 1 and analogs.

The first synthesis route to prepare the Glcp donor is shown in Scheme 2.6. The chemical
transformations from D-Glcp 12 to the diol 31 proceeded as expected. However, the regioselective
esterification to protect the HO-3-Glcp of the diol 31 proved to be problematic. A 1:1 ratio of the
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desired product 32 and the unwanted 33 was obtained. Attempts were made to go-ahead and
protect 2-OH with TBSOTf, but a pure product 36 could not be obtained. To incorporate the lev
acid through a different route, 4,6-protected β-D-thioGlcp 34 and 35 were obtained.
Unfortunately, like the benzyl intermediate 32, the by-product 34 could not be easily separated.
The intermediate 33 was collected and attempts were made to protect the OH-2-Glcp with TBS.
The TBS-protected thioGlcp 37 was shown to be impure after column chromatography. After
multiple failed attempts to prepare the Glcp donor from this route, we determined the βconfiguration would not allow for regioselective introduction to the HO-3- Glcp.

Scheme 2.6. Selective introduction of the lev. group for the protected glucosyl donor.

The next route opted for the allylcarbonyl (Alloc) group as a transient protecting group at
C-2-Glcp. It was believed Alloc would be a good protecting group because of neighboring group
participation required β-glycosylation for ipomoeassin F 1.36 Also, the mild protection and
deprotection conditions were compatible with many functional groups.37,

38

This route was

applicable for the synthesis of ipomoeassin F 1, the study of the C-4-Glcp, and aglycone modified
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analogs.7, 39, 40 The synthesis route of the Glcp donor is shown in Scheme 2.7. After a global
peracetylation of D-Glcp 12, the p-methoxylphenyl (PMP) group was installed at the C-1-Glcp. If
the reaction was left for a short time (4-6 hrs.), only the PMP-β-Glcp 39 would be obtained.
Whereas, if the reaction was left much longer (4-5 days), the more thermodynamically stable αGlcp 44 would be found. Following route 1, the PMP-β-Glcp 39 deacylated with sodium
methoxide followed by isopropylidenation at C-4-Glcp/C-6-Glcp (65%), to achieve the
intermediate 40. Unpredictably, the Steglich esterification did not occur exclusively at the more
reactive OH-3-Glcp 41.4, 41 The major product was 2-O-tig 42 in 51% at a 2.4:1 ratio of 2-O-tig
vs. 3-O-tig. We also attained 24% of the C-2-Glcp and the C-3-Glcp tig 43. The non-selectivity

Scheme 2.7. Preparation of the Glcp donor 48 using Alloc at C-2-Glcp.
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of the β-Glcp would be utilized in a later synthesis route of the Glcp donor. Since, it is well-known
that α-Glcp favors OH-2-Glcp regioselective esterification, we went back to focus on the (PMB)α-Glcp 44 (route 2).42 After a successful isopropylidenation to protect the C-4-Glcp/C-6-Glcp 45,
a successful regioselective esterification (80%) was performed at 2-O-Glcp with AllocCl at 0oC
46. Then, the tig acid acylated the remaining hydroxyl group with a good yield to give the Glcp
donor precursor 47 (85%). The PMP group was removed with CAN in AcCN/water to give the
hemiacetal in 80 %.

Finally, the Glcp donor 48 was obtained from the reaction of the

trichloroacetonitrile catalyzed by DBU.43 The synthesis of 48 took eight steps from D-Glcp 12
(15-20% yield). As stated earlier, this route was appropriate and efficient for the synthesis of
ipomoeassin F 1 and the other modified analogs. However, since the C-3-Glcp tig was introduced
at an early stage (46→47) of the overall synthesis route, this route was not applicable for the studies
of the C-3-Glcp tig moiety. Each analog would require the synthesis of a different Glcp donor
with a different C-3-Glcp modification.
The introduction of a lev group to the C-3-Glcp would offer a solution for the apparent
drawbacks of Scheme 2.6-2.7. It was well-known that the lev groups could be orthogonally
removed in the present of other acylated groups. Also, a lev protection could act as a transient
protection for the C-3-Glcp and be deprotected later in the synthesis. Then, an esterification
reaction could be performed to install modifications to the tig moiety.

The OH-3-Glcp

intermediate 49 was prepared from commercially available D-Glcp 13 in four steps (Scheme 2.7).
However, the conditions for removing the Alloc protecting group in 50 to obtain 53 were
problematic. When using sodium borohydride (NaBH4), the product was found to be 53, not 52,
where the ketone functionality in the lev moiety was reduced along with the removal of Alloc.
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Looking back, the side reaction should have been expected based on reactivity of the NaBH4 and
ketones.

Scheme 2.8. Attempted preparation of Glcp donor 51 using Alloc at C-2-Glcp.
After learning the drawbacks with some of the previous routes, we started to think about
using the same transient protection at both the C-2-Glcp and C-3-Glcp (Figure 2.7). If both
positions were protected with the same protection, they could be orthogonally de-protected later
in synthesis to give the C-4 ketone macrocycle diol intermediate 55. Then, a regioselective
esterification was envisioned to modify the C-3-Glcp 56 in the late stage of the synthesis. This
late stage modification would allow for a more convergent synthesis route than previously
considered. Also, this route would allow more time to be spent on synthetizing tig modifications
and not preparing complex disaccharide intermediates. Lev groups 57 were finally chosen because
they could be installed during the preparation of the Glucp donor synthesis and potentially a latestage deprotection could be performed. Hydrazine acetate had been shown to orthogonally deprotect lev group 54 in the presents of other esters and glyosidic bonds.38, 44, 45 Another benefit
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was the C-2-Glcp lev group could help form the (1→2)-β-disaccharide needed in the natural
product.

Figure 2.7. Reasoning for using the same transient protection at C-2/C-3-Glcp.
Scheme 2.9 shows the first synthesis route developed with C-2 and C-3-Glcp lev groups.
The diol intermediate 59 was prepared from the D-Glcp 12 in four steps by following the steps in
Scheme 2.7.7 59 was then utilized to introduce the lev groups to the C-2 and C-3 positions though
Steglich esterification to give 60. The purification of this intermediate was difficult because of the
dicyclohexylurea (DCU) bi-product. The anomeric p-methoxyphenyl group (PMP) was removed
with CAN in AcCN/H2O to give the hemiacetal and the trichloroacetimidate group installed to
furnish the Schmidt donor 61. However, the yield was only 45% for these two steps. This low
yield was unexpected, because published data showed that these reactions proceeded smoothly
(74% 60→61). The low yield for this transformation can possibly be explained by a few reasons.
During the work-up of the CAN reaction an emulsion was formed between the aqueous and DCM
layers, causing difficulty in obtaining the hemiacetal. Secondly, these deprotection conditions
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Scheme 2.9. Synthesis of the Glcp donor 61 with C-2 and C-3 lev protecting groups.

have been shown to be very sensitive to acid-labile groups, like the C-4/C-6 isopropylidene group.
If the reaction was left too long, the PMP and the C-4/C-6 isopropylidene group would be removed.
The third reason involved the in-stability of the Schmidt donor. It is well-know that Schmidt
donors are un-stable when exposed to acid or moisture, this causes the trichloroacetimidate donors
to decompose back to the hemiacetal.46 Because of the number of steps (eight steps 13→61) and
the overall yield, especially in the final two steps, another synthesis had to be developed to
efficiently prepare the Glcp donor. The experience from this synthesis route helped us gain the
knowledge that lev groups at the C-2 and C-3 would be good transient protecting groups.

Knowing the disadvantages of the previous routes, a new synthesis route was designed to
achieve a new Glcp donor. For this method a thioglycoside was utilized, instead of the PMP group
used in previous routes (Scheme 2.7-2.9). Anomeric thioglycoside protections have been routinely
utilized in carbohydrate synthesis because of their simple preparation and good stability. 1, 44, 45, 47
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They have been very useful for a wide range of glycosylation reactions though activating thiophilic
agents like NIS-TMSOTF, NIS-AgTOF, MeOTf, DMTST, among others.31, 32 However, we chose
to continue to make a trichloroacetimidate donor for the glycosylation reaction. Literature has
shown for the synthesis of the complex glycosides, thiophilic promoters can initiate unwanted side
reactions in a multifunctional glycone like ipomoeassin F 1.1
The synthesis route to prepare the Glcp donor 61 was achieved from D-Glcp 12 in seven steps
(Scheme 2.10).

The synthesis route offered several benefits compared to previous routes,

including decreased reaction times and the number of steps. For this route the D-Glcp 12 was
globally acetylated with Ac2O catalyzed by perchloric acid (HClO4) instead of Ac2O and pyridine.
This acylation method decreased the reaction time from overnight to 30 mins and allowed for
almost exclusively the β-peracetylated Glcp. The conversion to the thioGlcp 62 did not go to
completion giving only a 72% yield. The formation of the β-thioGlcp 62 was very dependent on
the quality of the boron trifluoride diethyletherate (BF3∙OEt2). Sometimes a higher ratio of the
BF3∙OEt2 would still not push the reaction forward, making the purification of the thioGlcp 62
more tedious. In the next two steps, the acetyl groups were removed by sodium methoxide, then

Scheme 2.10. Preparation of the Glcp donor 61 using thiotoluene protection.
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the C-4/C-6 were protected using dimethoxypropane (DMP) to form the isopropylidene acetal
63.48 Then, the lev groups could be easily installed to the C-2 and C-3 positions through Steglich
esterification. Similar to intermediate 60, the purification was a difficult because of the DCU byproduct.49 This problem was solved by removing some of the DCM under reduced pressure and
adding 2:1 (Hex:Et2O). This caused most of the DCU to become insoluble and the solution could
be filtered through Celite. Then, any remaining DCU was removed by column chromatography.
Another benefit of Scheme 2.10 was observed in the removal of the thiotolyl group at the anomeric
position. This route allowed for the orthogonal removal of the thiotolyl protection with NBS in
acetone/H2O to afford the hemiacetal 64.50, 51 This was a major benefit over previous syntheses of
the Glcp donor, because CAN was needed to remove anomeric PMB. The deprotection of the
thiotolyl group was time and temperature dependent. If the reaction was left longer than 15-20
mins or the temperature rose above -5oC, the isopropylidene acetal would start to be removed.
Finally, the trichloroacetimidate group was installed to furnish the Schmidt donor 61. This
synthesis route took seven steps and offered numerous benefits over previous route for the
preparation of the Glcp donor 61. The overall efficiency and the number of steps were the primary
reasons why Scheme 2.10 eventually was chosen to scale up the Glcp donor 61 for the study of
the tig moiety of ipomoeassin F 1.

2.5. Glycosylation of the Two Monosaccharides and Regio-selective Esterification

With both the Glcp donor 61 and the Fucp acceptor 9 in hand, a Schmidt regio-selective
glycosylation reaction was performed with a 1.2:1 ratio of 61 to 9 (Scheme 2.11).33, 34 The (1→2)β-disaccharide was obtained for a few specific reasons. First, the bulky-TBS group at the C-3-
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Scheme 2.11. Glycosylation of the Glcp donor 61 and Fucp acceptor 9, acylation at C-4Fucp, and removal of isopropylidene acetal to give the diol 6.

Fucp helped to block the OH-4-Fucp causing the glycosylation to occur preferentially at the OH2-Fucp. Second, the lev group at C-2-Glcp blocked the α-face of the Schmidt donor 61 resulting
in only the β-glycosylation product. Next, an acetylation was performed to the remaining hydroxyl
at the C-4-Fucp to give 65. After the acetyl group was installed, the isopropylidene acetal was
removed using camphor-10-sulfonic acid (CSA). This de-protection was time dependent, giving
the diol 6 after a few hours at RT. However, if the reaction was allowed stir longer or the CSA
was not properly quenched with NEt3 the acidic conditions would cause the -OTBS at C-3-Fucp
to be removed giving 66. The (1→2)-β-disaccharide diol 6 was a key intermediate in the synthesis
of ipomoeassin F analogs because modifications to the left-tether of the aglycone can be easily
coupled to the 6-OH-Glcp. Next, another trans-esterification reaction was performed with the
(1→2)-β-disaccharide 6 and 4-oxo-8-nonenic acid 14 to form the RCM precursor 67 (Scheme
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2.12). The greater nucleophilicity of the primary OH-6-Glcp over the secondary OH-4-Glcp was
utilized for the chemo-selective esterification. A significant amount (15-20%) of the di-substituted
product 68 was often observed. This drawback could be limited by the controlling the temperature
and the equivalents of the 4-oxo-8-nonenoic acid 14 (1.05-1.2 eq).

Scheme 2.12. Coupling of 4-oxo-8-nonenoic acid 14 and the (1→2)-β-disaccharide 6
using Steglich esterification conditions.

2.6. Macrocycle Formation and Cinnamoyl Introduction
Because of its favorable reactivity profile and high flexibility, a RCM reaction was
believed to be the best method to form the macrolactone ring (Scheme 2.13).52, 53 RCM was
adopted by both Postema9 and Fűrstner15 for the formation of the 20-membered macrolactone ring
of the ipomoeassins. From the diene 67, an RCM reaction was performed using Hoveyda-Grubbs
catalyst (II) (10 mol%) to yield the E/Z mixture.54, 55 Dilute conditions were very important for
the RCM reaction to prevent the polymerization of the diene 67. Then hydrogenation with Pd/C
in EtOH was performed on the E/Z double bond mixture to afford the saturated macrolactone 69
in 62% over two steps. These hydrogenation conditions were an improvement over previous
synthesis where Postema 9and Fűrstner15 could not use strong hydrogenation conditions due to
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Scheme 2.13. Preparing the macrocycle 69 and coupling of the cinn moiety to make 70.
incompatibility of the two α,β-unsaturated esters (cinn, C-4-Glcp and tig, C-3-Glcp). The cinn
moiety was introduced thorough an esterification reaction with HO-4-Glcp through Steglich
esterification conditions. A late-stage introduction of the cinn moiety gave the opportunity to
perform systematic SAR studies on the C-4-Glcp by modifying cinn moiety and then performing
final chemical transformations.

2.7. Protection of the C-4 Ketone of the Aglycone

After installation of the cinn moiety at C-4-Glcp 70, one transformation was needed to
obtain the C-4-oxo macrocycle diol intermediate 71, critical for the synthesis of C-3-Glcp modified
ipomoeassin F analogs (Figure 2.8). Based on the designed synthesis route, we envisioned using
hydrazine acetate (NH2NH2.AcOH) to orthogonally remove the C-2/C-3 lev protecting groups to
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yield 71. However, the intermediate 72 was obtained where the lev groups had been deprotected
to the hydroxyls (red), but the C-4 ketone had been converted into hydrazone (blue). Multiple
attempts were made to hydrolyzes the hydrazone 72 back to the ketone 71, but the stability of the
hydrazone prevented this transformation from occurring.

Figure 2.8. Removal of the C-2/C-3-Glcp lev groups in presents of C-4 ketone.
At this point in the synthesis, a decision had to be made about how to obtain the C-4 ketone
macrocycle diol 71. After considering different possibilities that could be explored, we determined
the two best options would be to prepare a different Glcp donor 61 or protect the C-4 ketone of
aglycone. Finally, we decided the best option would be to protect the C-4 ketone for a few reasons.
Preparing a different Glcp donor 61 was justifiable, but this meant going back to the beginning of
the synthesis and spending a significant amount of time exploring different routes. Since, the
current Glcp donor 61 had already been synthesized on a multi-gram scale. We did not want spend
time to develop another Glcp donor route. Protection the C-4 ketone did make the synthesis route
a few steps longer but provided an easier alterative than developing another Glcp donor synthesis
route.

Since the C-4 ketone to be protected, a synthesis route was developed prepare the 4-acetal8-nonenoic acid 5 from the 4-oxo-8-nonenoic acid 14 (Scheme 2.14). First, a direct protection of

80

the 14 4-oxo-8-nonenoic acid to protect the C-4 ketone was attempted. The direction protection
gave a mixture of the desired product 5 and an unwanted ethoxy ester. After multiple reaction
parameters (solvent, temperature, and equivalents of the ethylene glycol) were modified without
obtaining purely 4-acetal-8-nonenoic acid 5, we determined a step-wise protection must we
performed. So, the 4-oxo-noenoic acid 14 was converted to an ethyl ester 73 by ethanol (78%)
using Steglich conditions.56, 57 Then the C-4 ketone was protected by forming the acetal 74 with
ethylene glycol catalyzed by pyridinium p-toluenesulfonate (PPTS) (83%). The Rf values of
ketone 73 and acetal 74 were the same (Rf = 0.55), making the transformation difficult to monitor
by TLC. When the reaction was left overnight, and the excess of the ethylene glycol was added
to the reaction, the transformation easily went to completion. Lastly, the ethyl 4-acetal-8nonenoate 74 was treated with NaOH in MeOH to form the 4-acetal-8-nonenoic acid 5. The yield
of the four transformations was only 17-30%. Following Scheme 2.14 did make the synthesis
route of the left-tether three steps longer but give a scalable method to protect the C-4 ketone.

Scheme 2.14. The synthesis of the 4-acetal-8-nonenoic acid 5 from 4-oxo-8-nonenoic acid
14.
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2.8. Optimized RCM Precursor and Macrocycle Formation

Originally, a Steglich esterification (Method 1) was performed to couple the diol 6 and the
acid 5 (Scheme 2.15).

However, the Mukaiyama esterification (Method 2) offered a few

advantages over the Steglich esterification (Method 1).58 One advantage was found in the reaction
time of the trans-esterification. The Steglich esterification took 12 hrs. to completely convert the
acid 5 and diol 6 into the ester 4, whereas the Mukaiyama method took only one-two hrs. to
complete. This helped improve regioselectivity for the reaction from 6 → 4, caused a small
decrease in the percentage of C-4-Glcp ester 76 isolated. The biggest advantage was found in the
purification of the diene intermediate 4. A major drawback in the Steglich method was the
formation of DCU 80 as a by-product from the DCC 81 (Figure 2.9). The DCU was difficult to
remove with column chromatography, often, taking more than one purification to obtain pure diene
4. The Mukaiyama conditions made the purification of multiple esterification reactions easier;
this esterification method was utilized for future esterification reactions.

Scheme 2.15. Coupling of 4-acetal-8-nonenoic acid 5 and the (1→2)-β-disaccharide 6
using Steglich vs. Mukaiyama esterification conditions.
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Figure 2.9. General Steglich esterification mechanism 1:1 ratio of Product:DCU.
The macrocycle 87 was formed through a RCM/hydrogenation reaction as shown Scheme
2.16. Then, the cinn moiety 20 was introduced thorough an esterification reaction with the one
remaining hydroxyl group (C-4-Glcp). Originally, Steglich esterification method was utilized to

Scheme 2.16. Preparing the macrocycle 84 and coupling of the cinn moiety to construct 3.
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install the cinn moiety. However, during the scaling-up process we chose to use Mukaiyama
esterification conditions because of simpler work-up and purification (Figure 2.9).

2.9. Completion of the Key C-2/C-3 Glucosyl Diol Intermediate

After installation of the cinn moiety at C-4-Glcp 3, two transformations were needed to
obtain the diol intermediate 71 which was critical for the synthesis of C-3-Glcp modified
ipomoeassin F analogs (Scheme 2.17). The C-4 acetate protection allowed the lev groups on the
C-2/C-3-Glcp moieties to be easily removed with NH2NH2.AcOH to yield 2 (90 %). The
orthogonal de-protection seemed to work best with a DCM‒MeOH (9:1) solvent mixture. The C4 acetal 2 could be removed by CSA to give the key diol intermediate 71. This reaction proved to
be more problematic than anticipated, because no change could be observed in the Rf values on the

Scheme 2.17. Preparation of key C-2/C-3-Glcp diol intermediate 71 from macrocycle 3.
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TLC. After multiple trials, the reaction proceeded smoothly with 0.2 eq of CSA and solvent grade
MeOH. The transformation was time dependent if the reaction was left too long, the -OTBS
protecting group at C-3-Fucp would be removed giving the triol. A trace amount of H2O was
critical for the transformation from 2 to 71. The creation of simple, straight-forward, and
reproducible conditions to achieve the diol intermediate 71 was vital to the overall project.

2.10. Ipomoeassin F and C-3-Glucosyl Modified Analogs

Having completed the important diol intermediate 71, we wanted to determine if the
regioselective esterification to HO-3-Glcp would occur as anticipated. There were two main
reasons we believe esterification would occur regioselectivity at the HO-3-Glcp. In the Fürstner
synthesis, they performed a regioselective esterificaiton for tiglic acid (9:1 ratio in favor of 3-OHGlcp), however the Steglich esterification only included a non-cyclic1,2-β-disaccharide 88 and tig.
acid 89 as the coupling partners (Scheme 2.18). Another reason we believed the esterification
could occur regio-selectively is because the -OTBS group at the C-3-Fucp in 71. Based on
preliminary studies, the silyl protecting group would block the OH-2-Glcp, causing the
esterification to occur almost exclusively at the C-3-Glcp. In the final step, -OTBS at C-3-Fucp
could be removed with the mixture of tetra-n-butylammonium fluoride and AcOH (TBAF/AcOH)

Scheme 2.18. Reasoning for the the regioselective esterification to the HO-3-Glcp of
ipomoeassin F 1.
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Scheme 2.19. Completion of ipomoeassin F 1 and C-3-Glcp cinn acid analog 93.
to give the analogs. To confirm the hypothesis and literature supported reasonings work began to
syntheses ipomoeassin F 1 and C-3-Glcp modified analogs (Scheme 2.19). The regioselective
esterification of 71 proceeded as expected yielding the 3-O-tigloyl intermediate 91 and the 3-Ocinn intermediate 92 in high yield. The conformation of the esterification was established by 1H,
13

C, COSY and HMBC correlations shown in Figure 2.10. In the final step, the silyl ether was

deprotected with tetra-n-butylammonium fluoride (TBAF) and AcOH to yield ipomoeassin F 1.
The cinn analog 93 was obtained through the same de-protection conditions without difficulty.

Figure 2.10. Key COSY (Bold) and HMBC (arrows) correlations for ipomoeassin F 1.
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2.10.1. Cytotoxicity Testing of the C-3-Glucosyl Modified Ipomoeassin F. Analogs
In-house cytotoxicity evaluations were performed on ipomoeassin F 1, the cinn analog 93, and
two other analogs 94-95 (prepared by another lab member) on two human breast cancer cell lines
(MDA-MB-231 and MCF7). Table 2.1 shows the concentrations required for 50% cell death (IC50
values) compared to the vehicle-treated negative control. Unfortunately, when compared to
ipomoeassin F 1, all three of the analogs displayed significantly decreased potency. The IC50 for
the cinn analog 93 declined by 161 and 150-fold against MCF7 and MDA-MB-231, respectively.
While C-4-Glcp analogs 94-95 lost almost all bioactivity, further emphasizing previous studies
that showed the cinn moiety is vital to the bio-activity ipomoeassin F 1. These results proposed
the combination of an aliphatic α,β-unsaturated ester at C-3-Glcp and the aromatic α,β-unsaturated
ester at C-4-Glcp provide a synergistic contribution for ipomoeassin F 1 cytotoxicity.

Table 2.1. Cytotoxicity (IC50, µM) of Ipomo. F and C-3-Glcp Analogs
MDA-MB-231a
0.014

MCF-7a
0.070

Ipomoeassin F
1
93
2.1
11.3
94b
17.0
>25
b
95
>2.5
-c
a
The data were obtained from at least two independent experiments, and
standard errors are within 20%. b Prepared by another lab member. c Not
tested.
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2.11. C-3-Glucosyl Acylate Ipomoeassin F Analogs

Knowing regioselective esterification of the diol 71 proceeded as expected, work began on
a small library of analogs to study the importance of the tig moiety to the cytotoxicity of
ipomoeassin F. The C-3-Glcp position was chosen to make modifications, because this position
has been previously shown by Shi et al. to be vital to the activity of ipomoeassin F 1.40 From the
same study, the α,β-unsaturated esters were determined to be vital to the bioactive of ipomoeassin
F 1. When the α,β-unsaturated ester was saturated, a loss of 100-150 fold was observed for
multiple cell lines. So, we knew that any C-3-Glcp analogs needed to contain an α,β- unsaturated
ester. However, the role and importance of the α,β-methyl groups had not yet been determined.
Before any further C-3-Glcp modification or analogs were synthesized, the role and importance of
the α,β-methyl groups needed to be determined. Figure 2.11 shows the small library of C-3-Glcp
analogs 96-98 studied through this work with the modifications displayed in red. For the first
analog 96, the tig moiety is replaced by crotonic acid to investigate the α-methyl substituent. The

Figure 2.11. C-3-Glcp modified ipomoeassin F analogs 96-98.
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second analog 97 focused on the β-methyl group of the tig moiety with a replacement of
methylacrylic acid. The third analog 98 studied the role of both methyl groups by using acrylic
acid. Another reason these modifications were chosen was the three acids needed for the
modifications are commercially available. This allowed for more time to be spent on the synthesis
of analogs 96-98 and not preparing potential modifications for the C-3-Glcp moiety.
Systematically, studying each methyl group of the tig moiety would help determine the role and
importance of this position in the overall cytotoxicity of ipomoeassin F 1. The following section
presents the details of the syntheses of the C-3-Glcp ipomoeassin F analogs 96-98.

2.11.1.Modified Synthesis Route for Mukaiyama Esterification and One-Pot De-Protection
After scaling up the C-4-acetal macrocycle diol intermediate 2, we started to think about a
modified synthesis route to prepare the acrylate analogs 96-98. For the completion of ipomoeassin
F 1 (Scheme 2.20), the final step had been a de-protection of the -OTBS group at the C-3 of the

Scheme 2.20. Modified synthesis route of C-3 glucosyl modified ipomoeassin F analogs
from the key diol intermediate 2.
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Fucp moiety. However, we believed the C-4 cyclic acetal could be carried through the synthesis
until the final step. Then, a one-pot de-protection could be performed to de-protection both the C4 acetal and the silyl ether at C-3-Fucp. It is well-known that silyl ethers, such as -OTBS groups,
are acid-labile and can be removed under slightly acidic conditions. This was observed as an
unwanted side-product when the isopropylidene acetal was de-protected with CSA (65→6 Scheme
2.11). When the reaction was left too long or not properly quenched, both the isopropylidene
acetal and OTBS group would easily be removed giving the triol 66.
In the synthesis of a saponin family natural product, OSW-1 102, Deng et al. design a
similar reaction where multiple protecting groups (one TBS, one ethylene glycol ketal, and three
TES) were easily removed with Pd(MeCN)2Cl2 as a catalyst (Scheme 2.21). The modified
synthesis route (Scheme 2.20) offered a few advantages over the original route (Scheme 2.19).
First, Mukaiyama esterification conditions were chosen for the coupling reaction of the OH-3Glcp and the acrylic acids.

This esterification method offered advantages over Steglich

esterification, including a shorter reaction time, simpler workup, and purification process.
Secondly, performing a one-pot deprotection would remove one step in the total synthesis of the
ipomoeassin F analogs, allowing more time and material (diol intermediate 2) to prepare the C-3Glcp analogs. It was believed the changes to the original route would make C-3-Glcp analogs
more accessible and easier to achieve.

Scheme 2.21. Final step in the first synthesis of OSW-1 102.
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The modified synthesis route for the acrylic analogs 96-98 is shown in Scheme 2.22. The
regioselective esterification of the acids to the 3-O-Glcp was successful. The coupling reaction
with crotonic modification 103 was the fastest, taking only a few hours to complete, while the
methylacrylic 104 and acrylic 105 analogs had to be left 12 hrs.-24 hrs. for most of the C-4 acetal
diol intermediate 2 to be consumed (70-80%). Afterwards, the intermediates were concentrated,
and column chromatography was performed to obtain the C-3-Glcp modified intermediates. The
yield for the crotonic modification 103 was >70%, while the yields for the methylacrylic 104 and
acrylic 105 modifications were lower and inconsistent. The regioselectivity of the crotonic
modification 103 was confirmed by the 1H, 13C, COSY, and HMBC NMR spectra data. The typical
COSY and HMBC correlations were analogous to ipomoeassin F 1 shown in Figure 2.9. We
speculated that the bulky TBS group at 3-O-Fucp blocked the 2-OH-Glcp, causing the
esterification to only occur at 3-OH-Glcp. When 2.5 eq of the crotonic and methylacrylic acids
were needed to modify the C-3-Glcp, no C-2-Glcp acylated by-products were observed.

Scheme 2.22. Modified route for the esterification of the C-3-Glcp and one-pot deprotection.
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The one-pot deprotection of the -OTBS and the C-4 cyclic acetal proved to be more
difficult than anticipated. The crotonic analog 96 was the first analog attempted using the modified
one-pot deprotection. The C-4 cyclic acetal in 103 was removed with CSA (0.2 eq), after 12 hrs.
TBAF (1M in THF) and AcOH was added to the reaction mixture and stirred overnight at RT. At
that point, the TLC showed one spot and the reaction to be complete.

The mixture was

concentrated, then purified by column chromatography. However, after multiple columns using
Hex:EtOAc as the mobile phase, a pure 1H or

13

C-NMR could not be obtained. Believing the

impurities came be from elution mixture, the mobile phase was changed to DCM:MeOH.
However, the change in the mobile phase did not increase the purity of the crotonic analog 87.
The highest purity that could be obtained was 80-85% due to a complex mixture of signals
observed in the aliphatic region of the 1H- and
1

H-NMR 2.0-0.8 ppm and

13

13

C-NMR (See Chapter 3 Experimental Section,

C-NMR 45-20 ppm). Along with multiple purification methods,

Table 2.2. Cytotoxicity (IC50, nM) of Ipomo. F and Crotonic Analog
MDA-MB-231
MCF-7 (MTT)
Ipomoeassin F
14.0
70.0
1
96
13.4
200
a
The data were obtained from at least two independent experiments, and the
standard errors are within 20%.
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numerous work-up procedures were performed to remove any excess TBAF, silyl compounds
(TBSF or TBSOH), or acetic acid before performing column chromatography. Like the crotonic
analog 96 obtaining pure methacrylic 97 or acrylic 98 analogs was not possible for this synthesis
route. For the final deprotection of the acrylic analog 98, the yield varied when even the TLC of
the reaction showed one spot. The small amount of methylacrylic 97 and acrylic 98 analogs
obtained after purification by column chromatography showed a complex mixture of signals in the
aliphatic region. In-house cytotoxicity evaluations were performed on the crotonic analog 96 on
two human breast cancer cell lines (MDA-MB-231 and MCF7). The results showed that in
crotonic analog 96 retained most of the cytotoxicity as ipomoeassin F 1 (2-3 fold loss).

In November of 2017, a senior lab member was given 350-400 mg of the versatile diol 2
to attempt to prepare some of the acrylic analogs 96-98. This lab member had been successful in
preparing numerous analogs to facilitate SAR studies of ipomoeassin F 1. However, some of the
same problems were encountered, such as varying yields, multiple isomers in the final deprotection, and difficulty purifying the analogs by column chromatography.

Therefore, we

concluded that α,β-substitution of unsaturated ester (tig moiety, tri-substituted) is necessary to
easily obtain C-3-Glcp modified ipomoeassin F analogs.

2.12. Left-Tether Modification to Study the C-4 Ketone and the Macrocycle Ring Size

2.12.1. Synthesis of Bioisosteric Modifications

In 2016, Shi et al. become very interested in the role of the aglycone for the cytotoxicity
of ipomoeassin F 1, especially the C-4 ketone and macrocycle ring size. A C-4 deoxy aglycone
analog showed the C-4 ketone was not vital to the anti-cancer activity of ipomoeassin F 1.40 This
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analog made studies of the aglycone moiety very interesting, since almost all resin glycoside
contains tetradecanoic (C14) or hexadecenoic (C16) acid without structural functionality.63, 64 For
this study, the C-4 ketone was replaced with an ester functionality. Replacing the C-4 ketone with
an ester eliminated a few problems associated with the current synthesis route. For the current
aglycone synthesis route, the C-4 ketone had to be protected to selectively remove the C-2/C-3lev group later in the synthesis (Figure 2.8). Then, the C-4 acetal had to be de-protected to reform
the ketone (Scheme 2.17).

These problems caused the synthesis route to become longer,

specifically the aglycone (four steps vs. one step). The preparation of the 4-oxo-8-nonenoic acid
14 was another problem in the synthesis of the right tether of the aglycone (Scheme 2.3). This was
the first and limiting for the preparation of the left tether of the aglycone (<35%). Also, an oxygen
atom could be considered a bioisostere of methylene according to the Grimm’s Hydride
Displacement. A bioisostere is a compound resulting from the exchange of a specific atom or
collection of atoms. Often, the bioisosteric modified atom has the same hybridization or on the
same column of periodic table (e.g. carbon vs. silicon). For bioactive molecules, bioisosteric
substitutions have long been used by medical chemists to adjust activity, improve selectivity,
and/or stability during reduction metabolism.65-67 Replacement of the C-4 ketone with the ester
functionality shorten the synthesis of the aglycone (one vs. four), increased the yield of the lefttether of the aglycone, and provided critical SAR information about the aglycone of ipomoeassin
F 1.

Scheme 2.23 shows the two methods used to prepare 1-(2-propen-1-yl) ester acid 1-(buten1-yl) ester 108 and butanedioic acid 1-(propen-1-yl) ester 109. The longer acid 109 formed the
same size macrocycle as ipomoeassin F 1 (20-membered ring), while the shorter acid 108 was one
member smaller (19-membered ring). The literature called for using succinic anhydride 17 and
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Scheme 2.23. Two conditions for preparing the esters 108 and 109 for the left-tether of
the aglycone.
allyl alcohol 106 with benzene/ pyridine as a solvent. The reported yield was 79%; however, the
solvent mixture of benzene/ pyridine was a potential safety issue. Because of this potential issue
another method was utilized based on work by Shuller et al. For the new method, toluene (Tol)
was the solvent catalyzed by DMAP. The Tol/ DMAP method gave an 85% yield for the
butanedioic acid 1-(propen-1-yl) ester 108. The butanedioic acid 1-(buten-1-yl) ester 109 was
prepared by the same method as the shorter acid 108 with 81%.68 The route was adopted from a
method developed by Cheng et al.28, 56 The C-5-oxa analogs of ipomoeassin F 1 were finished by
another lab member in five steps from the diol intermediate 110 (Scheme 2.24). The 5-oxa analog
111 was found to be active with only a 3-5-fold loss in activity, making 111 a potential replacement
for ipomoeassin F 1 (Table 2.3). To our surprise, 19-membered 5-oxa analog 112 caused a
significant loss in the in the cytotoxicity (9-fold for both MDA-BD-231 and MCF7 when compared
to ipomoeassin F 1, Table 2.4). More analogs are needed to better understand the importance of
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the macrocycle’s size and the effect of the aglycone. These analogs displayed that the ring size
seems important for the biological activity of ipomoeassins.

Scheme 2.24. Synthesis of C-5 ester ipomoeassin F analogs 111 and 112.

TABLE 2.3. C-5 Aglycone Modified Analogs (IC50 Data nM)a,b
MDA-MB-231c

MCF7d MCF-10Ac

Ipomoeassin F 1

7.7

36.7

5.1

111

31.5

81.2

26.9

112

290.3

710.5

‒e

a 3-day

treatment.
Data was obtained from at least two independent experiments
(standard error <20%).
c Alamar Blue
d MTT.
e “‒” = not tested.
b

2.12.2. Synthesis of Left-Tether Modification to Study Ring Size
Last summer, Shi et al. became interested in the role the of the macrocycle ring size for the
overall cytotoxicity of ipomoeassin F 1. Unlike 5-oxa analogs 111 and 112, for this study focused
on the size and not any bioisosteric substitutions or modifications. For most resin glycosides, the
aglycone is made up of jalapinolic acid, (11S)-hydroxyhexadecanoic acid. The left tether of the
aglycone was easier to modify because this moiety was introduced later in the synthesis (Scheme
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2.17). So, two carboxylic acids, 4-oxo-7-octenoic acid 113 and 4-oxo-10-undecenoic acid 114,
were synthesized from Scheme 2.25.69 The route for these two intermediates followed the same
procedure as 4-oxo-8-nonenoic acid 14. Like the synthesis of 4-oxo-8-noenoic acid 14 (Scheme
2.3), the yields for these two carboxylic acids 129 and 130 were rather low (12 % and 21%). The
main reason for the low yield was any excess Grignard reagents again to the C-4 ketone, forming

Scheme 2.25. Preparation of the 4-oxo-7-octenoic acid 113 and 4-oxo-10-undecenoic
acid 114.
the tertiary alcohol. Both carboxylic acids (CA) 113 and 114 will be used to prepare analogs to
study the importance of the macrocycle size.

2.13. Potential Modifications to the C-3-Glucosyl Moiety

Since a significant amount of time was spent trying to obtain the acrylic analogs 96-98,
research began on further potential modification to the tig moiety of ipomoeassin F. At the time,
we believed the C-3-Glcp acrylic analogs 96-98 were obtainable through the developed synthesis
route and the difficulties were related to the purification in the final step (Scheme 2.22). From the
cinn analog 93, it was known aromatic modifications to the tig moiety resulted in a loss in
cytotoxicity, while the crotonic analog 96 showed that small modifications of the α,β-methyl
groups could be performed without greatly affecting the potency of ipomoeassin F 1. Based on
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these beliefs, the crotonic analog 96 could act as a structural scaffold for further modifications to
the tig moiety because of its comparable activity and structural similarity to ipomoeassin F 1.

Figure 2.12. The structures of a possible chemical probe of ipomoeassin F 1.
Based on these findings, we wanted to determine if further modifications could be made to the tig
moiety to develop a chemical probe to push ipomoeassins research into new area of drug discovery
and chemical biology (Figure 2.12).
2.13.1. The α,β-Unsaturated Acids Containing an Alkyne

The first group of potential modifications were based on the elongation of crotonic acid
(Scheme 2.26). Potentially, the terminal alkyne could be used for future click chemistry studies
and target identification. These acids were chosen because of their length and methylene carbons
between the α,β-double and terminal alkyne. If the carbon-chain of the acid was shorter, the
terminal alkyne proton would have to be protected. The α,β-unsaturated acids 117-119 were
prepared from the commercially available ethylene glycol 120 and the alkyne alcohols 121-122 in
three-four steps. The ethyl esters 124 and 125 were obtained using a one-pot Swern oxidation
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reaction from 121 and 122 respectively, followed by a Horner-Wadsworth-Emmons (H-W-E)
reaction. The conditions for the oxidation reaction and the H-W-E were modified from chemistry
developed by Masamune and Roush conditions developed in the late 1980s.59-61 The ether 121
was obtained from a Williamson ether synthesis of ethylene glycol 120 and propargyl bromide.
Then, the same Swern oxidation/H-W-E reaction conditions were utilized to obtain 123 from the
2-(2′-propynloxy) ethanol 120. Next, a hydrolysis reaction was performed with ethyl esters 124126 to give the corresponding acids 117-119. Because of potential polymerization and purification

Scheme 2.26. Potential alkyne modifications for C-3-Glcp ipomoeassin F analogs.
concerns with acids 117-118, only the (2E)-4-(2′-propynloxy)but-2-enoic acid 119 was used to
modify the C-3-Glcp moiety. Unfortunately, an inseparable mixture of two isomers was obtained
for the one-pot deprotection of the C-4 cyclic acetal and the -OTBS group at 3-O-Fucp.
2.13.2. Conjugated α,β-Unsaturated Double Bond Acids from Maleic Anhydride
The second set of potential modifications of the C-3-Glcp are shown in Scheme 2.27. The
propargyl maleic acid 128 was obtained by a ring opening reaction of the maleic anhydride 126
and propargyl alcohol 127. Then, the cis acid 128 was isomerized with cat. AlCl3 to give the trans-
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configured propargyl fumaric acid 129 in 77%. Like the cinn analog 93, these modifications
contain a conjugated α,β-unsaturated double bond. So, analogs based on the conjugated double

Scheme 2.27. Preparation the propargyl maleic acid 128 and propargyl fumaric acid 129
for C-3-Glcp modifications.
bond could be prepared easier than the acrylic analogs (Section 2.11).

Unfortunately, the

regioselective introduction of propargyl acids 128-129 to the diol intermediate 2 has not been
attempted but could be performed to study modifying the C-3-Glcp.
2.13.3. Synthesis of 4-OTBS-Crotonic Acid for the Development of a Chemical Probe
The third modification was based on crotonic acid (Scheme 2.28). This modification is
potentially interesting because the C-4 hydroxyl group could act as a handle for further
derivatization to develop a functional chemical probe (Figure 2.9). The route to reach 4-OTBS
crotonic acid 133 takes five transformations from the maleic anhydride 126 developed by Ortiz et
al. in 2015.62 The first step was altered from the published route, where the maleic anhydride 126
was opened up by ethanol to give the monoethyl maleic acid. Then, cat. AlCl3 was used to
isomerize the double bond to give the trans, monoethyl fumaric acid 130. We chose to perform
both transformations in one-pot, by refluxing the maleic anhydride 126 and ethanol in THF with
cat. AlCl3. The isomerization of the double bond to give the monoethyl fumaric acid 130 was
monitored by NMR and the difference in the coupling constant of the cis vs. trans double bond
(trans J = 16 Hz and cis J = 12 Hz). Next, a selective reduction of the carboxylic acid 130 to the
allyl alcohol 131 was performed in the presence of borane dimethylsulfide, followed by protection
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Scheme 2.28. The synthesis of 4-OTBS-crotonic acid 133 for the alteration the C-3-Glcp of
ipomoeassin F 1.
of the C-4 hydroxyl group with tert-butyldimethylsilyl chloride (TBSCl) to give 132 in 39% over
two steps. Finally, a hydrolysis of ethyl ester 132 with NaOH in THF:MeOH:H2O (4:1:1),
followed by acidification of the solution (pH = 4-5), gave the acid 133. The hydrolysis proved to
be more difficult than anticipated. The reaction could not be performed in MeOH and the -OTBS
was very acid-labile making the work-up very tedious. If the hydrolysis was attempted in MeOH,
a mixture of acid 133 and methyl 4-OTBS-crotonate would be obtained.
2.14. Future Studies on the C-3-Glcp Moiety of Ipomoeassin F
From this work, significant knowledge was gained about the importance of the tig and cinn
moieties for the overall anti-cancer activity of ipomoeassin F 1. Unfortunately, the acrylic analogs
96-98 to systematically study the α,β-methyl groups of the tig moiety were not obtainable by the
developed synthesis routes. These findings suggest the α,β-unsaturated double bond at C-3-Glcp
must be at least tri-substituted (tig moiety, ipomoeassin F 1) or part of an sp2 conjected system
(cinn analog 93) to easily and successfully study the C-3-Glcp moiety of ipomoeassin F 1.70 The
following section presents three potential classes of C-3-Glcp analogs that could be easily prepared
and applied to the developed synthesis route.
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2.14.1. Tetra-Substituted α,βUnsaturated Double Bond Analog
The first potential modification is 2,3-dimethylbutenoic acid 132 (Scheme 2.29). This
modification would examine the importance of the α,β-methyl groups of the tig moiety, while
possibly allowing easier purification than the less substituted acrylic analogs 96-98. The 2,3dimethylcrotonic acid 136 is commercially available (Sigma-Aldrich $509/1 g), but it can be
synthesized in two steps from triethyl 2-phosphonopionate 134 and acetone 135.71 Then, the 2,3dimethylcrotonate analog 137 can be obtained in two steps from the diol 2 through a regioselective
esterification and the one-pot de-protection of the transient protecting groups.

Scheme 2.29. Synthesis of 2,3-dimethylcrotonic analog 137.

2.14.2. Tri-substituted α,β-Unsaturated Double Bond Acids for Click Chemistry
Some potential C-3-Glcp modifications are shown in Scheme 2.30.

These possible

modifications could be used for Click Chemistry and are like the ones shown in Scheme 2.26. The
only difference is that these analogs contain a tri-substituted α-β-unsaturated double bond that
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closely mimics the tig moiety in ipomoeassin F 1. We do not believe that the terminal alkyne
proton should to be protected, based on a C-4-Glcp cinn analog that contained a propargyl group.
The major difference from Scheme 2.26 comes from triethyl 2-phosphonopionate 134 needed to
form on the tri-substituted double bond, instead of triethyl phosphonoacetate. An H-W-E reaction
can be adapted from chemistry published by Ambudka and Tang to form the ethyl ester 137.71-73
Then, a hydrolysis reaction with NaOH or LiOH can afford the acids 138. After preparing the
carboxylic acids, a regioselective trans-esterification can be performed between the acids 138 and
the diol intermediate 2, followed by removal of the transient protecting groups to obtain C-3-Glcp

Scheme 2.30. Potential modification for click chemistry based on the tri-substituted tiglic
acid.
ipomoeassin F analogs (Scheme 2.22).
2.14.3. Terminal Hydroxyl Modification for Cell Imaging or Target Identification
The final class of potential analogs 139 discussed are based on the 4-hydroxylcrotonic
modification (Figure 2.13). The hydroxyl group can act as a handle to introduce different structural
motifs to the tig moiety. Analogs 140-142 could be utilized in cellular localization studies and
protein pull-down experiments for activity-based protein profiling (ABPP). The coumarin 141
and biotin 142 modifications should be easily incorporated into the synthesis for the studies of the
C-3-Glcp of ipomoeassin F; however, the BODIPY analog 140 may be more difficult to synthesize
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because of stability concerns. If the BODIPY analog 140 is not obtainable, other fluorescent
molecules can be used, such as pyrene or anthracene.

Figure 2.13. Potential analogs 139-141 based on 4-hydroxyl tig mod. of ipomoeassin F 1.

The syntheses of the modified 4-hydroxyl tig acids 143 are shown in Scheme 2.31. Route
1 is a more direct path to achieve the tig modifications 143, while route 2 offers a back-up plan if
the hydroxyl group needs be protected with a silyl ether. For route 1, the 144 diol can be partially
oxidized by MnO2, then an H-W-E reaction can be performed to get the ethyl ester alcohol 145.74,
75

At this point, the potential modifications can be introduced through a donor-acceptor reaction

(method 1), a tosylate (method 2), or an inorganic base method (method 3). Method 1 or 2 should
be the ideal process to install the modifications because an inorganic base (method 3) could
potentially cause hydrolysis of the ethyl ester 146. The last step in route 1 is hydrolysis of the
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Scheme 2.31. The possible synthesis route of 4-hydroxyl tig modifications for
ipomoeassin F analogs.

ethyl ester 145 to achieve the carboxylic acids 143. Route 2 is a few steps longer but allows for
the protection of one of the alcohols with a silyl ether. First, the alcohol 144 can be protected with
TBSCl by using sodium hydride to give 147. Then, an H-W-E reaction can be performed, and the
TBS group can be removed with TBAF to give the primany alcohol 148. The last two steps in
route 2 utilized the same transformations as in route #1 to get the carboxylic acids 143. Like the
other potential C-3-Glcp modification, these tig modifications can be introduced to the diol 2 in
the next to last step through a regioselective esterification. The modifications to the C-3-Glcp
analogs presented in this section build on cinn analog 93 and acrylic analogs 96-98 (Section 2.11).
These C-3-Glcp modifications could limit some of the problems experienced with the acrylic
analogs 96-98 and provide new insights into the mechanism of action (MOA) of ipomoeassin F 1.
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2.15. Prospective and Future Direction for C-3-Glucosyl Modifications of Ipomo. F
Many challenges were encountered designing the synthesis route for late-stage
modification of the C-3-Glcp moiety of ipomoeassin F 1. The previous syntheses of ipomoeassin
F 1, provided a firm base to start designing a synthesis route. We knew the RCM strategy would
be the best method to construct the macrocycle and the increased nucleophilicity of C-3-OH could
be utilized to perform regioselective transformations.6, 7, 9, 15 To develop a convergent synthesis
route, the four moieties or building blocks of ipomoeassin F 1 were prepared separately (Section
2.2-2.5). This made the synthesis more efficient and allowed for modifications of the different
building blocks without greatly affecting the rest of the molecule. The synthesis of the (4S)nonenol 10 and the Fucp acceptor 9 were straight forward and proceeded as expected. The (4S)nonenol 10 was prepared from the (S)- epichlorohydrin 11 in three steps. While, the Fucp acceptor
9 was synthesized in five steps from the D-Fucp 13. During the scaling-up process, a cheaper
starting material needed to be utilized for a multi-gram synthesis. Diacetone-D-Gal 21 provided a
cheaper starting material for the Fucp acceptor 9 but did make the synthesis route 3-4 steps longer.
The synthesis of the Glcp donor 61 and 4-acetal-8-nonenoic acid 5 proved to be more
difficult. The criteria to develop an efficient, effective synthesis route for the Glcp donor were
transient protecting groups at the C-3-Glcp and C-4/C-6-Glcp positions. After a few ineffective
synthesis routes were investigated, we started to think about using the same transient group at C2/C-3 Glcp (Section 2.7). Lev groups were chosen as the transient protection for these two
positions. The lev groups helped form the β-(1→2)-disaccharide (neighboring group participation)
and allowed for an orthogonally deprotection in the late-stage of the synthesis (H2NNH2. AcOH).
Unfortunately, we found out the C-4 ketone was transformed to the stable C-4 hydrazone during
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the lev de-protection step. At this point a decision had to be made about the direction of the
synthesis, did we want to design another Glcp donor or protect the C-4 ketone? Since, the Glcp
donor 61 had already been prepared on a multi-gram scale, we chose to protect the C-4 ketone to
for the preparation of 4-acetal-8-nonenoic acid 5. This did make the synthesis of the left-tether of
the glycone four steps (previous syntheses, one step), but did allow for late-stage de-protection of
the C-2/C-3-lev groups (Section 2.9).
The macrocycle was successfully constructed by an RCM/hydrogenation reaction scheme
(Section 2.8 and 2.10). Since we chose to install the α,β-unsaturated esters in the late stage,
stronger hydrogenation conditions could be used reduce the cis/trans double bond. For the
previous syntheses, the cinn group had to be protected or a specific catalyst to achieve a selective
reduction of the cis/trans macrocycle.7-9 After the orthogonal de-protection of lev groups, a regioselective esterification to the HO-3-Glcp could be performed. Ipomoeassin F 1 and a C-3-Glcp
cinn analog 93 were completed after the de-protection of the silyl ether at C-3-Fucp (Section 2.10).
Ipomoeassin F 1, the cinn analog 93, and other two analogs 94-95 were tested against two breast
cancer cell lines to determine their IC50. When compared to ipomoeassin F 1, all the analogs were
significantly less potent (Table 2.1, µM range). Suggesting the positioning of the aromatic α,βunsaturated ester (C-4-Glcp cinn) and the small aliphatic ester (C-3-Glcp tig) provide a synergetic
contribution to the cytotoxicity of ipomoeassin F 1.
After scaling-up the versatile C-4 acetal macrocycle diol intermediate 2, we needed to
determine the importance of the α,β-methyl groups before further modifications could be made to
the C-3-Glcp moiety. So, a series of acrylate analogs 96-98 were envisioned, from a regioselective
esterification of the C-4 macrocycle diol 2 and commercially available acrylic acids. Ultimately,
this synthesis route did not allow for the preparation of the acylate analogs 96-98.
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The

regioselective esterification proceeded as expected with slight drop in yield, but difficulties were
encountered during the purifications of the final one-pot de-protection. These results lead us to
believe that the α,β-unsaturated ester must be at least tri-substituted (tig ipomoeassin F 1) or part
of the a sp2 conjugated system (C-3-Glcp cinn analog 93).
As the project concluded in the spring of 2018, we started to think about two questions.
First, is the current route better than previous synthesis routes for ipomoeassin F 1? Before the
current work, three syntheses of ipomoeassin F 1 had been published since 2009.7, 9, 15 All of these
syntheses utilized RCM for the construction of the macrocycle, and Schmidt donors for the
glycosylation reactions.11, 35, 76, 77 Each synthesis had advantages and disadvantages, but none of
the syntheses were efficient for medicinal chemistry studies of the tig moiety. The current work
built on the previous syntheses by incorporating a late-stage regioselective esterification reaction
to modify the C-3-Glcp moiety. This synthesis route can be utilized to further explore the
importance of the C-3-Glcp moiety for the bioactivity of ipomoeassin F 1.
The second question involved, “what could be the future direction for studying the C-3Glcp moiety for ipomoeassin F 1?” When thinking about the future direction of this project, it is
important to remember the lack of published literature data on ipomoeassins.19 Currently, very
little is known about the MOA of ipomoeassins.19, 39, 40 So, future work must be centered around
chemistry to develop analogs to push ipomoeassins research into new areas of drug discovery and
chemical biology. Section 2.13-14 discussed some potential modifications for the C-3-Glcp
moiety to facilitate further studies. The modifications are based on tig moiety of the natural
product (tri-substituted). We believe these modifications could limit some of the problems
experienced with the purification of the acylate analogs 96-98. These proposed analogs in could
provide vital insight into the MOA and potential biological target/targets of ipomoeassins.
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Another area of future research evolves modifications and optimization to the current
synthesis route. The synthesis of the left-tether of the aglycone was significantly longer (four steps
vs. one step) and give a lower overall yield when compared to previous syntheses (Section 2.2).
Developing a shorter, optimized synthesis route for the 4-acetal-8-nonenoic acid 5 would make
the current synthesis route more efficient. Schmidt donors were utilized for multiple glycosylation
reactions in the current route, because of their versatility and reliability.34, 43, 76 However, when
looking at the synthesis of the monosaccharides building blocks this presented a disadvantage in
the current synthesis route (Section 2.2-2.4). When preparing the Schmidt donor, we first must
selectively de-protect the anomeric group to give a hemiacetal, then make the Schmidt donor with
trichloroacetonitrile. This forced us to perform two extra chemical transformation and give a
moisture sensitive donor. Thioglycosides have been shown to be useful as donors for glycosylation
reactions. Developing a glycosylation reaction with the thioglycoside (Scheme 2.4) would
decrease the number of steps (2-3 steps) and give an air/moisture stable donor for glycosylation
reactions (β(1→2)-disaccharide). The regioselective esterification of the diol 6 and 4-acetal-8nonenoic acid 5 is another transformation that could be optimized (Section 2.7). The yield of this
reaction could not be fully optimized (<60%) and the purification of the desired product was
difficult because of the similar polarity of the triene bi-product.

These modifications and

optimizations are just a few aspects of the synthesis route that could investigated further. More
research is needed by both organic chemists and chemical biologists before ipomoeassins can reach
their full potential as a potential anti-cancer chemotherapeutic. This work provides a firm footing
for researchers to continue investigating the role of the tig moiety for the bioactive of ipomoeassin
F 1.
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2.16. Conclusion
The goal of this project was to design a synthesis route to study the role of the C-3-Glcp
moiety of ipomoeassin F 1. From a previous work, it was known the C-3-Glcp position was
important to the overall activity of ipomoeassin F 1, but a systematic study of the tig moiety had
not been performed. The developed synthesis route for the C-3-Glcp modified ipomoeassin F
analogs highlighted multiple regioselective reactions and improved reaction conditions over
previous syntheses. The two glycone moieties (Glcp 12 and Fucp 13) were prepared separately
from cheap, commercially available starting materials through straightforward transformations and
(1→2)-β-disaccharide 7 was formed from a regioselective glycosylation reaction. The aglycone
moiety was, also, divided into two parts, (4S)-nonenol 10 and 4-acetal-8-nonenoic acid 5. These
two moieties of the aglycone were connected after the glycosylation reaction through an RCM
reaction forming the macrocycle of ipomoeassin F 1. Separately preparing the two moieties
allowed for multiple aglycone analogs to be prepared without modifications complex (1→2)-βdisaccharide. Completion of the C-4 ketone macrocycle diol intermediate 71 was vital for the
developed synthesis route. Through a regioselective esterification reaction, ipomoeassin F 1 and
a cinn analog 93 analog were successfully synthesized. Proposed acrylic analogs 96-98 were not
obtainable through the developed synthesis route. A few different reaction conditions and eluent
systems were attempted without significant success. Through the synthesis of ipomoeassin F 1,
the cinn 93 and crotonic analog 96, this work provided new insights into the importance of the C3-Glcp moiety of ipomoeassin F 1. Aromatic modifications like the cinn analog 93 greatly
decrease the bioactivity, while a small modification like the crotonic analog 96 retained most of
the cytotoxicity of ipomoeassin F 1. The developed synthesis route provided a simple, scalable,
and effective synthesis route to study a vital moiety of ipomoeassin F 1. Future work based on
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established synthesis route and knowledge gained through this project will continue to push
ipomoeassins research into new areas of chemical biology and drug discovery research.
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CHAPTER 3. EXPERIENTIAL PROCEDURE

3.1. General Methods
Reactions were carried out in oven-dried glassware. All reagents were purchased from
commercial sources and were used without further purification unless specified. Except stated
otherwise, all reactions were carried out under a nitrogen atmosphere and monitored by thin layer
chromatography (TLC) using Silica Gel GF254 plates (Agela) with detection by charring with 5%
(v/v) H2SO4 in EtOH or by visualizing in UV light (254 nm). Column chromatography was
performed on silica gel (230–450 mesh, Sorbent). The ratio between silica gel and crude product
ranged from 100 to 50:1 (w/w). NMR data were collected on a Bruker 300 or 400 MHz NMR
spectrometer and a Bruker 300 or 400 MHz system.

1

H NMR spectra were obtained in

deuterochloroform (CDCl3) with chloroform (CHCl3, δH = 7.27 for 1H) as an internal reference.
C NMR spectra were proton decoupled and were in CDCl3 with CHCl3 (δC = 77.0 for 13C) as an

13

internal reference. Chemical shifts are reported in ppm (δ). Data are presented in the form:
chemical shift (multiplicity, coupling constants, and integration). 1H data are reported as though
they were first order. The errors between the coupling constants for two coupled protons were less
than 0.5 Hz, and the average number was reported. Proton assignments, when made, were done so
with the aid of COSY NMR spectra. For some compounds, HSQC and HMBC NMR were also
applied to assign the proton signals. Optical rotations were measured on an Autopol III Automatic
Polarimeter at 25 ± 1 oC for solutions in a 1.0 dm cell. High resolution mass spectrum (HRMS)
and were acquired in the ESI mode.
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3.2. Synthesis of the Aglycone of Ipomoeassin F

3.2.1. Preparation of the (4S)-nonen-4-ol

(2S)-1-chloro-2-heptanol 15. A mixture of Mg (4.08 g, 144.4 mmol), cat I2 and Dry THF
(120 mL) were heated to reflux (68-70 oC). While heating 0.5 mL of bromo-butane was added to
the mixture. One the refluxing temperature was reached, the bromo-butane (17.4 mL, 144.4 mmol)
was added dropwise (bubbling N2 atmosphere) to the mixture. After all the Mg had been converted
to the Grignard reagent the solution was cooled to RT. The butyl magnesium bromide was added
dropwise to a solution of (S)-epichlorohydrin 11 (10.16 g, 130.3 mmol), CuCN (1.17 g, 116.0
mmol) at -78 oC over 1 hr. The reaction was slowly warmed to -20 oC over 3-4 hrs (green to black
prep.). The reaction was quenched with sat. aq. NH4Cl (200 mL) and the solvent removed under
reduced pressure. The organic layer was extracted with Et2O (250 mL ∙ 2), dried over NaSO4,
filtered, and solvent carefully removed under reduce pressure. The α-chloro alcohol 15 was taken
to the next step without further purification. 1H NMR (300 MHz, CDCl3) δH 3.80 (m, 1H, 2 CH),
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3.49 (dd, J = 6.12 Hz, 1H Cl-CH2), 2.27 (m, 1H), 1.52 (m, 2H), 1.31 (m, 6H), 0.89 (t, J = 6 Hz,
3H, ‒CH3).

13

C NMR (CDCl3, 75 MHz) δC 71.5 (‒CH2), 50.6 (‒CH2), 34.3 (‒CH2), 31.7 (‒CH2),

25.2 (‒CH2), 22.6 (‒CH2), 14.0 (‒CH3). The 1H and

13

C NMR were identicatial to published

spectra data.17

2-pentyl-(2S)-oxirane 16. NaOH (36.0 g, 361.2 mmol) was added to a solution of the crude
α-chloro alcohol 15 (18.14 g, 120.4 mmol) at RT and allowed stirred for 4-5 hrs. The reaction was
monitored by TLC (silica, Hex-EtOAc 4:1, Rf = 0.74). Upon completion the reaction poured into
ice water and extracted with Et2O (200 mL ∙ 3). The organic layers were combined, dried over
NaSO4, filtered, and the Et2O was removed under reduced pressure. The epoxide 16 was used
direct in the next step. 1H NMR (CDCl3, 400 MHz) δH 2.94–2.88 (m, 1 H), 2.75 (dd, J = 5.0, 4.0,
Hz, 1H), 2.46 (dd, J = 5.0, 2.8 Hz, 1H), 1.56–1.28 (m, 8H), 0.90 (m, 3H, ‒CH3).13C NMR (100
MHz, CDCl3) δC 195.6 (O‒C‒O), 64.2 (O‒CH2), 32.2(‒CH2), 31.3 (‒CH2), 25.4 (‒CH2), 22.6 (‒
CH2), 14.1 (‒CH3). The spectroscopic data matched previously published literature data.18, 19

(4S)-nonenol 10. Vinylmagnesium bromide (175 mL, 109.4 mmol) was added dropwise
at -78 oC to a solution of the crude epoxide 16 (9.61 g, 66.6 mmol), CuCN (845 mg, 66.6 mmol),
and Dry THF (200 mL). The reaction was kept at -78 oC for 0.5 hrs and slowly warmed to 0 oC
over 3-4 hrs. The reaction was quenched with sat. aq. NH4Cl (150 mL) and the THF removed
under reduce pressure. Th organic layer was extracted with Et2O (225 mL ∙ 3) and the combined
organic layers washed with BRINE (200 mL). The organic layer was dried over NaSO 4, filtered,
and solvent removed under reduced pressure. The oil was purified by column chromatography
(silica, Hex-EtOAc, 10:1 → 6:1) to give the alcohol 10 in 64% (12.12 g) from (S)-epichlorohydrin.
1

H NMR (300 MHz, CDCl3) δH 5.84 (dd, J =17.2, 10.2, 7.1 Hz, 1H, HC=), 5.19–5.09 (m, 2H,
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=CH2), 3.65 (br, s, 1H, C‒OH), 2.37–2.25 (m, 1H, HC‒O), 2.20–2.07 (m, 2H), 1.67–1.56 (m, 2H),
1.53–1.21(m, 8H), 0.89 (t, J = 6.6 Hz, 3H, ‒CH3).

C NMR δC (75 MHz, CDCl3) δC 134.9 (=CH),

13

118.0 (H2C=), 70.7 (C‒H), 41.9 (‒CH2), 36.8 (‒CH2), 31.8 (‒CH2), 25.3 (‒CH2), 22.6 (‒CH2),
14.0 (‒CH3). The spectroscopic data matched those previously reported.20-22

3.2.2. Synthesis of 4-oxo-8-nonenoic acid

4-oxo-8-nonenoic acid 14. Mg (1.64 g, 6.8 mmol), I2 (trace), and, 5-bromopentene 18 (few
drops, initiate the Grignard reaction) Dry THF (100 mL) were combined, then heated to reflux
under a N2 atmosphere. Then, 5-bromopentene 18 (8.1 mL, 67.1 mmol) was added to the reaction
mixture dropwise over 30 mins and continued to heat at reflux for 2 hrs (trace amount of Mg). The
Grignard formation was cooled to RT, while succinic anhydride (7.35 g, 73.8 mmol) in THF (60
mL) cooled to 0oC. After cooling to RT, the Grignard reagent was added dropwise (1 hr.) to the
SA 17 and THF, then slowly warmed to RT overnight. TLC showed the reaction complete
(Hex:EtOAc:AcOH, 79.5:20:0.5). 1 M HCl (75 mL) quenched the reaction and the mixture was
stirred for 10 mins. Then, the THF was removed under reduced pressure. The aqueous layer was
the extracted with DCM (75 mL ∙ 2) then acidified with contc. HCl (pH =2-3). The aqueous layer
was extracted with DCM (40 mL ∙ 3). The combined organic layers were dried with NaSO4,
filtered, and removed under reduced pressure. Purification by column chromatography gave the
acid 14 in 32% (silica, Hex–EtOAc–AcOH 100:0:0→75:25:0.5). 1H NMR (400 MHz, CDCl3) δH
5.81-5.71 (m, 1H), 5.04-4.97 (m, 2H), 2.72 (t, 2H, J = 6.4 Hz), 2.63 (t, 2H, J = 6.4 Hz), 2.46 (t,
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2H, J = 7.2), 2.05 (t, 2H, J = 6.0 Hz), 1.70 (app. qui., 2H).

13

C NMR (100 MHz, CDCl3) δC 208.7

(C=O), 178.1, 137.8 (C=C), 115.9 (C=C), 41.7, 36.8, 32.9, 27.7, 24.7. The 1 H and 13C NMR data
were in accordance with the literature.23-25

3.3. Preparation of the Fucosyl Acceptor

3.3.1. Preparation of the D-Fucose from Diisopropylidene -Galactose

1,2:3,4-bis-O-(1-methylethylidene)-6-deoxy-6-iodo-α-D-galactopyranose 22.

Toluene

(500 mL) was added to flask of the diisopropylidene-galactose 21 (52.28 g, 200.8 mmol), PPh3
(63.21 g, 241.0 mmol), and imidazole (49.22 g, 723.1 mmol) at RT. Then, I2 (63.21 g, 241.0
mmol) was added to the reaction mixture and allowed to stir at 80 oC overnight as the reaction
turned a dark brown color. After completion of the reaction (silica, Hex-EtOAc 2:1, Rf = 0.76), the
reaction mixture was quenched with MeOH (10 mL), and the resulting solution was concentrated
to a residue. The reaction mixture was filtered through a pad of Celite and Na2S2O3 added until the

122

slurry turned a almost clear (yellow). The aqueous layer was extracted with DCM (400 mL∙2),
dried over NaSO4, and the solvent evaporated under reduced pressure. The syrup was purified by
column chromatography (silica, Hex-EtOAc 5:1→3:1) to give 22 in 70% (52.47 g). 1H NMR
(CDCl3, 400 MHz) δH 5.54 (d, J = 5.1 Hz, 1H, 1-H-Glcp), 4.61 (dd, J = 7.9, 2.5 Hz, 1H), 4.41
(dd, J = 7.9, 1.8 Hz, 1H), 4.30 (dd, J = 5.1, 2.5 Hz, 1H), 3.95 (td, J = 7.0, 1.8 Hz, 1H), 3.32 (dd, J
= 10.1, 6.9 Hz, 1H), 3.20 (dd, J = 10.1, 7.2 Hz, 1H), 1.55 (s, 3H, ‒CH3), 1.45 (s, 3H, ‒CH3), 1.36
(s, 3H, ‒CH3), 1.37 (s, 3H, ‒CH3), 1.33 (s, 3H, ‒CH3); 13C NMR (CDCl3, 100 MHz) δC 109.6 (O‒
C‒O), 108.8 (O‒C‒O), 96.8 (C-1), 71.7, 71.1, 70.6, 69.1, 26.1 (‒CH3), 26.0 (‒CH3), 25.1 (‒CH3),
24.6 (‒CH3). The 1H and 13C-NMR data matched previously published reports.33, 34

1,2:3,4-bis-O-(1-methylethylidene)-6-deoxy-α-D-galactopyranose 23. Pd/C (10 g) was
added to a solution of the iodo intermediate 22 (31.23 g, 84.3 mmol), DIEA (21.9 mL, 126.5
mmol), and MeOH (150 mL). Under a H2 atmosphere, the pressure was increased to 80 pounds
per square inch (PSI) and allowed to stir at RT overnight. TLC (silica, Hex-EtOAc 2:1) showed
the reaction was complete and the reaction was quenched with NEt3 and filtered through a pad of
Celite. The crude 6-deoxy-Gat 23 was used directly in the next step without further purification.
1

H NMR (400 MHz, CDCl3) δH 5.57 (d, J = 5.2 Hz, 1H, H-1-Fucp), 5.48 (dd, J = 8.1 Hz, 2.8 Hz,

1H, H-3-Fucp), 4.26 (dd, J = 5.3 Hz, 2.4 Hz, 1H, H-2-Fucp), 4.06 (dd, J = 1.6 Hz, 8.0 Hz, 1H, H4-Fucp), 3.89 (ddd, 1H, H-5-Fucp), 1.50 (s, 3H, ‒CH3), 1.44 (s, 3H, ‒CH3), 1.33 (s, 3H, ‒CH3),
1.30 (s, 3H, ‒CH3), 1.23 (d, J = 6.4 Hz, 3H, ‒CH3). 13C NMR (75 MHz, CDCl3) δC 109.0, 108.3,
96.6, 73.5, 70.9, 70.4, 63.5, 26.0 • 2, 24.9, 24.4, 15.9. The spectroscopic data matched those
previously reported.35, 36
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6-deoxy-α,β-D-galactopyranose 13. The crude 6-deoxy-gataltose intermediate 23 (44 g)
was dissolved in 80% acetic acid (400 mL) and heated to reflux (125 oC). The reaction was
allowed to stir at reflux overnight, when TLC (silica, Hex-EtOAc 6:1, Rf = 0.11) indicated the
reaction was finished. The reaction was cooled, then co-evaporated with Tol (200 mL∙ 3). The
slurry was dissolved in sat. aq. NaHCO3 (300 mL) and extracted with DCM (300 mL ∙ 3). The
combined organic layers were dried over NaSO4, filtered, and solvent removed under reduce
pressure. The crude D-Fucp 13 was used directly in the next step without further purification. 1H
NMR (400 MHz, D2O) δH 5.05 (d, J = 3.8 Hz, 1H, 1-H-Fucp), 4.41 (d, J = 7.9 Hz, 1H, H-1-Fucp),
4.06 (q, J = 6.7 Hz, 1H, H-5-Fucp), 3.74-3.64 (m, 4H, H-2-Fucp, H-3-Fucp, H-4-Fucp, H-5-Fucp),
3.59 (d, J = 2.8, 4-OH-Fucp), 3.50 (dd, J = 10.1 Hz, 3.4 Hz, 3-OH-Fucp), 3.31 (dd, J = 10.1 Hz,
7.9 Hz, 2-OH-Fucp), 1.10 (d, J = 6.3 Hz, 3H, H-6-Fucp), 1.07 (d, J = 6.4 Hz, 3H, H-6-Fucp).37, 38

1,2,3,4-O-tetracetate-6-deoxy-α,β-D-galactopyranose 24. The crude D-Fucp 13 (32.1 g,
195 mmol) was dissolved in acetic anhydride (75 mL), Py (140 mL), cat DMAP. The reaction
was allowed to stir at RT overnight, while turning a deep orange color. TLC (silica, Hex-EtOAc
2:1, Rf = 0.61) showed the reaction to be complete and the Py/AA was co-evaporated with Tol
(200 ∙ 3). The slurry was dissolved in sat. aq. NaHCO3 (300 mL) and extracted with DCM (300
mL ∙ 3). The combined organic layers were dried over NaSO4, filtered, and solvent removed under
reduce pressure. The residue was purified by column chromatography (silica, Hex-EtOAc,
4:1→3:1) to the peracetylated D-Fucp 66 in 48% three steps from 13. 1H NMR (400 MHz, CDCl3)
δH 6.30 (d, J = 3.0 Hz, 1H), 5.65 (d, J = 8.5 Hz, 1H), 5.30-5.23 (m, 5H), 5.05 (dd, J = 10.5, 3.5
Hz, 1H), 4.24 (q, J = 6.5 Hz, 1H), 3.93 (q, J = 6.5 Hz, 1H), 2.15-1.95 (series of s, 3H, ‒CH3), 1.19
(d, J = 6.5 Hz, 3H, ‒CH3), 1.12 (d, J = 6.5 Hz, 3H, ‒CH3). 13C NMR (100 MHz, CDCl3) δC 170.48,
170.46, 170.11, 169.94, 169.90, 169.4, 169.1, 166.4, 92.2, 89.9, 71.3, 70.6, 70.3, 70.0, 68.0, 67.9,

124

67.3, 66.5, 22.1, 20.9, 20.8, 20.63, 20.60, 20.57, 20.53, 15.92, 15.91. The 1H- and 13C-NMR were
identical to previous published data.39-41
3.3.2. Synthesis of the Fucosyl Acceptor from D-Fucose

2,3,4-O-triacetate-6-deoxy-α,β-D-galactopyranose 24i.

The peracetylated D-Fucp 24

(10.55 g, 31.7 mmol) was dissolved in Dry THF (150 mL) and BnNH2 (4.6 mL, 47.6 mmol). The
reaction was stirred at RT overnight and TLC showed the reaction to be complete (silica, HexEtOAc 1:1, Rf = 0.54, 0.49). The THF was removed under reduced pressure, the slurry diluted
with DCM (200 mL), washed with 5% HCl, then sat. aq. NaHCO3. The organic layer was
collected, dried over NaSO4, filtered, and DCM removed under reduced pressure. The syrup was
purified by column chromatography (silica, Hex-EtOAc, 2:1→1:2) to give the α,β-hemiacetal Dfucose 24i in 77% (7.15 g) and carried directly to the next step.42

1-(2,2,2-trichloroethanimidate)-2,3,4-triacetate-6-deoxy-α,β-D-galactopyranose

25.

Trichloroacetonitrile (12.8 mL, 128 mmol) and DBU (0.68 mL, 3.2 mmol) were added to a solution
of DCM (100 mL) and the hemiacetal 24i (9.30 g, 32.0 mmol) at RT. The reaction was stirred at
RT for 3-4 hrs, when TLC (silica, Hex-EtOAc 1:1, Rf = 0.71 and 0.77) indicated starting had been
used up. The reaction was quenched with NEt3 (0.5 mL) and the DCM reduced under reduced
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pressure. The residue was purified by column chromatography (silica, Hex-EtOAc, 4:1→1:1,
0.1% NEt3) to give the α,β-Schmidt donor 25 in 86% (10.6 g). 1H NMR (300 MHz, CDCl3) δH
8.64 (s, 1H), 6.59 (d, J = 3.5 Hz, 1H), 5.51-5.35 (m, 3 H), 4.43-4.37 (br q, J= 6.6 Hz, 1 H), 2.22,
2.05, and 2.04 (3 s, 3H), 1.15 (d, J = 6.6 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δC 170.4-170.0 ∙
3, 161.1, 93.9, 77.2, 70.5, 67.9, 66.9, 67.5, 20.7-20.6 ∙ 3, 15.9. The 1H and 13C NMR data were
identical to the published literature data.43, 44

((1S)-1-(2-propen-1-yl))hexyl-,2,3,4-O-triacetate-6-deoxy-β-D-galactopyranoside

26.

The Schmidt donor 25 (11.6 g, 26.7 mmol), (4S)-nonenol 11 (3.8 g, 24.0 mmol), and 4 Å MS (11
g) were dissolved in Dis. DCM (100 mL) and cooled to −10 °C over 30 mins. TMSOTf (400 μL,
2.7 mmol) was slowly added to the mixture and the reaction mixture was slowly warmed to RT
and was stirred for 1-3 hrs. TLC (silica, Hex-EtOAc, 3:1, Rf = 0.59) indicated that the all the
acceptor had been consumed. The reaction mixture was quenched with NEt3 (0.5 mL) and filtrated
through a pad of Celite. The filtrate was under reduced pressure to give a residue, then purified
by column chromatography (silica, Hex:EtOAc, 8:1 → 4:1) to give intermediate 26 in a 85% (9.4
g) as a yellowish syrup. [α]25D −9.4 (c 1 CHCl3); 1H NMR (400 MHz, CDCl3) δH 5.82−5.70 (m,
1H, CH2=CHCH2−), 5.23−5.11 (m, 2H, H-4-Fucp, H-2-Fucp), 5.08−4.96 (m, 3H, H-3-Fucp,
CH2=CHCH2−), 4.47 (d, J = 7.7 Hz, 1H, H-1-Fucp), 3.80−3.73 (m, 1H, H-5-Fucp), 3.65−3.58 (m,
1H, −CH2CHCH2−), 2.25−2.20 (m, 2H), 2.16 (s, 3H, CH3C=O), 2.02 (s, 3H, CH3C=O), 1.98 (s,
3H, CH3C=O), 1.63−1.46 (m, 2H), 1.39−1.22 (m, 6H), 1.20 (d, J = 6.4 Hz, 3H, H-6-Fucp), 0.88
(t, J = 6.7 Hz, 3H, ‒CH3).

13

C NMR (100 MHz, CDCl3) δC 170.9 170.3, 169.4, 134.4, 117.0,

100.4, 80.2, 71.3, 70.3, 69.3, 68.9, 38.4, 34.4, 31.7, 24.1, 22.5, 20.9, 20.7, 20.6, 16.1, 14.0. The
spectroscopic data were in accordance with the literature reports.45, 46
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[(1S)-1-(2-propen-1-yl)]hexyl-6-deoxy-β-D-galactopyranoside 27.

NaOMe (cat) was

added to a solution of Fucp 26 (12.2 g, 29.4 mmol) and MeOH (150 mL) at RT. The reaction was
stirred at RT overnight, while being monitored by TLC (silica, Hex-EtOac, 1:1 Rf = 0.15). The
reaction was neutralized with Amberlite IR-120 (H) ion exchange resin and filtered. The solvent
was removed under reduced pressure. The residue was purified by column chromatography (silica,
Hex-EtOAc, 2:1→1:1) to give the triol 27 in 85% (7.26 g). [α]25D −21.2 (c CHCl3); 1H NMR (400
MHz, CDCl3) δH 5.91−5.78 (m, 1H, CH2=CHCH2−), 5.20−5.02 (m, 2H, CH2=CHCH2−), 4.24 (d,
J = 7.6 Hz, 1H, H-1-Fucp), 3.74−3.53 (m, 5H, H-2-Fucp, H-3-Fucp, H-4-Fucp, H-5-Fucp,
−CH2CHCH2−), 3.36 (d, J = 4.8 Hz, 1H, ‒OH), 2.95 (br, 1H, ‒OH), 2.74 (d, J = 5.6 Hz, 1H, -OH),
2.40−2.22 (m, 2H), 1.67−1.48 (m, 2H), 1.42−1.21 (m, 9H), 0.89 (d, J = 6.9 Hz, 3H, H-6-Fucp).
C NMR (100 MHz, CDCl3) δC 134.9, 117.7, 102.3 (C-1), 79.2, 73.9, 72.1, 71.6, 70.5, 38.6, 34.7,
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31.8, 24.8, 22.6, 16.3, 14.1. The 1 H and 13C NMR data were in accordance with the literature.45,46

[(1S)-1-(2-propen-1-yl)]hexyl-6-deoxy-3-O-[(1,1-dimethylethyl)dimethylsilyl]-β-Dgalactopyranoside 9. Method 1. The triol 27 (3.37 g, 11.6 mmol) and the 1H-imidazole (2.38 g,
35.0 mmol) was dissolved in the minimal amount of the DMF (35 mL). After the reaction was
cooled to -10 oC, TBSCl (2.29 g, 15.1 mmol) was added to the reaction. The reaction was slowly
warm to RT and stirred for additional 2-3 hrs. When the TLC (silica, Hex-EtOAc 6:1, Rf = 0.69)
showed the reaction was starting to form by-product. The DMF was removed by reduced pressure.
The slurry was diluted with ether (50 mL) and the reaction was washed with water (40 mL 2) and
BRINE (35 mL). The combined organic layers were collected, dried over NaSO4, filtered, and
concentrated.

The residue was purified by column chromatography (silica, Hex-EtOAc,

14:1→8:1) to give the Fucp acceptor 9 in 42% (1.97 g). [α]25D −6.9 (c 1 CHCl3); 1H NMR (400
MHz, CDCl3) δH 5.91−5.74 (m, 1H, CH2=CHCH2−), 5.14−4.98 (m, 2H, CH2=CHCH2−), 4.20 (d,
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J = 7.8 Hz, 1H, H-1-Fucp), 3.73−3.65 (m, 1H, −CH2CHCH2−), 3.63 (dd, J = 9.2, 3.6 Hz, 1H, H3-Fucp), 3.59−3.48 (m, 3H, H-2-Fucp, H-4-Fucp, H-5-Fucp), 2.60 (br, 1H, −OH), 2.37−2.19 (m,
2H), 2.17 (d, J = 1.6 Hz, 1H, −OH), 1.67−1.47 (m, 2H), 1.39−1.22 (m, 9H), 0.97−0.84 (m, 12H),
0.15 (s, 3H, Si−CH3), 0.13 (s, 3H, Si−CH3).

13

C NMR (100 MHz, CDCl3) δC 135.1, 117.4, 102.2,

78.9, 74.9, 72.1, 72.1, 70.0, 38.5, 34.7, 31.8, 25.8(3), 24.7, 22.6, 18.1, 16.4, 14.1, −4.3, −4.9; IR
(film) ν = 3537, 2930, 2857, 1655, 1109, 1066, 997, 910, 839, 781; HRMS (ESI) m/z calcd. for
C21H42NaO5Si [M + Na]+ 425.2699, found 425.2698.

(1S)-1-(2-propen-1-yl)hexyl-6-deoxy-3-O-[(1,1-dimethylethyl)dimethylsilyl]-2,4diacetate-β-D-galactopyranoside 9i. The diol 9 (50 mg, 0.12 mmol) was dissolved in Py (4 mL,
then acetic anhydride (5100 μL) and DMAP were added to the solution at RT. The reaction
mixture was stirred at RT overnight, when TLC (silica, Hex-EtOAc) indicated that the reaction
was complete. The mixture was concentrated under reduced pressure and then co-evaporated with
toluene (2 . 20 mL) to give the crude product. The residue was purified by column chromatography
(silica, Hex-EtOAc 10:1) to give the acylated 9i (38 mg, 60%) as a colorless syrup. [α]25D −1.9 (c
1 CHCl3).1H NMR (400 MHz, CDCl3) δH 5.84−5.69 (m, 1H, CH2=CHCH2−), 5.11−4.97 (m, 4H,
CH2=CHCH2−, H-2-Fucp, H-4-Fucp), 4.38 (d, J = 8.0 Hz, 1H, H-1-Fucp), 3.78 (dd, J = 9.6, 3.6
Hz, 1H, H-3-Fucp), 3.70−3.63 (m, 1H, H-5- Fucp), 3.61−3.56 (m, 1H, −CH2CHCH2−), 2.26−2.14
(m, 2H), 2.11 (s, 3H, CH3C=O), 2.03 (s, 3H, CH3C=O), 1.63−1.19 (m, 8H), 1.17 (d, J = 6.4 Hz,
3H, H-6-Fucp), 0.88 (t, J = 6.8 Hz, 3H, −CH3), 0.83 (s, 6H), 0.07 (s, 3H, Si−CH3), 0.06 (s, 3H,
Si−CH3).

13

C NMR (100 MHz, CDCl3) δC 170.9, 169.2, 134.7, 116.9, 100.6, 79.9, 72.9, 72.3,

71.5, 69.0, 38.4, 34.4, 31.8, 25.4 ∙ 3 , 24.7, 22.6, 21.3, 20.9, 17.8, 16.3, 14.1, −4.8, −5.1. IR (film)
ν = 2928, 2855, 1744, 1371, 1231, 1119, 1063, 837, 781.
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3.4. Preparation of the Glucosyl Donor

3.4.1. Selective introduction of the lev. group for the protected glucosyl donor

1,2,3,4,6-pentaacetate-α,β-D-glucopyranose 12i. Method 1. Pyridine (60 mL), acetic
anhydride (30mL) was added to D-Glcp 13 (30.0 g, 0.167 mol) and allowed to stir at RT overnight.
At this point, TLC (silica, 1:1 Hex-EtOAc) showed the reaction was complete. The reaction was
concentrated under reduced pressure and the residue was dissolved in sat. aq. NaHCO3 (150 mL).
The aq. layer was extracted twice with DCM (150 mL). The organic layers were combined, dried
with NaSO4, filtered, and concentrated under reduced pressure. The yellow syrup 12i (65 g) was
used in the following step without any further purification. (1:1 Hex-EtOAc, Rf = 0.55) 1H NMR
(300 MHz; CDCl3) δH 6.29 (d, J = 3.2 Hz, 1 H, H-1α), 5.67 (d, J = 7.7 Hz, c0.4 H, H-1β), 5.44-5.35
(dd, J = 10.2 and 10.0 Hz, 1 H, H-3α), 5.29-5.21 (m, 0.4 H, H-3β), 5.17-5.04 (m, 2.8 H, H-2α, H2β, H-4β, H-4α), 4.30-4.26 (m, 1.4 H, H-6α, H-6αβ), 4.12-4.01 (m, 2.4 H, H-6α, H-6β, H-5α), 3.843.79 (0.4 H, H-5β), 2.19 (s, 4.2 H), 2.13 (s, 1.2 H), 2.09 (s, 4.2 H), 2.02 (s, 8.4 H). 13C NMR (75
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MHz, CDCl3) δc 170.4, 170.1, 169.5, 169.3, 168.6, 92.0 (C-1β), 89.4 (C-1α), 73.2 (Cβ), 70.6 (Cβ),
70.2 (2Cα,β), 69.5 (Cα), 68.2 (Cα), 61.7 (Cα,β), 21.0, 21.0, 20.8, 20.7. Spectral data matched those
previously reported. Method 2. D-Glcp 12 (20.65 g, 0.14 mol) was slowly added to a mixture of
acetic anhydride (90 mL) and HClO4 (0.7 mL) over 0.5-1 hr at 0 oC. The reaction was allowed to
warm slowly over 30 mins as the reaction turned from yellow to clear color. TLC (silica, 2:1 HexEtOAc) showed the reaction to be complete. The reaction mixture was co-evaporated with Tol
(150 mL) three times after quenching reaction. The mixture was dissolved in sat. aq. NaHCO3
(100 mL) and extracted twice with DCM (150 mL). The organic layers were combined, dried with
NaSO4, filtered, and concentrated under reduced pressure. The 1H and 13 C-NMR matched those
of the Method 1.1, 2

2,3,4,6-tetraacetate-α,β-D-glucopyranose 29. Benzylamine (4.56 mL, 47.6 mmol) was
added at to a solution of peracetate D-Glcp 12i (10.55 g, 31.7 mmol) and THF (150 mL) at RT and
allowed to stir for 24 hrs. The THF was removed under reduced pressure, diluted with DCM (150
mL), washed with 5% aq. HCl (100 mL), washed with sat. aq. NaHCO3 (100 mL). The organic
layer was dried with NaSO4, filtered, and concentrated under reduce pressure. The syrup was
purified by column chromatography (silica, Hex-EtOAc 2:1→1:1) to give the hemiacetate 29 (6.33
g, 21.8 mmol, α:β 1:4) in 68.7%. 1H NMR (400 MHz, CDCl3) δH 5.44 (t, 1H, J = 9.9 Hz, H3α),
5.35 (t, 1H, J = 3.5 Hz, H-1α), 5.14 (t, 1H, J = 9.8 Hz, Hβ), 4.98 (t, 2H, J = 9.9 Hz, H-4α+β), 4.93
(d, 1H, J = 8.2 Hz, Hβ) 4.79 (dd, 2H, J = 10.1 Hz, 3.5 Hz), 4.20-4.14 (m, 2H), 4.07 (m, 2H), 3.66
(t, 2H, J = 6.6 Hz), 2.00 (6H), 2.00 (6H), 1.95(6H), 1.93 (6H).13C NMR (100 MHz, CDCl3):
δC 171.0, 170.9, 170.3, 170.3, 170.3, 169.8, 169.6, (β): 95.1 (C-1), 72.9 (C-2), 72.5 (C-3), 71.8 (C4), 68.4 (C-5), 67.9 (C-6) (α), 89.1 (C-1), 71.2 (C-2), 69.9 (C-3), 68.5 (C-4), 66.9 (C-5), 62.0 (C-
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6), 25.49 (−CH3), 20.7 (−CH3), 20.7 (−CH3), 20.6 (−CH3), 20.6 (−CH3), 20.5 (−CH3). The 1Hand 13C-NMR data were identical to those previously reported.3, 4

1-(2,2,2-trichloroethanimidate)-2,3,4,6-tetraacetate-α,β-D-glucopyranose 29i.

CCl3CN

(6.42 mL, 62.8 mmol) and DBU (0.34 mL, 1.5 mmol) were are added to the mixture of the
hemiacetal 29 (4.56 g, 15.7 mmol). The reaction was allowed to stir at RT for 3 hrs as the mixture
turned an orange-brown color. The reaction was quenched with 1 mL of NEt3 after the TLC (silica
Hex-EtOAc 1:1 Rf = 0.65) showed the reaction to be complete. The mixture was quenched with
NEt3 (0.5 mL) concentrated under reduced pressure. The Schmidt donor 29i was obtained in 85.6%
(5.86g), after purification by column chromatography (silica, Hex-EtOAc 4:1→1:1, few drops of
NEt3). 1H NMR (400 MHz, CDCl3): δH 8.68 (s, 1H, C=NH), 6.51 (d, 1H, J = 3.9 Hz, H-1-Glcp),
5.51 (t, 1H, J = 9.9 Hz, H-4-Glcp), 5.13 (t, 1H, J = 9.9 Hz, H-3-Glcp), 5.09 (dd, 1H, J = 10.3 Hz,
3.7 Hz, H-2-Glcp), 4.24 (dd, 1H, J = 12.0, 3.8 Hz, H-6α-Glcp), 4.19-4.15 (m, 1H, H-5-Glcp) 4.09
(dd, 1H, J = 12.0 Hz, 1.8 Hz, H-6β-Glcp), 2.02 (s, 3H, −CH3), 2.00 (s, 3H, −CH3), 1.98 (s, 3H,
−CH3), 1.97 (s, 3H, −CH3). The 13C-NMR was not obtained because of the stability of the donor.
The 1H-NMR spectra match previously reported data.5, 6

Benzyl-2,3,4,6-tetraacetate-β-D-glucopyranoside 30. BnOH (4.2 mL, 40.2 mmol) and 4 Å
MS (5 g) were added to a solution of the Schmidt donor 29i and Dry DCM (200 mL). The reaction
was cooled to 0 oC and TMSOTf (0.1 eq) was added dropwise to the solution. The reaction was
allowed to slowly warm to RT overnight. The reaction was monitored by TLC (silica, Hex-EtOAc
2:1 Rf = 0.65) and showed the reaction went to 80-90% completion. After quenching the reaction
with NEt3, filtered through a pad of Celite using acetone as an eluent, and concentrated under
reduced pressure. The residue was purified by column chromatography (silica Hex-EtOAc 6:1→
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1:1) to give the β-benzyl glucoside 30 in 69% (6.078 g). 1H NMR (400 MHz, CDCl3) δH 7.28–
7.45 (m, 5H, Ar−H), 5.25–5.01 (m, 3H), 4.91 (d, J = 6.8 Hz, 1H, 1-H-Glcp), 4.51–4.72 (m, 2H),
4.24–4.12 (m, 2H), 3.71–3.62 (d, J = 4.1 Hz, 1H), 2.09 (s, 3H, −CH3), 2.05 (s, 3H, −CH3), 2.03 (s,
3H, −CH3), 2.02 (s, 3H, −CH3); 13C NMR (100 MHz, CDCl3) δ 170.80 (C=O), 170.50 (C=O),
169.6 (C=O), 169.4 (C=O), 136.3 (C=C), 129.7 (C=C), 129.8 ∙ 2 (C=C), 129.9 ∙ 2 (C=C), 128.3
(C=C), 98.8 (C-1), 77.1, 73.6, 73.1, 71.6, 71.6, 71.5, 69.0, 68.3, 68.0, 62.6, 62.5, 21.2 (−CH3), 21.0
(−CH3), 20.8 (−CH3), 20.8 (−CH3). The spectroscopic data matched previous literature reports.5,6
Benzyl-β-D-glucopyranoside 30i. The β-benzyl glucoside 30 (2.27 g, mmol) was dissolved
in the MeOH (15 mL) and cat NaOMe (35 mg, 30 mmol). The reaction was allowed to stir at RT
overnight, when the TLC (silica, EtOAc: MeOH 10:1, Rf = 0.15) showed the reaction to me
complete. The reaction was neutralized with Amberlite IR-120 (H), ion exchange resin and
filtered. The solvent was removed under reduced pressure. The crude tetraol 30i was recrystallized in methanol and used directly in the next step. (400 MHz, CD3OD) δH 7.33-7.17 (m,
5H, Ar-H), 4.88 (d, J = 11.8, 1H, H2C-Ar), 4.57(d, J = 11.8, 1H, H2C-Ar), 4.25 (d, J = 7.7, 1H,
Hz, H-1-Glcp), 3.80 (dd, J = 11.9, 2.1 Hz, 1H, H-6-Glcp), 3.59 (dd, J = 11.9, 5.5 Hz, 1H, H-6Glcp), 3.25-3.13 (m, 4H, H-2, H-3, H-4 & H-5); (100 MHz, CDCl3) δC 137.8 (C=C), 128.8 ∙ 2
(C=C), 128.5 ∙ 2 (C=C), 128.2 (C=C), 102.3, (C-1) 76.7, 75.9, 73.8, 71.6, 69.7, 61.6. The spectral
data matched those previously reported.7, 8

Benzyl-4,6-O-(1-methylethylidene)-β-D-glucopyranoside. 31. The tetraol 30i (1.54 g, 5.6
mmol) was dissolved in the minimum amount DMF and dimethoxypropane (2.8 mL, 22.8 mmol).
Cat. p-TsOH (21 mg, 0.1 mmol) was added to the reaction mixture and allowed to stir for 36 hrs.
The reaction was quenched with 0.2 mL of NEt3 and co-evaporated with Tol 3 times. The reside
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was purified by column chromatography to the give in the diol 31 (silica, Hex-EtOAc, 4:1→1:1,
0.1% NEt3). (TLC silica, Rf = 0.63 Hex:EtOAc 6:1) 1H NMR (400 MHz, CDCl3) δH 7.40-7.28
(m, 5H, Ar−H), 4.91 (d, J = 11.2 Hz, 1H, −H2C−Ar), 4.61 (d, J = 11.6, 1H, −H2C−Ar), 4.44 (d, J
= 7.6, 1H, H-1-Glcp), 3.95 (dd, J = 8.4 3.2 Hz, 1H, H-6-Glcp), 3.82 (t, J = 10.4 Hz, 1H, H-6-Glcp),
3.67-3.57 (m, 2H, H-2-Glcp, H-3-Glcp), 3.50 (t, J = 8 Hz, 1H, H-4-Glcp), 3.30-3.26 (m, 1H, H-5Glcp), 1.49 (s, 3H, −CH3), 1.44 (s, 3H, −CH3); δC (100 MHz, CDCl3) 136.4 (C=C), 128.3∙ 2
(C=C), 127.9∙ 2 (C=C), 127.9 (C=C), 101.9 (O-C-O), 99.5 (C-1), 74.41, 73.2, 72.9, 71.2, 67.1 (C6), 61.8, 28.8 (−CH3), 18.8 (−CH3).9, 10

Benzyl-4,6-O-(1-methylethylidene)-2 or 3-levulinic-β-D-glucopyranoside. 32 or 34. The
solution of the acetal 31 (261 mg, 0.84 mmol), lev acid (110 mg, 0.93 mmol) DMAP (1.5 mg,
0.084 mmol), Dry DCM DCM (20 mL) was cooled to 0 oC. Then, DCC (191 mg, 0.93 mmol) was
slowly added to the reaction mixture and allowed to slowly warm to RT overnight. TLC showed
the reaction to be complete with a mixture of the two products (silica, Hex-EtOAc, 1:1 Rf = 0.65).
The DCM was partially removed under reduced pressure, then diluted with Et2O (40 mL) and Hex
(20 mL) to precipitate any DCU. The mixture was filtered through a pad of Celite and the solvent
removed under reduced pressure. The syrup was purified by column chromatography (silica, HexEtOAc 4:1→1:1, NEt3). 1H NMR (400 MHz, CDCl3) δH 7.29-7.20 (m, 5 H), 4.87 (t, J = 9.2 Hz,
1H) 4.79 (d, J = 12.0 Hz, −CH2), 4.52 (d, J = 12.4 Hz, −CH2), 3.89 (dd, J = 8.1 Hz, 2.9 Hz, 1H),
3.75 (t, J = 10.4 Hz, 1H), 3.66 (t, J = 9.2 Hz, 1H), 3.58 (t, J = 9.2 Hz, 1H), 3.49-3.39 (b, OH), 3.19
(m, 1H), 2.67 (m, CH2), 2.48 (m, CH2), 2.08 (s,CH3), 1.44 (s, CH3), 1.37 (s, CH3); (100 MHz,
CDCl3) δC 206.9 (C=O), 171.6 (C=O) 136.7, 128.0 . 2, 127.5, 127.4 . 2, 99.6, 99.5 (C-1), 74.2,
72.9, 71.9, 70.4, 66.9 (C-6), 61.6 (−CH2), 37.7 (−CH3), 29.4 (−CH3), 28.6 (−CH3), 27.6 (−CH3),
18.7 (−CH3).
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Benzyl-2-O-dimethyl-tert-butyl-silyl-4-oxopentanoate-4,6-O-(1-methylethylidene)-β-Dglucopyranoside 36. The alcohol 32 (101 mg, 0.25 mmol) was dissolved in the Dry DCM and
2,6-lutidiene (0.143 mL, 1.24 mmol). After the mixture was cooled to 0oC, TMSOf (0.11 mL, 0.5
mmol) was added dropwise. The reaction was warmed to RT overnight. The TLC (silica, HexEtOAc 6:1, Rf = 0.64) said the reaction was complete and the solvent was removed under reduced
pressure. The residue was purified by column chromatography (silica, Hex-EtOAc 10:1→5:1,
0.1% NEt3) to the C-2-O-silyl ether 22 in 89% (0.557). However, the 1H- and 13C-NMR of 22 was
not definitive, so another method was developed to the glucosyl donor for glycosylation.

4-(methylthio)phenyl-2-O-dimethyl-tert-butyl-silyl-4-oxopentanoate-4,6-O-(1-methylethylidene) β -D-glucopyranoside 37. The was attempted through the same method as the β-benzylglucoside 37. (silica, Hex-EtOAc 6:1→ 4:1, Rf = 0.68, 0.78, 0.1% NEt3). A pure 1H- or 13C-NMR
of the β-thiol-glucoside 37 could not be obtained, causing the need another route to prepare the
glucosyl donor.

3.4.2. Preparation of the Glucosyl Donor using Alloc at C-2-Glcp

1,2,3,4,6-pentaacetate-α,β-D-glucopyranoside 38. Followed Method 1 previous discussed
as 12i. The 1H and 13 C-NMR matched those of the Method 1.
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4-methoxyphenyl,2,3,4,6-tetraacetate-β-D-glucopyranoside 38i.

The peracetylated

glucoside 24 (10 g, 25.6 mmol) and DCM (100 mL) was cooled to 0oC, then slowly added BF3 .
Et2O (8.1 mL, 64.1 mmol). The reaction was stirred for 4-6 hrs at RT. The reaction was quenched
with sat. aq. NaHCO3, then extracted with DCM (100 mL . 2). The organic layers were collected,
dried over MgSO4 and the filtrate was removed under reduced pressure. The residue was purified
with column chromatography (silica, Hex-EtOAc, 5:1 → 2:1) to the β-glycoside 38i in 73%. 1H
NMR (400 MHz, CDCl3) δH 7.21 (d, J = 9 Hz, 2H, Ar−H), 6.88 (d, J = 9 Hz, 2H, Ar−H), 5.205.20-5.00 (m, 3H), 4.82 (d, J = 12.1 Hz, 1H, H2C−O−Ar), 4.56 (d, J = 12.1 Hz, 1H, H2C−O−Ar),
4.52 (d, J = 7.9 Hz, 1H, 1-H-Glcp), 4.28 (dd, J = 12.1, 5.3 Hz, 1H, H-6-Glcp), 4.19 (dd, J = 12.1,
5.3 Hz, 1H, H-6-Glcp), 3.81 (s, 3H, Ar-O-CH3), 3.87 (ddd, J = 10.1, 5.2, 2.5 Hz, 1H, 5-H-Glcp),
2.11 (s, 3H, −CH3), 2.02 (s, 3H, −CH3), 2.00 (s, 3H, −CH3), 1.99 (s, 3H, −CH3). (100 MHz,
CDCl3) δC 170.5 (C=O), 170.2 (C=O), 169.3 (C=O), 169.2 (C=O), 159.4 (C=C), 129.4 ∙ 2 (C=C),
129.4 ∙ 2 (C=C), 113.7 (C=C), 98.7 (C-1), 72.7, 71.7, 71.1, 70.3, 68.3, 61.9, 55.1, 20.6 (−CH3),
20.5 (−CH3), 20.5 (−CH3), 20.4 (−CH3). The spectra data matched previously reported data.11
4-methoxyphenyl-β-D-glucopyranoside 39. The β-glucoside 38i (5.8 g, 12.8 mmol) was
dissolved in MeOH (60 mL) and cat. NaOMe (70 mg, 1.28 mmol). The reaction was stirred at RT
overnight, when the TLC (silica, EtOAc: MeOH 10:1, Rf = 0.19) showed the reaction to me
complete. The reaction was neutralized with Amberlite IR-120 (H) ion exchange resin and filtered.
The solvent was removed under reduced pressure. The crude tetraol 39 was used directly in the
next step without further purification. 1H NMR (400 MHz, CDCl3) δH 7.31 (d, J = 7.8 Hz, 2H,
Ar−H), 6.89 (d, J = 7.8, 2H, Ar−H), 5.19-5.00 (br, 4H), 4.74 (d, J = 11.8 Hz, 1H, H2C−O−Ar),
4.49 (d, J = 11.8 Hz, 1H, H2C−O−Ar), 4.20 (d, J = 7.9 Hz, 1H, 1-H-Glcp), 3.72 (s, 3H,
Ar−O−CH3), 3.71-3.67 (m, 1H), 3.48 (dd, J = 11.1, 5.2 Hz, 1H), 3.15-3.01 (m, 4H). (100 MHz,
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CDCl3) δC 158.7 (C=C), 129.9 ∙ 2 (C=C), 129.4 ∙ 2 (C=C), 113.5 (C=C) 101.8 (C-1) 77.0, 76.8,
73.5, 70.2, 69.2, 61.2, 55.1.

4-methoxyphenyl-4,6-O-(1-methylethylidene)-β-D-glucopyranoside 40.

The crude β-

tetraol 39 (1.54 g, 5.6 mmol) was dissolved in the minimum amount DMF (10 mL) and DMP (2.8
mL, 22.8 mmol). Cat. p-TsOH (21 mg, 0.1 mmol) was added to the reaction mixture and allowed
to stir for 36 hrs. The reaction was quenched with 0.2 mL of NEt3 and co-evaporated with Tol 3
times. The reside was purified by column chromatography (silica, Hex-EtOAc, 2:1→1:2, 0.1%
NEt3) to give 40 in 69% (1.07 g). (TLC silica, Rf = 0.75 EtOAc-MeOH 10:1).

4-methoxyphenyl-3-O-tigloyl-4,6-O-isopropylidene-β-D-glucopyranoside. After cooling
to 0oC, DCC (566.7 mg, 2.74 mmol) was added to a cold solution of the β-diolglucoside 40 (746.6
g, 2.28 mmol), tig acid (247 mg, 2.74 mmol), and DMAP (27.9 mg, 0.228 mmol) in DCM (25
mL). The reaction was warmed to RT and stirred overnight. At this point, TLC (silica, HexEtOAc, 2:1, Rf = 0.53) showed the reaction was complete. The solvent was partially removed,
then Hex (60 mL) and Et2O (30 mL) were added and stirred for 30 mins. The precipitate (DCU)
formed was filtered through a pad of Celite using DCM (20 mL) as the eluent, and the filtrate was
concentrated in vacuo. The residue was purified by column chromatography (silica, Hex-EtOAc
5:1 → 1:2, 0.1% NEt3) to give 41 (195 mg, 21%), 42 (420 mg, 50%), and 43 (273 mg, 26%) as
white amorphous solids.
Compound 41. [α]25D −64.4 (c 1 CHCl3).

1

H NMR (400 MHz; CDCl3): δH 7.03−6.97 (m,

2H, 2 ∙ Ar−H), 6.98−6.91 (m, 1H, MeCHC(Me)C=O), 6.85−6.80 (m, 2H, 2 ∙ Ar−H), 5.12 (t, J =
9.6 Hz, 1H, H-3-Glcp), 4.93 (d, J = 7.6 Hz, 1H, H-1-Glcp), 3.98 (dd, J = 10.8, 5.2 Hz, 1H, H-6Glcp), 3.85−3.75 (m, 6H, H-2-Glcp, H-4, H-6-Glcp, −OCH3), 3.48−3.41 (m, 1H, H-5-Glcp), 3.21
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(d, J = 3.6 Hz, 1H, HO-2-Glcp), 1.90−1.80 (m, 6H, CH3CHC(CH3)C=O), 1.48 (s, 3H, (CH3)2CO), 1.39 (s, 3H, (CH3)2C-O).

13

C NMR (100 MHz, CDCl3) δC 168.6 (C=O), 155.6 (C=C), 150.9

(C=C), 138.7 (C=C), 128.1 (C=C), 118.6 ∙ 2 (C=C), 114.52 ∙ (C=C), 102.9 (O‒C‒O), 99.7 (C-1),
74.8, 73.6, 71.1, 67.4, 62.1, 55.6, 28.9, 18.9, 14.5, 12.1.
Compound 42. [α]25D −57.1 (c 1 CHCl3); 1H NMR (400 MHz, CDCl3) δH 6.99−6.89 (m,
1H, MeCHC(Me)C=O, Ar−H), 6.84− 6.77 (m, 2H, Ar−H), 5.15 (dd, J = 9.2, 8.0 Hz, 1H, H-2Glcp), 4.99 (d, J = 7.6 Hz, 1H, H-1-Glcp), 3.99 (dd, J = 10.8, 5.6 Hz, 1H, H-6-Glcp), 3.90−3.80
(m, 2H, H-3-Glcp, H-6-Glcp), 3.78−3.72 (m, 4H, H-4-Glcp, −OCH3), 3.43−3.35 (m, 1H, H-5Glcp), 2.89 (br, 1H, HO-3-Glcp), 1.90−1.78 (m, 6H, CH3CHC(CH3)C=O), 1.55 (s, 3H, (CH3)2C),
1.46 (s, 3H, (CH3)2C).

C NMR (100 MHz, CDCl3) δC 167.7 (C=O), 155.6 (C=C), 151.1 (C=C),

13

138.9 (C=C), 127.9 (C=C), 118.7 ∙ 2 (C=C), 114.5 ∙ 2 (C=C), 101.1 (O‒C‒O), 99.9 (C-1), 74.8,
73.5, 73.0, 67.2, 61.9, 55.6, 28.9, 19.0, 14.5, 12.2.
Compound 43. [α]25D +8.0 (c 1 CHCl3); 1H NMR (400 MHz, CDCl3) δH 6.96−6.88 (m,
2H, Ar‒H), 6.86−6.76 (m, 4H, 2 .Ar−H, 2 .H3CHCCH3C=O), 5.38−5.27 (m, 2H, H-2-Glcp, H-3Glcp), 5.10−5.00 (d, J = 7.2 Hz, 1H, H-1-Glcp), 4.00 (dd, J = 11.2, 5.6 Hz, 1H, H-6-Glcp), 3.94−
3.80 (m, 2H, H-4-Glcp, H-6-Glcp), 3.76 (s, 3H, Ar−OCH3), 3.54−3.46 (m, 1H, H-5-Glcp),
1.82−1.73 (m, 12H, 2 ∙ CH3CHC(CH3)C=O), 1.49 (s, 3H, (CH3)2C−), 1.39 (s, 3H, (CH3)2C−).

13

C

NMR (100 MHz, CDCl3) δC 167.1 (C=O), 166.5 (C=O), 155.6 (C=C), 151.1 (C=C), 138.3 (C=C),
138.0 (C=C), 128.0 (C=C), 127.8 (C=C), 118.8 ∙ 2 (C=C), 114.5 ∙ 2 (C=C), 101.2 (O‒C‒O), 99.7,
72.1, 72.0, 71.4, 67.6, 62.1, 55.6, 28.9, 18.9, 14.4, 14.4, 12.1, 12.1.
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4-methoxyphenyl, 2,3,4,6-tetraacetate-α-D-glucopyranoside 38ii. The α-PMP-glucoside
38ii was achieved through the same method as the β-PMP-glucoside 38i. The reaction time was
lengthened to 4-5 days to allow the β-intermediate to isomerize to the α-PMP in 80% (4.11 g).12
H-NMR data.
4-methoxyphenyl-α-D-glucopyranoside 44. To obtain the tetraol 44 the same procedure
was followed as the β-PMP-glucoside 39. The tetraol 44 was attained in 90% (2.15 g) and carried
to the next step without further purification.
4-methoxyphenyl-4,6-O-(1-methylethylidene)-α-D-glucoside 44i.

To a cold (0 °C)

solution of the 44 (70.0 g, 179 mmol) and p-methoxyphenol (33.4 g, 269 mmol) in Dry DCM (800
mL) was added BF3 . OEt2 (111 mL, 897 mmol) over 30 min. The mixture was then heated to 35
°C and agitated for 4 days, at the end of which time TLC (Hex−EtOAc, 2:1) indicated that the
reaction was complete. The reaction mixture was poured onto crushed ice, and the excess BF3 .
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OEt2 was neutralized by the careful addition of saturated aqueous NaHCO3 solution. The organic
layer was washed with brine, dried (Na2SO4), and concentrated in vacuo to provide a syrup. The
syrup was dried under high vacuum for 2 h before being dissolved in MeOH (500 mL). NaOMe
(800 mg) was added to the reaction mixture at RT and stirred for 2 hrs. The residue was purified
by column chromatography (silica, EtOAc−MeOH, 1:0 → 10:1) to afford p-methoxyphenyl-α-Dglucopyranoside 44i (30.8 g, 60% over two steps) as a white solid. To a solution of compound 44i
(28.8 g, 101 mmol) in DMF (200 mL) containing TsOH · H2O (0.38 g, 2.0 mmol) was added DMP
(11.6 mL, 121 mmol) under nitrogen atmosphere. The mixture was stirred for 6 hrs. at RT, when
TLC showed the reaction to be complete (Hex−EtOAc, 1:2). The reaction was quenched with
NEt3 (0.5 mL) and then diluted with EtOAc (400 mL) and washed with water (400 mL . 3) and
brine (100 mL). The aqueous layer was extracted with EtOAc (400 mL . 2). The combined organic
layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified
by column chromatography (silica, Hex−EtOAc, 2:1 → 1:1) to give compound 45 (30.2 g, 92%)
as a white foam: [α]25D +124.7 (c 1 CHCl3); 1H NMR (400 MHz, CDCl3) δH 7.02−6.96 (m, 2H, 2
· Ar−H), 6.84−6.79 (m, 2H, 2 · Ar−H), 5.41 (d, J = 3.6 Hz, 1H, H-1-Glcp), 4.00 (td, J = 9.2, 2.0
Hz, 1H), 3.88−3.66 (m, 7H, H-2, H-5, 2 · H-6-Glcp, −OCH3), 3.61 (t, J = 8.8 Hz, 1H), 3.45−3.40
(m, 1H, −OH), 3.00−2.92 (m, 1H, −OH), 1.52 (s, 3H, (CH3)2C−), 1.44 (s, 3H, (CH3)2C−).

13

C

NMR (100 MHz, CDCl3) δC 155.4, 150.2, 118.4 · 2, 114.6 ·2, 99.8, 98.6, 73.4, 72.8, 71.9, 64.0,
62.1, 55.6, 29.0, 19.1.

4-methoxyphenyl-2-O-(allyloxycarbonyl)-4,6-O-isopropylidene-α-D-glucopyranoside 46.
The diol 45 (13.50 g, 41.6 mmol) was dissolved in a mixture of DCM (200 mL), Py (13.3 mL,
166.7 mmol) and DMAP (506.7 mg, 4.2 mmol), then under an N2 atmosphere, allyl chloroformate
(4.86 mL, 45.9 mmol) in DCM (50 mL) was added dropwise to the solution at −30 °C over 30
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min. The reaction mixture was gradually warm to 0 °C over 30 min, when TLC (silica, HexEtOAc, 2:1) showed the reaction was complete. The reaction mixture was then quenched with
MeOH (0.5 mL) and washed with 1 M HCl (100 mL), sat. aq. NaHCO3 (100 mL), and brine sol.
(100 mL). The aqueous layer was extracted with DCM (200 mL). The combined organic layer
was dried over Na2SO4 and concentrated under reduced pressure. The syrup was purified by
column chromatography (silica, Hex-EtOAc, 5:1→2:1, 0.1% NEt3) to give 46 in 81% (14.1 g) as
a white foam. [α]25D +152.9 (c 1 CHCl3); 1H NMR (400 MHz, CDCl3) δH 7.02−6.95 (m, 2H, 2 ∙
Ar−H), 6.85−6.77 (m, 2H, 2 ∙ Ar−H), 5.96−5.85 (m, 1H, CH2=CHCH2−), 5.65 (d, J = 3.8 Hz, 1H,
H-1-Glcp), 5.38−5.22 (m, 2H, CH2=CHCH2−), 4.72 (dd, J = 9.6, 3.6 Hz, 1H, H-2-Glcp), 4.66−4.58
(m, 2H, CH2=CHCH2−), 4.26 (t, J = 9.3 Hz, 1H, H-3-Glcp), 3.91−3.81 (m, 2H, H-5-Glcp, H-6Glcp), 3.81−3.74 (m, 4H, H-6-Glcp, −OCH3), 3.75−3.63 (m, 1H, H-4-Glcp), 3.04 (br, 1H, ‒OH),
1.54 (s, 3H, (CH3)2C‒O), 1.45 (s, 3H, (CH3)2C‒O). 13C NMR (100 MHz, CDCl3) δC 155.3, 154.4,
150.3, 131.1, 119.2, 118.2 ∙ 2, 114.5 ∙ 2, 100.0, 95.8, 76.7, 73.7, 68.97, 68.8, 63.7, 62.1, 55.6, 28.9,
19.1.

4-methoxyphenyl-2-O-(allyloxycarbonyl)-3-O-tigloyl-4,6-O-isopropylidene-α-D-glucopyranoside 47. DCC (5.73 g, 27.8 mmol) was added in one portion to a -10 °C DCM (100 mL)
solution of alcohol 46 (7.6 g, 18.5 mmol), tig acid (2.78 g, 27.8 mmol), and DMAP (226.7 mg,
1.85 mmol). The reaction was slowly warmed to RT and stirred overnight. At this point, TLC
(silica, Hex-EtOAc, 2:1) showed the reaction was complete. The reaction mixture was diluted
with Et2O (100 mL) and Hex (50 mL), stirred for 15 min, and then filtered through a pad of Celite
using Et2O (50 mL) as the eluent, and the filtrate was concentrated in vacuo. The residue was
purified by column chromatography (silica, Hex-EtOAc, 8:1 → 5:1, 0.1% NEt3) to give
intermediate 47 in 85% (8.10 g) as a colorless syrup. [α]25D +127.5 (c 1 CHCl3); 1H NMR (400
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MHz, MeOD) δH 7.05−6.98 (m, 2H, 2 ∙ Ar‒H), 6.93−6.83 (m, 3H, MeCHC(Me)2, 2 ∙ Ar‒H),
5.96−5.75 (m, 1H, ‒CH2= CHCH2−), 5.67 (d, J = 3.6 Hz, 1H, H-1-Glcp), 5.57 (t, J = 10.0 Hz, 1H,
H-3-Glcp), 5.29−5.15 (m, 2H, CH2=CHCH2−), 4.96 (dd, J = 10.1, 3.6 Hz, 1H, H-4-Glcp),
4.65−4.51 (m, 2H, CH2=CHCH2−), 4.01−3.79 (m, 4H, H-4-Glcp, H-5-Glcp, 2 . H-6-Glcp), 3.75
(s, 3H, −OCH3), 3.75 (d, J = 4.7 Hz, 3H), 1.86−1.74 (m, 6H, CH3CHC(CH3)‒C=O), 1.51 (s, 3H,
(CH3)2C‒O), 1.35 (s, 3H, (CH3)2C‒O).

13

C NMR (100 MHz, MeOD) δ 168.4, 157.0, 155.6, 151.7,

139.6, 132.8, 129.2, 119.4 ∙ 2, 118.9, 115.7 ∙2, 101.2, 97.7, 75.9, 73.1, 70.8, 69.8, 65.7, 63.1, 56.0,
29.3, 19.4, 14.5, 12.2. IR (film) ν = 2993, 2940, 1747, 1718, 1652, 1510, 1277, 1244, 1211, 1042;
HRMS (ESI) m/z called for C25H32NaO10 [M + Na]+ 515.1893, found 515.1875.

hemiacetal-2-O-(allyloxycarbonyl)-3-O-tigloyl-4,6-O-isopropylidene-α,β-D-glucopyranoside 47i. To a solution of the α-PMP-glucoside 47 (7.26 g, 14.7 mmol) in AcCN/H2O (9:1
72 mL: 8 mL) was added a solution of CAN (16.2 g, 29.5 mmol) in H2O (10 mL) over 5 min at
−10 °C. The mixture was stirred for 10 mins at the same temperature, at the end of which time
TLC (silica, 2:1, Hex-EtOAc) indicated that the reaction was complete. The reaction was
quenched with saturated aqueous NaHCO3 and extracted with EtOAc (400 mL ∙ 2). The combined
organic phase was dried over Na2SO4 and concentrated under reduced pressure. The obtained α,βhemiacetal glucoside 47i was purified by column chromatography (silica, Hex-EtOAc, 4:1→1:1,
0.1% NEt3) and proceeded to the next step.

trichloroacetimidate-2-O-[(allyloxy)carbonyl]-3-O-tigloyl-4,6-O-isopropylidene-α,β-Dglucopyranoside 48. Trichloroacetonitrile (5.93 mL, 58.7 mmol) was added to a solution of the
obtained α,β-hemiacetal 47i in DCM (60 mL) at RT, then DBU (0.22 mL, 1.47 mmol). The
mixture was stirred at RT overnight (turned red-orange color), TLC (silica, Hex-EtOAc, 4:1, Rf =
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0.55, 0.49) showed the reaction was complete. The reaction was quenched with NEt3 (1 mL) and
the solvent was removed under reduced pressure.

The residue was purified by column

chromatography (silica, Hex-EtOAc, 6:1 → 1:1) to afford the glucosyl donor 48 (4.23 g, 51% over
two steps) as a colorless syrup. [α]25D +59.6 (c 1 CHCl3). 1H NMR (400 MHz, CDCl3) δH 8.66
(s, 1H, CNHCCl3), 6.90−6.83 (m, 1H, MeCHC(Me)C=O), 6.57 (d, J = 4.0 Hz, 1H, H-1-Glcp),
5.93−5.76 (m, 1H, CH2=CHCH2−), 5.61 (t, J = 9.6 Hz, 1H, H-3-Glcp), 5.36−5.17 (m, 2H,
CH2=CHCH2−), 5.03 (dd, J = 9.6, 4.0 Hz, 1H, H-2-Glcp), 4.65−4.54 (m, 2H, CH2=CHCH2−),
4.05−3.72 (m, 4H, H-2-Glcp, H-4-Glcp, H-5-Glcp, 2 ∙ H-6-Glcp), 1.90−1.76 (m, 6H,
CH3CHC(CH3)C=O), 1.49 (s, 3H, (CH3)2C‒O), 1.41 (s, 3H, (CH3)2C‒O).

13

C NMR (100 MHz,

CDCl3) δC 166.5, 161.2, 154.2, 138.0, 131.1, 128.0, 118.7, 100.0, 93.6, 74.1, 71.7, 69.07, 68.97,
66.2, 62.0, 28.9, 18.8, 14.4, 12.1.

3.4.3. Attempted Preparation of Glucosyl Donor using Alloc at C-2-Glcp

4-methoxyphenyl-2-O-(allyloxycarbonyl)-3-O-levulinoyl-4,6-O-isopropylidene-D-α-glucopyranoside 50. The alcohol 50 was obtained in four steps from D-Glcp 12 through the procedure
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discussed previously (3.1.2, Route 2). A solution of the alcohol 49 (3.51 g, 8.5 mmol), lev. acid
(1.19 g, 10.2 mmol) (DMAP (1.25 g, 4.2 mmol), and DCM (50 mL) were cooled to -10 oC. Then
DCC (2.12 10.2 mmol) was added to the solution in portion and the reaction allowed to slowly
warm to RT overnight. The TLC (silica, Hex-EtOAc, 2:1, Rf = 0.61). The solvent was partially
removed, then Hex (40 mL) and Et2O (20 mL) were added, then stirred for 20 min to precipitate
the DCU. The mixture was filtered through a pad of Celite using Et2O (20 mL) as the eluent, and
the filtrate was concentrated under reduced pressure. The residue was purified by column
chromatography (silica, Hex-EtOAc 5:1 → 1:2, 0.1% NEt3) to give intermediate 50 in 93% (3.91
g). 50 was not fully characterized and continued to the next step.

4-hemiacetal-2-O-(allyloxycarbonyl)-3-O-levulinoyl-4,6-O-isopropylidene-α,β-D-glucopyranoside 50i. After cooling to 0 oC, the CAN (5.53 g, 9.77 mmol) dissolved in H2O (8 mL) and
added dropwise to a solution of compound 50 (1.24 g, 2.4 mmol), AcCN (30 mL), and H2O (7
mL). The reaction was kept at 0oC for 10 mins as the reaction was monitored by TLC (silica, HexEtOAc 1:1, Rf = 0.47). Sat. aq. NaHCO3 (40 mL) was added to the reaction causing the reaction
to change colors (yellow → clear) and extracted with EtOAc (50 mL∙ 3). The organic layers were
combined, dried over NaSO4, filtered and solvent removed under reduced pressure. The syrup was
purified by column chromatography (silica, Hex-EtOAc 3:1 → 1:1, NEt3 0.1%) to give hemiacetal
50i in 35.4% (0.348 g).
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3.4.4. Synthesis of the Glucosyl Donor with C-2 and C-3 Lev Protecting Groups.

4-methoxyphenyl-2,3-O-levulinoyl-4,6-O-isopropylidene-β-D-glucopyranoside 60. The
alcohol 59 was obtained in four steps from D-Glcp 12 through the procedure discussed previously
(Section 3.1.2). A solution of the diol 59 (6.25 g, 19.15 mmol), lev. acid (6.68 g, 57.5 mmol),
DMAP (4.75 g, 3.75 mmol), and DCM (50 mL) were cooled to -10 oC. Then DCC (7.11 g, 34.5
mmol) was added to the solution in portion and the reaction allowed to slowly warm to RT
overnight. The TLC (silica, Hex-EtOAc, 2:1, Rf = 0.51). The solvent was partially removed, then
Hex (10 mL) and Et2O (20 mL) were added and stirred for 15 min to precipitate the DCU. The
mixture was filtered through a pad of Celite using Et2O (20 mL) as the eluent, and the filtrate was
concentrated under reduced pressure. The residue was purified by column chromatography (silica,
Hex-EtOAc 4:1→1:2, 0.1% NEt3) to give intermediate in 60 in 85% (9.2 g). [α]25D –21.1° (c 1
CHCl3); 1H NMR (400 MHz, CDCl3) δH 7.01 – 6.90 (m, 2H, 2 ∙ Ar‒H), 6.86 – 6.76 (m, 2H, 2 ∙

144

Ar‒H), 5.27 – 5.13 (m, 2H, H-2-Glcp, H-3-Glcp), 5.00 – 4.90 (m, 1H, H-1-Glcp), 3.98 (dd, J =
10.8, 5.2 Hz, 1H, H-6-Glcp), 3.88 – 3.70 (m, 5H, H-4- Glcp, H-6- Glcp, ‒OCH3), 3.50 – 3.35 (m,
1H, H-5-Glcp), 2.89 – 2.69 (m, 4H, CH3-C=O(CH2)2C=O), 2.69 – 2.52 (m, 4H, CH3C=O(CH2)2C=O), 2.18 (s, 3H, CH3-C=O(CH2)2C=O), 2.16 (s, 3H, CH3-C=O(CH2)2C=O), 1.48 (s,
3H, (CH3)2C), 1.38 (s, 3H, (CH3)2C).

13

C NMR (100 MHz, CDCl3) δC 206.35, 206.23, 171.89, S9

171.42, 155.69, 150.97, 118.73 ∙ 2, 114.51∙ 2, 100.98, 99.80, 71.99, 71.93, 71.08, 67.48, 61.92,
55.58, 37.75, 37.69, 29.76, 29.73, 28.85, 27.89, 27.76, 18.84.

hemiacetal-2,3-O-levulinoyl-4,6-O-isopropylidene-α,β-D-glucopyranoside 60i.

To a

solution of the β-PMP-glucoside 60 (2.68 g, 5.13 mmol) in AcCN/H2O (8:1 45 mL) and was added
a solution of CAN (5.62 g, 10.2 mmol) in H2O (5 mL) over 5 min at −10 °C. The mixture was
stirred for 10 mins at the same temperature, when TLC (silica, 2:1, Hex-EtOAc) indicated that the
reaction was complete. The reaction was quenched with sat. aqus. NaHCO3 and extracted with
Et2O (60 mL ∙ 2). The combined organic phase was dried over Na2SO4 and concentrated under
reduced pressure. The obtained α,β-hemiacetal Glcp 60i was purified by column chromatography
(silica, Hex-EtOAc, 4:1→1:1, 0.1% NEt3) and proceeded to the next step.

trichloroacetimidate-2,3-O-levulinoyl-4,6-O-isopropylidene-α,β-D-glucopyranoside

60.

CCl3CN (8.35 g, 83.0 mmol) and DBU (0.31 mL, 2.01 mmol) were are added to the mixture of the
α,β-hemiacetal 59i (8.64 g, 20.8 mmol). The reaction was allowed to stir at RT for 3-5 hrs. as the
mixture turned an orange-brown color. The reaction was quenched with 0.5 mL of NEt3 after the
TLC (silica Hex-EtOAc 1:1 Rf = 0.65) showed the reaction to be complete. The mixture was
concentrated under reduced pressure. The Schmidt donor 60 was obtained in 85% (9.90 g), after
purification by column chromatography (silica, Hex-EtOAc 4:1 →1:1, few drops of NEt3). [α]25D
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+ 52.4° (c 1 CHCl3). 1H NMR (400 MHz, CDCl3) δH 8.71, 8.64 (2s, 1H, OCNHCCl3), 6.45 (d, J
= 4.5 Hz, 1H, H-1-Glcp), 5.49 (t, J = 9.6 Hz, 1H, H-3-Glcp), 5.12 (dd, J = 10.0, 4.0 Hz, 1H, H-2Glcp), 3.98 – 3.87 (m, 2H, H-5, H-6-Glcp), 3.84 – 3.68 (m, 2H, H-4-Glcp, H-6-Glcp), 2.90 – 2.46
(m, 8H, 2 ∙ CH3‒C=O(CH2)2C‒O), 2.17 (s, 3H, CH3-C=O(CH2)3C-O), 2.16, 2.15 (2s, 3H, CH3‒
C=O(CH2)2C‒O), 1.49, 1.48 (2s, 3H, (CH3)2C‒O), 1.40, 1.39 (2s, 3H, (CH3)2C‒O).

13

C NMR

(100 MHz, CDCl3) δC 206.3, 206.2, 171.81, 171.7, 160.9, 99.9, 93.6, 90.7, 71.3, 70.3, 69.1, 66.0,
61.94, 37.7, 37.5, 29.7, 29.7, 28.7, 27.8, 27.5, 18.9.

3.4.5. Preparation of the Glucosyl Donor using Thiotolyl Protection

4-(methylthio)phenyl-2,3,4,6-tetraacetate-β-D-glucopyranoside 62.

The peracetylated

glucose 12i (27 g, 69.3 mmol) obtained though Method 2 (Section 3.4.1) was dissolved in Dry
DCM (300 mL) with 4-methylthiophenol (12.9 g, 138.7 mmol) and cooled to -10 oC. Then, the
BF3 ∙ OEt2 was slowly added and reaction stirred 12-48 hrs at RT. The reaction was monitored by
TLC (silica, Hex-EtOAc 2:1, Rf = 0.54). The reaction time can be decrease with the use of an
ultrasonic bath. The reaction mixture was slowly poured into crushed ice and stirred for 10 mins.
The reaction was neutralized with careful addition of sat. aq. NaHCO3 (200 mL) and extracted
(300 mL ∙ 2) with DCM. The combined organic layers were dried over NaSO4, filtered, and the
solvent removed under reduced pressure. The residue was purified with column chromatography
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(silica, Hex-EtOAc, 5:1-1:1) to the β-thioGlcp 62 in 70% (85% BORSM). 1H NMR (400 MHz,
CDCl3) δH 7.38 (d, J = 7.8 Hz, 2H, 2 ∙ Ar‒H), 7.12 (d, J = 7.8 Hz, 2H, 2 ∙ Ar‒H), 5.20 (t, J = 9.6
Hz, 1H, H-3-Glcp), 5.01 (t, J = 9.6 Hz, 1H, H-4-Glcp), 4.93 (t, J = 9.7 Hz, 1H, H-2-Glcp), 4.62
(d, J = 10.1 Hz, 1H, H-1-Glcp), 4.23-4.14 (m, 2H, H-6-Glcp), 3.69 (ddd, J = 2.3, 4.3, 7.4 Hz, 1H,
H-5-Glcp), 2.34 (s, 3H, S‒Tol‒CH3), 2.08 (s, 3H, ‒CH3), 2.08 (s, 3H, ‒CH3), 2.00 (s, 3H, ‒CH3),
1.99 (s, 3H, ‒CH3).

C NMR (100 MHz, CDCl3) δC 170.6 (C=O), 170.1 (C=O), 169.4 (C=O),

13

169.3 (C=O), 138.7 (C=C), 133.7 ∙ 2 (C=C), 129.6 ∙ 2 (C=C), 127.4 (C=C), 85.7 (C-1), 75.8, 73.8,
69.8, 68.2, 62.1, 21.2 (‒CH3), 20.7 (‒CH3), 20.7 (‒CH3), 20.5(‒CH3), 20.4 (‒CH3). The 1H- and
13

C-NMR spectroscopic data matched previous report literature.13, 14
4-(methylthio)phenyl-β-D-glucopyranoside 62i. The β-thioGlcp 62 (23.6 g, 51.9 mmol)

was dissolved in MeOH (200 mL) and cat NaOMe (0.280 g, 5.2 mmol). The reaction was stirred
at RT for 6-12 hrs, when the TLC (silica, EtOAc: MeOH 10:1, Rf = 0.15) showed the reaction to
be complete. The reaction was neutralized with Amberlite IR-120 (H) ion exchange resin and
filtered. The solvent was removed under reduced pressure. The crude tetraol 62i was used directly
in the next step without further purification. 1H NMR (400 MHz, CD3OD) δH 7.44 (d, J = 7.7, 2H,
2 ∙ Ar‒H), 7.11 (d, J = 7.8, 2H, 2 ∙ Ar‒H), 4.50 (d, J = 9.5, 1H, H-1-Glcp), 3.89 (d, J = 2.5, 1H),
3.76-3.71 (m, 2H), 3.59 (t, J = 9.2, 1H), 3.56-3.48 (m, 2H, H-5-Glcp), 2.30 (s, 3H, Ph ‒CH3).

13

C

NMR (100 MHz, CD3OD) δ 138.5 (C=C), 133.0 ∙ 2 (C=C), 132.2 ∙ 2 (C=C), 130.7 (C=C), 90.8
(C-1), 80.7, 76.5, 71.1, 70.5, 62.7, 21.2 (Ph‒CH3). The 1H- and 13C-NMR spectra data match those
previously reported.13, 15

4-(methylthio)phenyl-4,6-O-isopropylidine-β-D-glucopyranoside 63. The crude tetraol
62i (16.8 g, 58.6 mmol) was dissolved in the minimal amount of DMF (80 mL), then DMP (66
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mL, 234 mmol) and cat. p-TsOH (223 mg, 1.1 mg) added to the solution at RT. The reaction was
allowed to at RT overnight, while monitoring the reaction though TLC (Hex-EtOAc, 2:1, Rf =
0.49). The reaction was quenched with NEt3 (0.5 mL), diluted with Tol, and solvent removed
under reduced pressure. The crude syrup was dissolved in EtOAc (150 mL), washed with BRINE
∙ 2, dried over NaSO4, filtered, and the EtOAc under reduced pressure. The syrup was purified
using column chromatography (silica, Hex-EtOAc 4:1→1:2) to the C-4,C-6-protected glucoside
63 in 75% (15.75 g) clear syrup; 1H NMR (400 MHz, CDCl3) δH 7.40 (d, J = 8.2 Hz, 2H, 2 ∙ Ar‒
H), 7.13 (d, J = 8.1 Hz, 2H, 2 ∙ Ar‒H), 4.58 (d, J = 9.6 Hz, 1H, C-1-Glcp), 3.94 (dd, J = 10.4, 5.2
Hz, 1H), 3.76 (t, J = 10.8 Hz, 1H), 3.68 (t, J = 8.4 Hz, 1H), 3.51 (t, J = 9.6 Hz, 1H), 3.41– 3.27
(m, 2H), 3.10 (br, 1H, ‒OH), 2.90 (br, 1H, ‒OH), 2.61 (s, 3H, Ph‒CH3), 1.49 (s, 3H, O‒C‒CH3),
1.42 (s, 3H, O‒C‒CH3).

C NMR (100 MHz, CDCl3) δH 138.68 (C=C), 133.43 ∙ 2 (C=C), 129.84

13

∙ 2 (C=C), 127.50 (C=C), 99.80 (O‒C‒O), 88.80 (C-1), 74.91, 72.89, 72.66, 71.52, 61.97, 28.94
(Ph‒CH3), 21.12 (O‒C‒CH3), 19.10 (O‒C‒CH3). All spectroscopic data matched previously
published data.16

4-(methylthio)phenyl-2,3-O-levulinoyl-4,6-isopropylidine-β-D-glucopyranoside

63i.

DCC (23.13 g, 112 mmol) was added one portion to a cooled solution (0oC) of DCM (300 mL),
the diol 63 (12.2 g, 37.3 mmol), lev. acid (13.0 g, 112mmol), and DMAP (991 mg, 7.4 mmol).
The reaction was stirred at RT overnight, as the reaction started to turn form white precipitate
(DCU), and the reaction turned a reddish-brown color. After TLC (silica, Hex-EtOAc, 3:1, Rf =
0.58) showed the reaction to be complete the DCM was partially removed under reduced pressure.
The reaction was diluted with Et2O (200 mL) and Hex (100 mL) to cause the DCU to crash out of
the solution. The slurry was filtered through a pad of Celite and concentrated under reduced
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pressure.

The residue was purified through column chromatography (silica, Hex-EtOAc,

2:1→1:1) to give the 2,3-lev-glucoside 63i in 90% (17.5 g). Went directly to the next step.

Hemiacetal-2,3-O-levulinoyl-4,6-O-isopropylidene-α,β-D-glucopyranoside 64. The 2,3O-lev glucoside 63i was dissolved in the mixture of Ac/H2O (9:1, 108 mL: 12 mL) was cooled to
-10 oC. Then, NBS (15.1 mmol, 89.2 mmol) was slowly added over five mins to the mixture and
stirred at -10 oC for 5-10 mins. After TLC (silica, Hex-EtOAc, Rf = 0.51, 0.42) showed the reaction
to be complete, sat. aq. Na2S2O3 (40 mL, orange to clear) followed by sat. aq. NaHCO3 (120 mL,
bubbling) were added to the reaction. The mixture was partially removed under reduced pressure
and the organic layer extracted with DCM . 2 (150 mL). The combined organic layers were
collected, dried over NaSO4, filtered, and removed under reduced pressure. The residue was
purified with column chromatography (silica, Hex-EtOAc, 4:1→EtOAc) to the give the α,βhemiacetal 64 in 80%.

Trichloroacetimidate-2,3-O-levulinoyl-4,6-O-isopropylidene-α,β -D-glucopyranoside 61.
The Schmidt donor 61 was prepare from the hemiacetal glucoside 60 through the same method as
60i → 61.

3.5. Glycosylation, Acylation, C-4/C-6 Glucosyl De-protection
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(4S)1-nonenyl2,3-di-O-levulinoyl-4,6-O-isopropylidene-β-D-glucopyranosyl-(1→2)-3-O
tertbutyldimethylsilyl-β-D- fucopyranoside 7. in Dis DCM (50 mL), the Fucp acceptor 9 (6.10 g,
15.1 mmol), Glcp donor 61 (9.83 g, 16.7 mmol), and 4 Å molecular sieves (9.8 g) were cooled to
–10 oC while stirring. Then, TMSOTf (310 µL, 1.51 mmol) was added to the mixture. The reaction
was slowly added to warm over 1hr, when TLC (silica, Hex:EtOAc 2:1, Rf = 0.41) showed the
fucosyl acceptor to be consumed. The reaction mixture was quenched with NEt3 (0.5 mL) and
filtrated through a pad of Celite (DCM 25 mL). The filtrate was removed under reduced pressure
to give a syrup that was purified by column chromatography (silica, Hex-EtOAc, 4:1 → 1:1) to
give the (1→2)-β-disaccharide 7 (8.61 g, 71%) as a colorless syrup. [α]D25 –27.3° (c 1 CHCl3).
1

H NMR (400 MHz, CDCl3) δH 6.01 – 5.86 (m, 1H, CH2=CH‒CH2‒), 5.13 (d, J = 8.0 Hz, 1H, H-

1-Glp), 5.10 – 5.00 (m, 3H, CH2=CH‒CH2‒, H-3-Glup), 4.88 (dd, J = 9.2, 7.6 Hz, 1H, H-2-Glup),
4.29 (d, J = 7.6 Hz, 1H, H-1-Fucp), 3.95 (dd, J = 10.8, 5.2 Hz, 1H, H-6-Glup), 3.83 – 3.62 (m, 5H,
H-4-Glup, H-6-Glup, H-2-Fucp, H-3-Fucp, H-4-Fucp), 3.54 – 3.47 (m, 2H, H-5-Fucp, ‒CH2‒CH‒
CH2‒), 3.30–3.24 (m, 1H, H-5-Glup), 2.85–2.50 (m, 9H, OH-4-Fucp, 2 ∙ CH3‒C(O)CH2CH2C=O),
2.34 – 2.24 (m, 2H), 2.17 (2s, 6H, 2 ∙ CH3C(O)CH2CH2C=O), 1.57 – 1.48 (m, 2H), 1.46 (s, 3H,
(CH3)2C), 1.40 – 1.20 (m, 12H, (CH3)2C, H-6-Fucp), 0.92 (s, 9H), 0.89 (t, J = 6.8 Hz, 3H, ‒CH3),
0.17 (s, 3H, CH3‒Si), 0.12 (s, 3H, CH3‒Si).

13

C NMR (100 MHz, CDCl3) δC 206.37, 206.26,

171.96, 171.23, 135.24, 116.47, 101.05, 99.65, 99.49, 79.07, 75.86, 75.45, 73.78, 72.63, 72.52,
71.32, 69.59, 67.35, 62.10, 38.27, 37.72, 37.63, 34.28, 31.82, 29.79, 29.77, 28.87, 27.88, 27.80,
25.93(3), 24.54, 22.58, 18.84, 18.03, 16.34, 14.07, –4.25, – 4.62.

(4S)-1-nonen-4S-yl-2,3-di-O-levulinoyl-4,6-O-isopropylidene-β-D-glucopyranosyl(1→2)-4-O-acetyl-3-O-tert-butyldimethylsilyl-β-D-fucopyranoside 65.

Acetic anhydride was

added to a cold solution (-10 oC) of compound 7 (4.10 g, 5.15 mmol) and DMAP (314 mg, 2.1
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mmol) in Py (35 mL). The reaction mixture was heated to 40oC and stirred overnight, when TLC
(silica, Hex–EtOAc 2:1, Rf = 0.51) indicated that the reaction was complete. The reaction mixture
was concentrated under reduced pressure, then co-evaporated with toluene (40 mL ∙ 2). The
residue was purified by column chromatography (silica, Hex–EtOAc, 4:1 → 1:1) to afford C-4Fucp acetylated intermediate 65 in 72% (3.10 g) as a colorless syrup. [α]25D –19.8° (c 1 CHCl3).
1

H NMR (400 MHz, CDCl3) δC 6.04 – 5.94 (m, 1H, CH2=CH‒CH2‒), 5.14 – 5.04 (m, 4H,

CH2=CH‒CH2‒, H-1-Glup, H-3-Glup), 5.00 (m, 1H, H-4-Fucp), 4.90 (dd, J = 9.2, 7.6 Hz, 1H, H2-Glcp), 4.29 (d, J = 7.6 Hz, 1H, H-1-Fucp), 3.98 (dd, J = 10.8, 5.2 Hz, 1H, H-6-Glup), 3.88 (dd,
J = 9.6, 8.0 Hz, 1H, H-2-Fucp), 3.83 – 3.74 (m, 2H, H-6-Glcp, H-3-Fucp), 3.68 (t, J = 9.6 Hz, 1H,
H-4-Glcp), 3.64 – 3.57 (m, 2H, H-5-Fucp, ‒CH2‒CH‒CH2‒), 3.33 – 3.25 (m, 1H, H-5-Glcp), 2.86
– 2.53 (m, 8H, 2 ∙ CH3C(O)CH2CH2C=O), 2.35 – 2.27 (m, 2H), 2.17 (2s, 6H, 2 ∙
CH3C(O)CH2CH2C=O), 2.16 (s, 3H, CH3‒C=O), 1.59 – 1.48 (m, 2H), 1.47 (s, 3H, (CH3)2C), 1.41
– 1.21 (m, 9H, (CH3)2C), 1.12 (d, J = 6.4 Hz, 3H, H-6-Fucp), 0.95 – 0.84 (m, 12H), 0.14 (s, 3H,
CH3‒Si), 0.10 (s, 3H, CH3‒Si).

13

C NMR (100 MHz, CDCl3) δC 206.39, 206.18, 171.92, 171.35,

170.75, 135.37, 116.35, 101.44, 99.67, 99.38, 80.35, 75.22, 73.42 ∙ 3, 72.39, 71.51, 68.81, 67.36,
62.16, 38.33, 37.71 ∙ 2, 34.19, 31.79, 29.77, 29.76, 28.86, 27.85 ∙ 2, 25.81 ∙ 3, 24.54, 22.58, 20.88,
18.82, 17.74, 16.46, 14.02, –4.46 ∙ 2.

(4S)-1-nonen-4S-yl-2,3-di-O-levulinoyl-β-D-glucopyranosyl-(1→2)-4-O-acetyl-3-O-tertbutyldimethylsilyl-β-D-fucopyranoside 6. CSA (140 mg, 0.63 mmol) was added in one portion to
a solution of 65 (2.67 g, 3.16 mmol) in MeOH (50 mL) at room temperature. The reaction mixture
was stirred for 3 hrs. at which point TLC (silica, Hex−EtOAc 1:1, Rf = 0.25) showed the starting
material was gone. Water (0.5 mL) was added to the reaction mixture and stirred for another 20
min. The reaction was quenched with NEt3 (few drops) and concentrated. The residue was purified

151

by column chromatography (silica, Hex‒EtOAc, 2:1 to 1:1) gave diol 6 (2.31 g, 91%) as a colorless
syrup. [α]25D −13.6° (c 1, CHCl3). 1H NMR (400 MHz, CDCl3) δH 6.01−5.86 (m, 1H, CH2=CH‒
CH2‒), 5.12− 4.95 (m, 5H, CH2=CH‒CH2‒, H-1-Glcp, H-3-Glcp, H-4-Fucp), 4.89 (dd, J = 9.6,
7.6 Hz, 1H, H-2-Glcp), 4.26 (d, J = 7.6 Hz, 1H, H-1-Fucp), 3.96−3.83 (m, 2H, H-6-Glcp, H-2Fucp), 3.82−3.68 (m, 3H, H-4-Glcp, H-6-Glcp, H-3-Fucp), 3.64−3.55 (m, 2H, H-5-Fucp,
−CH2−CH−CH2−), 3.52 (d, J = 3.6 Hz, 1H, ‒OH), 3.44−3.35 (m, 1H, H-5-Glcp), 2.88−2.48 (m,
9H), 2.34−2.24 (m, 2H), 2.17 (s, 3H, CH3C(O)CH2CH2C=O), 2.15 (s, 3H, CH3C
(O)CH2CH2C=O), 2.13 (s, 3H, CH3‒C=O), 1.60−1.42 (m, 2H), 1.37−1.20 (m, 6H), 1.11 (d, J =
6.4 Hz, 3H, H-6-Fucp), 0.89−0.81 (m, 12H), 0.12 (s, 3H, CH3‒Si), 0.09 (s, 3H, CH3‒Si).

13

C NMR

(100 MHz, CDCl3) δC 208.2, 206.1, 173.0, 171.4, 170.8, 135.1, 116.7, 101.3, 98.7, 80.6, 76.2,
74.9, 74.8, 73.5, 73.3, 72.1, 69.6, 68.8, 61.9, 38.3 ∙ 2, 37.6, 34.3, 31.7, 29.7 ∙ 2, 28.0, 27.9, 25.7 ∙
3, 24.7, 22.5, 20.9, 17.7, 16.5, 14.0, −4.4, −4.6. HRMS (ESI) m/z calcd for C39H66NaO15Si [M +
Na]+ 825.4063, found 825.4061.

3.6. Synthesis of 4-acetyl-8-nonenoic acid
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Monoethyl 8-nonenoate 73. DCC (1.75 g, 8.47 mmol) was added in one portion to a 0ºC
CH2Cl2 (20 mL) solution of 4-oxo-8-nonenoic acid 14 (1.20 g, 7.06 mmol), EtOH (2.1 mL, 35.3
mmol) and 4-dimethylaminopyridine (86 mg, 0.071 mmol). The reaction was allowed to warm to
ambient temperature and stirred overnight. At this point, TLC (silica, Hex–EtOAc, 2:1) showed
the reaction was complete. The reaction mixture was diluted with Et2O (20 mL) and Hex (10 mL),
stirred for 20 mins. then filtered through a pad of Celite using ether (10 mL) as the eluent and the
filtrate concentrated in vacuo. The residue was purified by column chromatography (silica, Hex–
EtOAc, 10:1→6:1) gave 73 (1.15 g, 79%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δH 5.83
– 5.70 (m, 1H, CH2=CH-CH2-), 5.08 – 4.94 (m, 2H, CH2=CH-CH2-), 4.13 (dd, J = 14.4, 7.2 Hz,
2H), 2.72 (t, J = 6.4 Hz, 2H), 2.58 (t, J = 6.4 Hz, 2H), 2.47 (t, J = 7.4 Hz, 2H), 2.10 – 2.02 (m,
2H), 1.75 – 1.65 (m, 2H), 1.26 (t, J = 7.0 Hz, 3H, –CH3).

C NMR (100 MHz, CDCl3) δC 208.9,

13

172.8, 137.9, 115.2, 60.6, 41.9, 37.1, 33. 0, 28.0, 22.7, 14.1. HRMS (ESI) m/z calcd for
C11H18NaO3 [M + Na]+ 221.1148, found 221.1151.

Monoethyl 4-acetal-8-nonenoate 74. Ethyl 4-oxo-8-nonenoic ester 73 (914 mg, 4.61
mmol), ethylene glycol (2.32 mL, 41.5 mmol) and PPTS (174 mg, 0.69 mmol) were dissolved in
toluene (20 mL).

The reaction mixture was heated to reflux under Dean-Stark conditions

overnight. The mixture was cooled to RT and extracted with sat. aq. NaHCO3 (50 mL). The
organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was
purified by column chromatography (silica, Hex–EtOAc, 5:1 → 4:1) gave the acetal 74 (966 mg,
87%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δH 5.85 – 5.70 (m, 1H, CH2=CH‒CH2‒),
5.04 – 4.90 (m, 2H, CH2=CH‒CH2‒), 4.11 (dd, J = 14.0, 7.2 Hz, 2H), 3.91 (s, 4H), 2.37 – 2.31 (m,
2H), 2.07 – 2.00 (m, 2H), 2.00 – 1.94 (m, 2H), 1.62 – 1.55 (m, 2H), 1.50 – 1.40 (m, 2H), 1.24 (t,
J = 7.0 Hz, 3H, ‒CH3).

13

C NMR (100 MHz, CDCl3) δC 173.5, 138.4, 114.7, 110.7, 65.0 ∙ 2, 60.2,
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36.7, 33.7, 32.0, 28.9, 23.0, 14.2. HRMS (ESI) m/z calcd. for C13H22NaO4 [M + Na]+ 265.1410,
found 265.1414.

4-acetal-8-nonenoic acid 5. To a solution of ethyl ester 74 (738 mg, 3.05 mmol) in MeOH
(10 mL) was added NaOH (2 M solution in H2O, 6.1 mL, 12.2 mmol) at 0 ºC. The mixture was
allowed to slowly warm to RT and was stirred overnight. TLC analysis (silica, Hex–EtOAc, 1:1)
showed it was complete. The mixture was concentrated under reduced pressure and the residue
was dissolved in sat. aq. NaHCO3 (20 mL) and extracted with EtOAc (40 mL . 2). Next, the
aqueous layer was acidified with 10% w/v aq. Weak HCl (pH = 4) and extracted again twice with
EtOAc. The latter organic layers were dried over Na2SO4 and concentrated under reduced pressure.
The residue was purified by column chromatography (silica, Hex–EtOAc–AcOH, 2:1:0.05 →
1:1:0.05) gave compound 5 (550 mg, 82%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δH 11.59
(br, 1H, COOH), 5.84 – 5.72 (m, 1H, CH2=CH-CH2‒), 5.05 – 4.91 (m, 2H, CH2=CH-CH2‒), 3.95
(s, 4H), 2.41 (t, J = 7.6 Hz, 2H), 2.10 – 1.96 (m, 4H), 1.64 – 1.55 (m, 2H), 1.52 – 1.40 (m, 2H).
C NMR (100 MHz, CDCl3) δC 179.8, 138.4, 114.8, 110.7, 65.1 ∙ 2, 36.8, 33.7, 31.8, 28.6, 23.0.

13

HRMS (ESI) m/z calcd for C11H18NaO4 [M + Na]+ 237.1097, found 237.1101.

3.7. Macrocycle Formation and Cinnamoyl Coupling
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Diene 4. Method 1. The (1→2)-β-disaccharide 6 (1.70 g, 2.11 mmol), 4-acetal-8-nonenoic
acid 5 (0.50 g, 2.32 mmol), and DMAP (25 mg, 0.21 mmol) were dissolved in DCM (30 mL) and
cooled to 0oC. Then, DCC (478 mg, 2.11 mmol) was added in one portion and the reaction was
allowed to slowly warm to RT, overnight. TLC (silica, Hex‒EtOAc 1:1, Rf = 0.59) showed the
reaction was complete. The solvent was partially under reduced pressure, then diluted with Et2O
(40 mL) and Hex (20 mL), stirred for 15 min then filtered through a pad of Celite using ether (20
mL) as the eluent and the filtrate under reduced pressure. The residue was purified by column
chromatography (silica, Hex−EtOAc, 5:1 → 1:1) gave diene 4 in 52% (1.64 g) as a colorless syrup.
Method 2. The diol 6 (1.19 g, 1.48 mmol) was dissolved in the DCM, then added 1-methyl-2chloropyrdium iodide (CMPI) (750 mg, 2.97 mmol), DMAP (90 mg, 0.7mmol), and the CA 5 (90
mg, 0.74 mmol). After the reaction was cooled to 0oC, then NEt3 (2.1 mL, 14.8 mmol) was added
and the reaction was allowed to slowly warm to RT over 1-2 hrs. At this point TLC showed the
reaction to be complete (silica, Hex‒EtOAc 1:1, Rf = 0.62). The reaction was concentrated under
reduced pressure and purified by column chromatography (silica, Hex−EtOAc, 5:1 → 1:1) to give
the diene 4 in 62%. [α]D25 −18.0° (c 1, CHCl3). 1H NMR (400 MHz, CDCl3) δH 6.09−5.95 (m,
1H, CH2=CH‒CH2‒), 5.85−5.71 (m, 1H, CH2=CH‒CH2‒), 5.12−4.84 (m, 8H, 2 ∙ CH2=CH‒CH2‒
, H-1-Glcp, H-2-Glcp, H-3-Glcp, H-4-Fucp), 4.46 (dd, J = 12.0, 3.8 Hz, 1H, H-6-Glcp), 4.32−4.23
(m, 2H, H-6-Glcp, H-1-Fucp), 4.01−3.85 (m, 5H, H-2-Fucp, −OCH2CH2O−), 3.79 (dd, J = 9.6,
3.8 Hz, 1H, H-3-Fucp), 3.71−3.55 (m, 3H, H-4-Glcp, H-5-Fucp, −CH2−CH−CH2−), 3.52−3.42
(m, 2H, H-5-Glcp, ‒OH), 2.86−2.49 (m, 8H), 2.45−2.35 (m, 2H), 2.32−2.27 (m, 2H), 2.17 (2s, 6H,
2 ∙ CH3C (O)CH2CH2C=O), 2.13 (s, 3H, CH3‒C=O), 2.09−1.98 (m, 4H), 1.62−1.41 (m, 6H),
1.38−1.20 (m, 6H), 1.12 (d, J = 6.5 Hz, 3H, H-6-Fucp), 0.91−0.83 (m, 12H), 0.13 (s, 3H, CH3‒
Si), 0.10 (s, 3H, CH3‒Si).

C NMR (100 MHz, CDCl3) δC 207.4, 206.1, 174.1, 172.9, 171.3,

13
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170.7, 138.4, 135.6, 116.4, 114.8, 110.8, 101.5, 98.9, 80.7, 75.4, 75.0, 73.9, 73.6, 73.5, 72.4, 68.8,
68.7, 65.1, 65.0, 62.9, 38.5, 38.1, 37.7, 36.9, 34.2, 33.7, 32.1, 31.8, 29.8 ∙ 2, 28.7, 28.0, 27.8, 25.8
∙ 3, 24.6, 23.0, 22.6, 20.9, 17.7, 16.5, 14.0, −4.4, −4.5. HRMS (ESI) m/z calcd. for C50H82NaO18Si
[M + Na]+ 1021.5163, found 1021.5150.

RCM Product 4i. To a solution of diene 4 (2.41 g, 2.41 mmol) in DCM (800 mL) was
added Hoveyda-Grubbs catalyst 2nd generation (151 mg, 0.24 mmol) in one portion at room
temperature. The reaction mixture was refluxed (40 oC) overnight. At this point, TLC (silica,
Hex–EtOAc 1:1, Rf =0.49) showed the reaction was complete. The reaction was cooled to ambient
temperature and then concentrated. Flash chromatography (silica, Hex–EtOAc, 2:1 → 1:1) gave
RCM products 4i (1.91 g, 82%) as a colorless syrup which was not fully characterized. The
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obtained isomers were subjected to hydrogenation in next step and the product was fully
characterized.

Hydrogenation Product 87. The cis/trans RCM products 4i (1.91 g, 1.97 mmol) were
dissolved in EtOH (40 mL) was added 10% Pd/C (100 mg) in one portion at room temperature.
The reaction was then stirred under an atmosphere of hydrogen overnight at the same temperature.
At this point, TLC (silica, 1:1 Hex–EtOAc) showed the reaction was complete. The reaction
mixture was filtered through a pad of Celite using EtOAc (10 mL) as the eluent and the resulting
filtrate concentrated. Flash chromatography (silica, Hex:EtOAc, 2:1 → 1:1) gave 87 (1.55 g, 81
%) as a white foam. [α]D25 –26.7° (c 1 CHCl3). 1H NMR (300 MHz, CDCl3) δH 5.11 (d, J = 7.8
Hz, 1H, H-1-Glup), 5.05 (t, J = 9.6 Hz, 1H, H-3-Glup), 5.01 – 4.96 (m, 1H, H-4-Fucp), 4.91 (dd,
J = 12.6, 2.4 Hz, 1H, H-6-Glup), 4.84 (dd, J = 9.6, 8.1 Hz, 1H, H-2-Glup), 4.20 (d, J = 7.8Hz, 1H,
H-1-Fucp), 4.13 – 3.83 (m, 8H, H-4-Glup, H-6-Glup, H-2-Fucp, H-3-Fucp, ‒OCH2CH2O‒), 3.68
– 3.31 (m, 4H, H-5-Glup, H-5-Fucp, OH, ‒CH2-CH-CH2‒), 2.84 – 2.71 (m, 4H), 2.68 – 2.35 (m,
6H), 2.32 – 2.20 (m, 1H), 2.16 (s, 6H, CH3‒C=O), 2.10 (s, 3H, CH3‒C=O), 2.09 – 1.87 (m, 1H),
1.71 – 1.20 (m, 20H), 1.11 (d, J = 6.3 Hz, 3H, H-6-Fucp), 0.95 – 0.81 (m, 12H), 0.17 (s, 3H, CH3‒
Si), 0.13 (s, 3H, CH3‒Si).

13

C NMR (75 MHz, CDCl3) δC 206.9, 206.3, 175.5, 172.3, 171.3, 170.8,

111.0, 102.0, 98.9, 82.4, 75.0, 74.8, 74.6, 73.6, 73.5, 72.1, 68.7, 67.3, 64.6, 64.5, 62.3, 37.9, 37.7,
35.9, 34.5, 33.9, 31.9, 31.5, 29.8, 29.7, 29.0, 28.5, 27.9, 25.8 ∙ 3, 25.0, 23.3, 22.6, 20.9, 17.6, 16.6,
14.0, –4.1, –4.6. HRMS (ESI) m/z calcd for C48H80NaO18Si [M + Na]+ 995.5006, found 995.5012.

Compound 3. Method 1. The macrocycle 87 (106 mg, 0.11 mmol) was dissolved in DCM
(5-7 mL), cinnamic acid (40 mg, 0.17 mmol) and DMAP (3.2 mg, 0.01 mmol). The mixture was
cooled to 0oC and DCC (40 mg, 0.17 mmol) in one portion. The reaction was allowed to slowly
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warm to RT overnight. TLC showed the reaction to be complete and the DCM was partially
removed under reduced pressure. The mixture was diluted with Et2O (4 mL) and Hex (2 mL) and
stirred for 20 min. Then, filtered through a pad to Celite to remove the DCU and washed with
Et2O. The solvent was removed under reduced pressure and purified by column chromatography
(silica, Hex−EtOAc, 3:1 → 1:2) to give the 87 in 71%. Method 2. CMPI (138 mg, 0.541 mmol),
DMAP (22.0 mg, 0.180 mmol) and NEt3 (0.50 mL, 3.6 mmol) were added to a solution of 87 (351
mg, 0.361 mmol) and cinn acid (80.0 mg, 0.539 mmol) in dry DCM (3 mL) at -10 oC. The reaction
was allowed to slowly warm to ambient temperature and stirred overnight. At this point, TLC
(silica, 2:1 Hex–EtOAc) showed the reaction was complete. The reaction mixture was diluted
with DCM (15 mL) washed with sat. NaHCO3 (10 mL) and extracted with DCM (15 mL). The
combined organic extracts were dried over Na2SO4. Evaporation of the solvent followed by
purification of the residue by column chromatography (silica, Hexanes−EtOAc, 3:1 → 1:2) to give
3 (345 mg, 88%) as a colorless syrup. [α]D25 –16.9° (c 1 CHCl3). 1H NMR (300 MHz, CDCl3) δH
7.64 (d, J = 15.9 Hz, 1H, Ph-CH=C-), 7.56 – 7.47 (m, 2H, 2 × Ar‒H), 7.43 – 7.35 (m, 3H, 3 × Ar‒
H), 6.35 (d, J = 15.9 Hz, 1H, Ph‒CH=CH-), 5.32 – 5.18 (m, 3H, H-3-Glcp, H-4-Glcp, H-1-Glcp),
5.04 – 4.92 (m, 2H, H-4-Fucp, H-2-Glcp), 4.35 (dd, J = 12.3, 3.0 Hz, 1H, H-6-Glcp), 4.27 (d, J =
7.5 Hz, 1H, H-1-Fucp), 4.12 (dd, J = 12.1, 2.4 Hz, 1H, H-6-Glcp), 4.04 – 3.83 (m, 6H, H-2-Fucp,
H-3-Fucp, ‒OCH2CH2O‒), 3.76 – 3.53 (m, 3H, H-5-Glup, H-5-Fucp, ‒CH2‒CH‒CH2‒), 2.83 –
2.75 (m, 2H), 2.70 – 2.31 (m, 8H), 2.17 (s, 3H, CH3C=OCH2CH2C=OO), 2.11 (s, 3H, CH3-C=OO),
2.08 (s, 3H, CH3‒COCH2CH2C=OO), 2.05 – 1.84 (m, 2H), 1.73 – 1.21 (m, 20H), 1.13 (d, J = 6.3
Hz, 3H, H-6-Fucp), 0.95 – 0.83 (m, 12H), 0.19 (s, 3H, CH3‒Si), 0.14 (s, 3H, CH3‒Si).

13

C NMR

(75 MHz, CDCl3) δC 206.2, 206.1, 173.0, 171.9, 171.2, 170.8, 165.0, 146.1, 134.1, 130.5, 128.8 ∙
2, 128.3 ∙ 2, 116.7, 111.3, 103.5, 101.4, 98.9, 81.9, 74.5, 74.1, 73.6, 73.0, 72.2, 71.9, 68.3, 68.5,
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64.5, 61.7, 37.8, 37.7, 34.6, 34.3, 33.7, 32.0, 31.2, 30.0, 29.8, 29.6, 29.0, 28.3, 27.9, 27.8, 25.9 ∙ 3,
24.6, 24.0, 22.9, 22.6, 20.9, 17.8, 16.6, 14.1, –4.3, –4.5. HRMS (ESI) m/z calcd for C57H86NaO19Si
[M + Na]+ 1125.5425, found 1125.5414.

3.8. De-protection of the C-2 and C-3 Glucosyl Lev Groups and the C-4 Cyclic Acetal

Compound 2. Hydrazine acetate (0.350 g, 3.70 mmol) was added in one portion to a
solution of intermediate 3 (0.680 mg, 0.620 mmol) in 2:1 DCM/MeOH (6 mL) at room
temperature. The reaction mixture was stirred for 0.5 hr, at which point TLC (silica, 2:1 Hex–
EtOAc, Rf = 0.51) showed the reaction was complete. Then the reaction was quenched with sat.
aq. NaHCO3 (10 mL) and extracted with DCM (15 mL ∙ 2). The combined organic extracts were
dried over Na2SO4, evaporated and purified by column chromatography (silica, Hex–EtOAc, 3:1→
1:1) to afford compound 2 (520 mg, 90%) as a colorless syrup. [α] 25D 0.8° (c1 CHCl3). 1H NMR
(400 MHz, CDCl3) δH 7.73 (d, J = 16.0 Hz, 1H, Ph‒CH=C‒), 7.56 – 7.50 (m, 2H, 2 . Ar‒H), 7.42
– 7.37 (m, 3H, 3 . Ar‒H), 6.46 (d, J = 16.0 Hz, 1H, Ph‒CH=CH‒), 5.15 – 5.06 (m, 2H, H-4-Glup,
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H-4-Fucp), 4.65 (d, J = 7.6 Hz, 1H, H-1-Glcp), 4.41 (d, J = 7.6 Hz, 1H, H-1-Fucp), 4.26 (dd, J =
12.0, 4.0 Hz, 1H, H-6-Glcp), 4.18 (dd, J = 12.0, 4.0 Hz, 1H, H-6-Glcp), 3.98 – 3.60 (m, 11H, H3-Glup, H-5-Glcp, H-2-Fucp, H-3-Fucp, H-5-Fucp, OH, ‒OCH2CH2O‒, -CH2‒CH‒CH2‒), 3.50 –
3.41 (m, 1H, H-2-Glup), 2.64 (d, J = 2.4 Hz, 1H, ‒OH), 2.40 – 2.25 (m, 2H), 2.13 (s, 3H, CH3‒
C=O), 2.05 – 1.86 (m, 2H), 1.61 – 1.48 (m, 6H), 1.41 – 1.20 (m, 14H), 1.15 (d, J = 6.4 Hz, 3H, H6-Fucp), 0.95 – 0.86 (m, 12H), 0.22 (s, 3H, CH3‒Si), 0.18 (s, 3H, CH3‒Si).

13

C NMR (100 MHz,

CDCl3) δC 173.1, 170.7, 166.2, 146.2, 134.1, 130.5, 128.9 ∙ 2, 128.2 ∙ 2, 117.1, 111.2, 103.5, 101.1,
79.8, 78.5, 76.0, 73.6, 73.0, 72.7, 72.5, 71.3, 68.7, 64.6, 64.5, 63.5, 35.1, 33.9, 33.3, 32.0, 31.3,
29.7, 28.9, 28.4, 25.9 ∙ 3, 24.3, 24.0, 22.6 ∙ 2, 20.8, 17.9, 16.5, 14.1, –4.3, –4.6. HRMS (ESI) m/z
calcd for C47H74NaO15Si [M + Na]+ 929.4689, found 929.4692.

Compound 71. CSA (58.9 mg, 0.254 mmol) was added in one portion to a solution of 2
(1.15 g, 1.27 mmol) in MeOH (30 mL) and H2O (0.3 mL) at room temperature. The reaction
mixture was stirred for 12 h at which point TLC (silica, 1:1 Hex−EtOAc, Rf = 0.51) showed it was
complete. The reaction was quenched with NEt3 (70 μL, few drops) and concentrated. The residue
was purified by column chromatography (silica, Hex−EtOAc, 1:3 → 1:2) gave compound 4 (72%)
as a colorless syrup. [α]25D −13.4° (c CHCl3). 1H NMR (400 MHz, CDCl3) δH 7.77 (d, J = 16.0
Hz, 1H, Ph‒CH =C‒), 7.58−7.51 (m, 2H, 2 .Ar‒H), 7.43−7.37 (m, 3H, 3 .Ar‒H), 6.51 (d, J = 16.0
Hz, 1H, Ph‒CH=CH), 5.16−5.08 (m, 2H, H-4- Glcp, H-4-Fucp), 4.59 (d, J = 7.6 Hz, 1H, H-1Glcp), 4.40 (d, J = 7.6 Hz, 1H, H-1-Fucp), 4.34 (dd, J = 12.0, 2.4 Hz, 1H, H-6-Glcp), 4.19 (dd, J
= 12.0, 5.2 Hz, 1H, H-6-Glcp), 4.02 (d, J = 1.6 Hz, 1H, ‒OH), 3.96−3.89 (m, 1H, H-2-Fucp), 3.85
(dd, J = 9.6, 3.2 Hz, 1H, H-3- Fucp), 3.83−3.75 (m, 1H, H-3-Glcp), 3.73−3.60 (m, 3H, H-5-Glcp,
H-5-Fucp, −CH2−CH−CH2−), 3.48−3.40 (m, 1H, H-2-Glcp), 2.75− 2.40 (m, 6H), 2.14 (s, 3H,
CH3‒C=O), 1.70−1.61 (m, 2H), 1.59− 1.45 (m, 4H), 1.39−1.20 (m, 12H), 1.15 (d, J = 6.0 Hz, 3H,
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H-6- Fucp), 0.95−0.84 (m, 12H), 0.22 (s, 3H, CH3-Si), 0.19 (s, 3H, CH3-Si).

13

C NMR (100 MHz,

CDCl3) δ 210.3, 171.6, 170.7, 166.2, 146.1, 134.2, 130.6, 129.0 .2, 128.2 .2, 117.2, 104.0, 101.2,
80.3, 79.0, 76.1, 73.5, 73.1, 72.8, 72.2, 71.6, 68.8, 63.3, 42.0, 37.3, 34.1, 33.3, 32.0, 29.5, 29.1,
28.5, 25.9 3, 25.1, 24.4, 23.6, 22.6, 20.9, 17.9, 16.5, 14.1, −4.3, −4.6. HRMS (ESI) m/z calcd for
C45H70NaO14Si [M + Na]+ 885.4427, found 885.4432.

3.9. Ipomoeassin F and C-3-Glucosyl Modified Analogs

3.9.1. DCC/DMAP Esterification and -OTBS De-protection Method

Ipomoeassin F 1. Compound 91. Method 1. DCC (14.3 mg, 69.6 µmol) was added in one
portion to a 0 °C DCM (3-4 mL) solution of 71 (30 mg, 34.8 µmol), tig acid (7.0 mg, 69.6 µmol)
and DMAP (0.5 mg, 3.5 µmol). The reaction was warmed to ambient temperature and stirred
overnight at RT. The TLC (silica, 3:1 Hex−EtOAc, Rf = 0.41) showed the reaction was complete.
The reaction mixture was diluted with Et2O (2 mL) and Hex (1 mL), stirred for 20 min then filtered
through a pad of Celite using Et2O (5 mL) as the eluent and the filtrate concentrated in vacuo. The
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residue was purified by column chromatography (silica, Hex−EtOAc, 6:1 → 3:1) in 81% (26 mg)
as a colorless syrup. [α]25D −38.7° (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δH 7.67 (d, J =
16.0 Hz, 1H, Ph‒CH=C‒), 7.55−7.48 (m, 2H, 2 Ar‒H), 7.43−7.36 (m, 3H, 3 .Ar‒H), 6.87−6.78
(m, 1H, Me−CH−C (Me) ‒C=O), 6.38 (d, J = 16.0 Hz, 1H, Ph‒CH=CH‒), 5.33 (t, J = 9.6 Hz, 1H,
H-3-Glcp), 5.23 (t, J = 9.6 Hz, 1H, H-4-Glcp), 5.10−5.08 (m, 1H, H-4-Fucp), 4.70 (d, 1H, J = 8.0
Hz, H-1-Glcp), 4.38 (d, 1H, J = 7.6 Hz, H-1-Fucp), 4.31−4.18 (m, 2H, H-6-Glcp), 3.94 (dd, J =
7.6, 10 Hz, 1H, H-2-Fucp), 3.89− 3.80 (m, 2H, ‒OH, H-3-Fucp), 3.78−3.72 (m, 1H, H-5-Glcp),
3.71− 3.55 (m, 3H, H-2-Glcp, H-5-Fucp, −CH2−CH−CH2−), 2.70−2.42 (m, 6H), 2.11 (s, 3H, CH3‒
C=O), 1.79−1.63 (m, 8H), 1.60−1.43 (m, 4H), 1.40−1.20 (m, 12H), 1.14 (d, J = 6.4 Hz, 3H, H-6Fucp), 0.94−0.83 (m, 12H), 0.22 (s, 3H, CH3‒Si), 0.18 (s, 3H, CH3‒Si).
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C NMR (100 MHz,

CDCl3) δC 210.1, 171.4, 170.8, 167.5, 165.6, 146.0, 138.1, 134.0, 130.6, 128.9 .2, 128.2 .2, 127.9,
116.8, 104.2, 101.2, 80.2, 79.0, 74.5, 72.9, 72.8, 72.0, 69.9, 68.8, 63.3, 42.0, 37.4, 34.1, 33.2, 32.0,
29.6, 29.0, 28.6, 25.8 .3, 25.1, 24.4, 23.7, 22.6, 20.9, 17.9, 16.5, 14.4, 14.1, 12.0, −4.4, −4.6.
HRMS (ESI) m/z calcd for C50H76NaO15Si [M + Na]+ 967.4846, found 967.4834. Method 2.
CMPI 71 (16.3 mg, 67.1 µmol), DMAP ( 0.5 mg, 0.007 mmol) and NEt3 (48 μL, 0.330 mmol)
were added to a solution of 71 (29.0 mg, 33.6 µmol) and tig acid (6.5 mg, 67.1 µmol) in dry DCM
(4 mL) at 0 °C. The reaction was allowed to warm to ambient temperature and stirred for 4 h. At
this point, TLC (silica, Hex−EtOAc, 2:1 Rf =0.21) showed the reaction was complete. Evaporation
of the solvent followed by purification of the residue by column chromatography (silica,
Hex−EtOAc, 5:1 → 3:1) to give 91 (25.4 mg, 79%) as a colorless syrup. The 1H and 13C NMR
data of 91 obtained via method 2 were identical to those of 91 obtained via method 1.

Ipomoeassin F 1. To a solution of 91 (20 mg, 22.6 µmol) in THF (2 mL) was added AcOH
(67 μL, 2.23 mmol) and TBAF (1 M solution in THF, 0.58 mL, 1.06 mmol) at 0 °C. The reaction
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was allowed to warm to ambient temperature and stirred overnight. At this point, TLC (silica,
Hex−EtOAc, 1:1, Rf = 0.15) showed the reaction was complete. The reaction mixture was
concentrated under reduced pressure. The residue was purified by column chromatography (silica,
Hex−EtOAc, 2:1 → 1:1) gave synthetic ipomoeassin F 1 (12.1 mg, 70%) as a colorless film. [α]D
25

−51.2° (c CHCl3).

1

H NMR (400 MHz, CDCl3) δH 7.63 (d, J = 16.0 Hz, 1H, Ph−CH=C−),

7.55−7.45 (m, 2H, 2

.Ar−H),

7.45−7.35 (m, 3H, 3

.

Ar−H), 6.93−6.87 (m, 1H,

CH3−CH−CCH3−C=O), 6.35 (d, J = 16.0 Hz, 1H, Ph−CH=CH−), 5.33 (t, J = 9.6 Hz, 1H, H-4Glcp), 5.18−5.11 (m, 2H, H-3-Glcp, H-4-Fucp), 4.62 (d, J = 7.6 Hz, 1H, H-1-Glcp), 4.56 (d, J =
1.6 Hz, 1H, −OH), 4.47 (dd, J = 12.4, 3.6 Hz, 1H, H-6-Glcp), 4.41 (d, J = 8.0 Hz, 1H, H-1-Fucp),
4.15 (dd, J = 12.4, 2.4 Hz, 1H, H-6-Glcp), 3.96−3.88 (m, 2H, −OH, H-3-Fucp), 3.78−3.73 (m, 1H,
H-5-Glcp), 3.73−3.59 (m, 4H, H-2-Glcp, H-2-Fucp, H-5-Fucp, −CH2−CH−CH2−), 2.85−2.38 (m,
6H), 2.18 (s, 3H, CH3−C=O), 1.80−1.72 (m, 6H, CH3−CH−C (CH3)−C=O), 1.72−1.62 (m, 2H),
1.58− 1.46 (m, 4H), 1.41−1.22 (m, 12H), 1.19 (t, J = 6.5 Hz, 3H, H-6-Fucp), 0.90 (t, J = 6.8 Hz,
3H, −CH3).

C NMR (100 MHz, CDCl3) δC 210.0, 171.8, 171.7, 168.9, 165.4, 146.2, 139.9,

13

134.0, 130.6, 128.9 . 2, 128.3 . 2, 127.5, 116.7, 105.7, 100.2, 82.9, 79.8, 75.8, 74.0, 72.7, 72.6, 72.6,
68.8, 67.4, 61.8, 41.9, 37.6, 34.4, 33.1, 31.9, 29.1, 29.0, 28.4, 24.7, 24.5, 23.5, 22.7, 20.9, 16.3,
14.6, 14.1, 12.0. The 1H, 13C NMR data were in accordance with the literature. 47-49

Cinnamoyl Analog 93. Compound 92. Method 1. DCC (5.7 mg, 27.8 µmol) was added
in one portion to a 0 °C DCM (3-4 mL) solution of 71 (16 mg, 18.5 µmol), cinn acid (4.1 mg, 27.8
µmol) and DMAP (0.3 mg, 2.8 µmol). The reaction was allowed to warm to ambient temperature
and stirred overnight at RT. The TLC (silica, 3:1 Hex−EtOAc, Rf = 0.51) showed the reaction
was complete. The reaction mixture was diluted with diethyl ether (2 mL) and hexanes (1 mL),
stirred for 20 min then filtered through a pad of Celite using diethyl ether (5 mL) as the eluent and
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the filtrate concentrated in vacuo. The residue was purified by column chromatography (silica,
Hex−EtOAc, 6:1 → 3:1) in 86% 92 (15.3 mg) as a colorless syrup. Method 2. CMPI (13.0 mg,
0.051 mmol), DMAP, 9.3 mg, 0.076 mmol) and NEt3 (36 μL, 0.25 mmol) were added to a solution
of 71 (22.0 mg, 0.025 mmol) and cinnamic acid (7.6 mg, 0.051 mmol) in dry CH2Cl2 (2 mL) at 0
°C. The reaction was allowed to warm to ambient temperature and stirred for 1 hr. At this point,
TLC (silica, 2:1 Hex−EtOAc) showed the reaction was complete. Evaporation of the solvent
followed by purification of the residue by column chromatography (silica, Hex−EtOAc, 5:1 →
3:1) to give 92 (20.4 mg, 81%) as a colorless syrup. Then to a solution of 92 (11.6 mg, 11.7 µmol)
in THF (2 mL) was added AcOH (67 μL, 11.7 µmol) and TBAF (1 M solution in THF, 0.58 mL,
58.o mmol) at 0 °C. The reaction was allowed to warm to ambient temperature and stirred
overnight. At this point, TLC (silica, Hex:EtOAc, 1:1 Rf = 0.15) showed the reaction was
complete. The reaction mixture was concentrated under reduced pressure. The residue was
purified by column chromatography (silica, Hex−EtOAc, 2:1 → 1:2) gave the cinnamoyl analog
(8.0 mg, 78%) as a white powder. [α]D 25 −127° (c 0.2, CHCl3). 1H NMR (400 MHz, CDCl3) δH
7.68 (d, J = 16.0 Hz, 1H, Ph−CH=C−), 7.64 (d, J = 16.0 Hz, 1H, Ph−CH=C−), 7.53− 7.43 (m, 4H,
4 .Ar‒H), 7.39−7.31 (m, 6H, 6 .Ar‒H), 6.41 (d, J = 16.0 Hz, 1H, Ph−CH=CH), 6.35 (d, J = 16.0
Hz, 1H, Ph−CH=CH−), 5.33 (t, J = 9.5 Hz, 1H, H-4-Glcp), 5.28 (t, J = 9.4 Hz, 1H, H3-Glcp), 5.14
(d, J = 3.2 Hz, 1H, H-4-Fucp), 4.65 (d, J = 8.1 Hz, 1H, H-1-Glcp), 4.55−4.41 (m, 3H, H-6-Glcp,
H-1-Fucp, −OH), 4.18 (dd, J = 12.4, 2.0 Hz, 1H, H-6-Glcp), 3.95 (dd, J = 9.6, 3.6 Hz, 1H, H-3Fucp), 3.83−3.62 (m, 6H, H-2-Glcp, H-5-Glcp, H-2-Fucp, H-5-Fucp, −CH2−CH−CH2−, −OH),
2.85−2.40 (m, 6H), 2.19 (s, 3H, CH3−C=O), 1.72−1.22 (m, 18H), 1.20 (d, J = 6.5 Hz, 3H, H-6Fucp), 0.90 (t, J = 6.7 Hz, 3H, −CH3).

C NMR (100 MHz, CDCl3) δC 210.0, 172.0, 171.7, 167.3,

13

165.5, 146.6, 146.3, 134.1, 134.0, 130.6, 130.6, 128.9 .2, 128.8 .2, 128.3 2, 128.3 2, 116.7, 116.6,
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105.6, 100.3, 82.4, 79.7, 75.5, 73.8, 72.8, 72.7, 72.5, 68.8, 67.8, 61.9, 41.9, 37.6, 34.3, 33.0, 31.9,
29.1, 29.0, 28.3, 24.6, 24.5, 23.4, 22.7, 20.9, 16.3, 14.1. HRMS (ESI) m/z calcd for C48H62NaO15
[M + Na]+ 901.3981, found 901.3978.

3.9.2. Modified Synthesis Route of Mukaiyama Esterification and One-Pot De-Protection

Crotonic Analog 96. CMPI 75 (18.6 mg, 0.0721 mmol), DMAP (2.2 mg, 0.018 mmol) and
NEt3 (0.05 mL, 0.320 mmol) were added to a solution of 2 (29.8 mg, 0.320 mmol) and crotonic
acid (6.2 mg, 0.072 mmol) in dry DCM (2 mL) at -10 oC. The reaction was allowed to slowly
warm to ambient temperature and stirred overnight. The TLC showed the reaction was 60%
complete. So, the reaction was left to stir for 24 hrs, when the TLC (silica, 2:1 Hexanes–EtOAc)
showed the reaction was complete. The reaction mixture was diluted with DCM (5 mL) in a
centrifuge tube, washed with sat. NaHCO3 (10 mL) and extracted with DCM (5 mL . 2). The
combined organic extracts were dried over Na2SO4. Evaporation of the solvent followed by
purification of the residue by column chromatography (silica, Hexanes−EtOAc, 3:1 → 1:1) to give
103 in 74% (24 mg, 74%) as a foamy syrup. 103 was not fully characterized and all the protecting
group removed in the following transformations. CSA (2.50 mg, 0.0108 mmol) was added to a
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solution of MeOH (2 mL) and the 103 (20.9 mg, 0.0215 mmol). The reaction was heated to 30 oC
and stirred for 12 hrs to remove the C-4 cyclic acetal. Then, acetic acid (61 μL, 1.08 mmol) and
TBAF (1 M in THF, 0.538 μL) were added to the reaction and stirred at 30 oC for 12 hrs. The
TLC (1:1Hex−EtOAc, Rf = 0.15) showed the reaction was complete. The reaction mixture was
diluted with DCM (3 mL) in a centrifuge tube, washed with water (3 mL), and extracted with DCM
(4 mL). The combined organic extracts were dried over Na2SO4 and concentrated. Column
chromatography (silica, Hex−EtOAc, 2:1 → 1:1, DCM−MeOH, 100:1 → 20:1) was utilized to
purify the crotonic analog 96 (16 mg, 85%) as a clear syrup. 1H NMR (400 MHz, CDCl3) δH 7.64
(d, J = 16.0 Hz, 1H, Ph−CH=C−), 7.52−7.50 (m, 2H, 2 .Ar‒H), 7.40−7.39 (m, 3H, 3 Ar‒H),
6.93−6.87 (m, 1H, Me−CH−CH−C=O), 6.35 (d, J = 16.0 Hz, 1H, Ph−CH=CH−), 5.82 (d, J = 17.2
Hz, 1H, Me−CH−CH−C=O), 5.27 (t, J = 19.6 Hz, 1H, H-4-Glcp), 5.19 (t, J = 9.2 Hz, 1H, H-3Glcp), 5.15 (d, J = 4.5 Hz, H-4-Fucp), 4.61 (d, J = 7.6 Hz, 1H, H-1-Glcp), 4.63-4.41 (m, −OH, H1-Fucp), 4.13 (dd, J = 12.4, 3.6 Hz, 1H, H-6-Glcp), 3.93 (dd, J = 12.4, 2.4 Hz, 1H, H-6-Glcp),
3.76 (m, 6H, −OH, H-3-Fucp, H-5-Glcp, H-2-Fuc,−CH2−CH−CH2), 2.82-2.41 (m, 5 H) 2.85−2.38
(m, 6H), 2.18 (s, 3H, CH3−C=O), 1.83 (d, J = 6.8 Hz 3H, CH3−CH−CH−C=O), 1.72−1.62 (m,
2H), 1.58− 1.46 (m, 4H), 1.41−1.22 (m, 12H), 1.19 (t, J = 6.5 Hz, 3H, H-6-Fucp), 0.90 (t, J = 6.8
Hz, 3H, −CH3).

13

C NMR (100 MHz, CDCl3) δC 210.0, 171.8, 171.7, 168.9, 165.4, 146.2, 139.9,

134.0, 130.6, 128.9 . 2, 128.3 . 2, 127.5, 116.6, 105.5, 100.1, 82.9, 79.8, 75.8, 74.0, 72.7, 72.6, 72.6,
68.8, 67.4, 61.8, 41.9, 37.6, 34.4, 33.1, 31.9, 29.1, 29.0, 28.4, 24.7, 24.5, 23.5, 22.7, 20.9, 16.3,
14.1. Unfortunately, the crotonic analog 87 was not good enough to publish by this method.

Methylacrylic Analog 97. The diol 2 (37 mg, 40.8 µmol) was dissolved in DCM (2-3 mL), then
CMPI 74 (26.0 mg, 102.0 µmol), methylacrylic acid (16 µL, 102 µmol), and DMAP (2.5 mg, 21
µmol). NEt3 was added to the reaction mixture in one portion at 0oC and reaction was slowly
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allowed to warm to RT overnight. TLC (Hex−EtOAc, 1:1 Rf = 0.15) showed the reaction to
complete to be complete. The reaction mixture was diluted with DCM (3 mL) and washed with
water and extracted with DCM (5 mL). The combined organic layers were dried over Na2SO4 and
concentrated. The residue purified though column chromatography (Hex−EtOAc, 2:1 → 1:1,
DCM−MeOH, 100:1 → 20:1) to give 104 in 44% (19 mg). 1H NMR (300 MHz, CDCl3) δH 7.65
(d, J = 16.0 Hz, 1H), 7.52-7.49 (m, 2H), 7.39- 7.37 (m, 3H), 6.36 (d, J = 16.2 Hz, 1H), 6.07 (s,
1H), 5.52 (s, 1H), 5.34 (t, J = 9.6, 1H), 5.39 (t, J = 9.6, 1H), 5.08 (d, J = 3.0 Hz, 1H), 4.76 (d, J =
7.8 Hz, 1H), 4.41 (d, J = 7.5 Hz, 1H), 4.21 (m, 2H), 3.96 (t, J = 9.9 Hz, 1H), 3.85 (m, 6H), 3.82 (t,
J = 3.6 Hz, 1H), 3.69 (t, J =5.4 Hz, 1H), 3.62 (m, 2H), 2.34 (m, 2H), 2.12 (s, 3H), 1.87 (s, 3H),
1.56 (m, 8H), 1.34 (m, 18H), 1.14 (d, J = 6.3 Hz), 0.91-0.87 (m, 12H), 0.21 (s, 3H), 0.17 (s, 3H).
C NMR (100 MHz, CDCl3) δC 173.2, 170.8, 166.8, 165.6, 146.2, 135.6, 134.0, 130.5, 128.9 .2,

13

128.3 . 2, 126.2, 116.7, 111.3, 103.0, 101.01, 79.5, 78.7, 77.2, 74.3, 73.3, 72.9, 72.7, 72.4, 69.4,
68.8, 64.6, 64.5, 63.4, 36.6, 35.1, 33.9, 33.2, 31.9, 29.7, 29.0, 28.5, 25.8 . 3, 24.6, 24.3, 24.0, 22.7,
22.6, 20.9, 18.2, 17.8, 16.5, 14.1, -4.4, -4.6. 104 was not fully characterized before going to next
step. CSA (2.50 mg, 0.0108 mmol) was added to a solution of MeOH (2 mL) and the 104 (20.9
mg, 0.0215 mmol). The reaction was heated to 30oC and stirred for 12 hrs. to remove the C-4
cyclic acetal. Then, acetic acid (61 μL, 1.08 mmol) and TBAF (1 M in THF, 0.538 μL) were added
to the reaction and stirred at 30oC for 12 hrs. The TLC (1:1 Hex−EtOAc, Rf = 0.15) showed the
reaction was complete. The reaction mixture was diluted with DCM (3 mL) in a centrifuge tube,
washed with water (3 mL), and extracted with DCM (4 mL). The combined organic extracts were
dried over Na2SO4 and concentrated. Column chromatography (silica, Hexanes−EtOAc, 2:1 →
1:1, DCM−MeOH, 100:1 → 20:1) was utilized to purify the 97 methylacrylic analog (16 mg, 85%)
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as a clear syrup. A complex mixture of signals was observed in the H-NMR and C-NMR of the
methylacrylic analog 97.

Acrylic Analog 98. The diol 2 (30 mg, 33.1 µmol) was dissolved in DCM (2-3 mL), then
CMPI 75 (21.0 mg, 82.8 µmol), acrylic acid (6 µL, 82.8 µmol), and DMAP (2.0 mg, 16.6 µmol).
NEt3 (0.46 mL, 33.1 µmol) was added to the reaction mixture in one portion at 0oC and reaction
was slowly allowed to warm to RT overnight. TLC (Hex−EtOAc, 1:1 Rf = 0.15) showed the
reaction to complete to be complete. The reaction mixture was diluted with DCM (3 mL) and
washed with water and extracted with DCM (5 mL). The combined organic layers were dried over
Na2SO4 and concentrated. The residue purified though column chromatography (Hex−EtOAc, 2:1
→ 1:1, DCM−MeOH, 100:1 → 20:1) to give 105 in 44% (14 mg). The 105 was not characterized
and proceeded directly to the next step. CSA (2.2 mg, 0.0108 mmol) was added to a solution of
MeOH (2 mL) and 105 (15 mg, 14.6 mol). The reaction was heated to 35 oC and stirred for 12
hrs. to remove the C-4 cyclic acetal. Then, acetic acid (44 μL, 730 µmol) mol) and TBAF (1 M in
THF, 0.384 μL) were added to the reaction and stirred at 30oC for 12 hrs. The TLC (1:1
Hex−EtOAc, Rf = 0.15) showed the reaction was complete. The reaction mixture was diluted with
DCM (3 mL) in a centrifuge tube, washed with water (3 mL), and extracted with DCM (4 mL).
The combined organic extracts were dried over Na2SO4 and concentrated.

Column

chromatography (silica, Hexanes−EtOAc, 2:1 → 1:1, DCM−MeOH, 100:1 → 20:1) was utilized
to purify the 98 acrylic analog as white crystals. An insufficient amount of 98 was obtained and
making spectroscopy data unattainable.
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3.10. Left-tether Aglycone Modifications

1-(3-buten-1-yl) ester butanedioic acid 109. Method 1: 1-buten-4-ol 107 (0.92 mL, 10.9
mmol) was added dropwise to a solution of succinic anhydride 17 (1.00 g, 9.99 mmol), and
benzene: pyridine (3:1 4 mL). The reaction mixture was heated to reflux (120 oC) and stirred
overnight. At this point, TLC (Hex-EtOAc 3:2, Rf = 0.65) showed the reaction was complete. The
reaction was cooled to RT, then diluted with Et2O (50 mL), washed with 5% HCl solution (25
mL), and a BRINE solution. The organic layer was dried over Na2SO4 and concentrated under
reduced pressure. The residue was purified by column chromatography (Hex:EtOAc 5:1→2:1) to
give the acid 109 (1.4 g 81%) as a colorless oil. Method 2. 1-buten-4-ol 107 (0.424 mL, 4.99
mmol) was added dropwise to a solution of succinic anhydride 17 (0.495 g, 4.99 mmol), DMAP
(61 mg, 0.500 mmol), and toluene (7 mL). The reaction mixture was heated to reflux (120 oC) and
stirred overnight. TLC (Hex:EtOAc 3:2, Rf = 0.65) showed the reaction was complete. The
reaction was cooled to RT and concentrated under reduced pressure. The residue was purified by
column chromatography (Hex:EtOAc 5:1→2:1) to give 108 (0.845 g 85%) as a colorless oil. 1H
NMR (CDCI3, 400 MHz) δH 10.1 (br s, 1 H COOH), 5.83-5.71 (m, 1H, CH=), 5.15-5.06 (m, 2H,
=CH2), 4.16 (t, J= 9, 2H, OCH2), 2.72-2.60 (m, 2 H), 2.42-2.36 (m, 2H), 2.41 (t, J= 20 Hz, 2H),
2.07-1.97 (m, 4H).

13

C NMR (100 MHz, CDCl3) δC 178.5 (O=C‒O), 172.3, 134.0, 117.5, 64.1,
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33.2, 29.1, 29.0. The 1H and 13C NMR of both methods were the same, matching published spectra
data.23

1-(2-propen-1-yl) ester butanedioic acid 108. The acid 108 was synthesized in 81% from
succinic anhydride 17 (1.00 g, 9.99 mmol) and allyl alcohol (0.66 mL, 15.00 mmol) from Method
2 of the synthesis of 108

1

H NMR (300 MHz, CDCl3) δH 11.66 (br, 1H), 6.00−5.81 (m, 1H),

5.39−5.15 (m, 2H), 4.65−4.50 (m, 2H), 2.78−2.59 (m, 4H).

13

C NMR (75 MHz, CDCl3) δC 178.6,

172.0, 132.0, 118.5, 65.6, 29.0, 28.9.26-28

4-oxo-4-(2-propen-1-ylamino)-butanoic acid 107i. The allyl amine (0.91 mL, 13.01 mmol)
was added to a solution of Dis. THF (8 mL) and succinic anhydride 17 (1.01 g, 10.1 mmol) at 0
o

C. The reaction was left to stir at RT overnight (white crystals). The solvent was removed under

reduced pressure. The crude acid was recrystallized in Et2O to give the acid 107i in 82% (1.31 g).
1

H NMR (400 MHz, DMSO-d6) 10.34 (br s, 1H, O=C-OH), 6.33-5.98 (br s, 1H, NH), 5.79 (m,

1H, CH2=CH), 5.20-5.15 (m, 2H,CH2=CH), 3.90 (M, 2H, HNCH2), 2.72 (t, J = 6.8 Hz, 2H,
CH2C=O), 2.54 (t, J = 6.7 Hz); 13C NMR (100 MHz, DMSO-d6) 174.4 (COOH), 171.5 (CONH),
135.0 (HC=CH2), 115.4 (HC=CH2), 41.6 (O=CNHCH2), 30.6 (H2C-COOH), 29.7 (H2C-CONH).
Spectral data matched those previously reported.29, 30
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4-oxo-7-octenoic acid 113. The acid 113 was prepared from the succinic anhydride 17
(856 mg, 85.5 mmol) and 115 4-maganism-bromide-1-butene (0.75 mL, 80.1 mmol) by the same
method as 4-oxo-8-nonenoic acid 14 in 12% (164 mg). 1H NMR (300 MHz, CDCl3) δH 10.51 (br
s, 1H, COOH), 5.80 (ddt, J = 16.8, 12.9, 6.5 Hz Hz, 1H, HC=CH2), 5.10-4.90 (m, 2H, HC=CH2),
2.76-2.67 (m, 2H, CH2), 2.40-2.28 (m, 2H, CH2).

13

C NMR (75 MHz, CDCl3) δC 207.9, 179.8,

136.8, 115.3, 41.7, 36.9, 27.7, 27.5. The 1H NMR and

13

C NMR were identical to literature

published data.31, 32

4-oxo-9-undecenoic acid 114. The longer left-tether acid 114 was obtain through same procedure
as 4-oxo-8-nonenoic acid 14 from succinic anhydride 17 (684 mg, 6.83 mmol) and 7-maganismbromide-1-heptene 116 (0.94 mL, 61.8 mmol) in 21%.

C NMR (75 MHz, CDCl3) δC 209.2,

13

178.9,139.0,114.6, 42.8,36.9, 33.7, 28.8, 28.8, 28.6, 24.5.

3.11. Potential Modifications to the C-3-Glcp Moiety of Ipomoeassin F

Ethyl (2E)-hept-2-en-6-ynoate 118. Oxalyl chloride (1.21 mL, 14.2 mmol) was added to
THF (10 mL) and cool to -78 oC over 30 mins. Then a solution of DMSO (1.08 mL, 15.6 mmol)
in THF (10 mL) was added dropwise over 15 mins and allowed to stir at -78 oC for 30 mins. The
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4-pentynol 115 (1.11 mL, 12.0 mmol) in THF (7 mL) was dropwise over 15 mins and stirred at 78 oC for 45 mins. To the THF solution, NEt3 (5.0 mL, 36.0 mmol) was added dropwise over 15
mins and stirred for 1 hr. at -78 oC for 1 hr. As each the reagents were added, white precipitate
started to form. After stirring at -78 oC for 1hr, the reaction mixture slowly warmed to RT over 34 hrs. The reaction mixture was filtered through Celite and washed with 15-20 mL of THF. The
filtrate was carefully removed under reduced pressure and stored under nitrogen at -5 oC for 30
mins. While the Swern Ox. was warming to RT, a solution of NaH (358 mg, 15.0 mmol) and THF
(10 mL) was cooled to -5 oC over 15 mins. Then, triethyl phosphonoacetate (3.01 mL, 15.6 mmol)
was added dropwise over 15 mins. The mixture turned into a homogenous solution over the next
45 mins while being stirred at 0 oC. Then, solution was warmed slowly to RT overnight. TLC
(Hex−EtOAc 3:1 Rf = 0.75) showed the reaction was complete and the solvent was concentrated
to give a yellow oil. Saturated ammonium chloride was added to the oil and extracted with diethyl
ether (25 mL .4). The ether layer was dried with NaSO4, filtered, and the removed under reduced
pressure. The yellow oil was purified by flash column chromatography (Hex−EtOAc, 12:1 to 8:1)
to give the (2E)-ethyl ester 118 in 65% (1.30 g). 1H NMR (300 MHz, CDCl3) δH 6.95 (dt, J =
15.6, 6.3 Hz, 1H), 5.87 (dt, J = 15.6, 1.5, 1H), 4.17 (q, J = 6.9 Hz, 2H), 2.42 (m, 2H), 2.35 (m,
2H), 1.99 (t, J = 2.4 Hz, 1H), 1.27 (t, J = 7.2 Hz, 3H).

13

C NMR (75 MHz, CDCl3) δC 166.5, 146.5,

122.7, 82.8, 69.6, 60.5, 31.15, 17.15, 14.4. The 1H NMR and 13C NMR were identical to literature
published data.50, 51
(2E)-hept-2-en-6-ynoic acid 111. A mixture of the THF: MeOH: water (4:1:1) was added
to the ethyl ester 118 (101 mg, 0.66 mmol) at RT followed by 0.5 LiOH (3.9 mL, 1.91 mmol).
The reaction was stirred at RT overnight. The THF and MeOH was removed under reduced
pressure, then acidified by 10% KHSO4 (pH= 3-4). The acidic aqueous layer was extracted with
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DCM (3 * 20 mL). The organic layer was dried with NaSO4, filtered and removed under reduced
pressure. The crude acid was purified with column chromatography (14:1 to 6:1, Hex: EtOAc) to
give 118 (60 mg, 75%). 1H NMR (300 MHz, CDCl3) δH 10.8 (b, 1H), 7.11 (dt, J =15.6, 6.6 Hz,
1H), 5.91 (dt, J = 15.6, 1.6 Hz, 1H), 2.47 (m, 2H), 2.47 (m, 2H), 2.38 (m, 2H), 2.01 (t, J = 2.4,
1H). 13C NMR (75 MHz, CDCl3) δC 171.9, 149.3, 121.9, 82.4, 69.6, 31.0, 17.2. The spectroscopic
data matched previous published data.52

Ethyl (2E)-octa-2-en-7-ynoate 119. The same Swern Ox/H-W-E reaction procedure was
used to get the ethyl ester 119 as 118 except the starting material was 5-hexynol 115 (1 g) in 55 %
(925 mg) over two steps. 1H NMR (300 MHz, CDCl3) δH 6.95 (dt, J =14. 9, 6.9 Hz, 1H), 5.86 (dt,
1H, J = 15.1, 1.5 Hz, 1H), 4.19 (q, J = 7.2 H, 2H), 2.34 (q, J = 6.9 Hz, 2H), 2.23 (dt, J = 6.9 Hz,
2.7 Hz, 2H), 1.98 (t, J = 2.7 Hz, 1H), 1.70 (m, 1H) 1.29 (t, J = 7.2, 3H).

13

C NMR (75 MHz,

CDCl3) δC 166.5, 147.8, 122.1, 83.5, 69.0, 60.2, 30.9, 26.7, 17.8, 14.2. The 1H NMR and 13C NMR
were identical to literature published data.50, 53

(2E)-octa-2-en-7-yonic acid 112. The same hydrolysis conditions were used to obtain the acid 112
as in 60%. 1H NMR (300 MHz, CDCl3) δH 11.28 (b, 1H), 7.07 (dt, J = 15.1 Hz, 6.9 Hz,1H), 5.87
(d, 1H), 2.37 (m, 2H), 2.41 (dt, J = 8.2 Hz, 2.4 Hz, 2H), 1.99 (t, J = 2.7 Hz, 1H), 1.71 (m, 2H).
C NMR (75 MHz, CDCl3) δC 172.1, 150.8, 121.3, 83.2, 69.1, 30.9, 26.4, 17.2. The NMR data

13

was consistent with published literature data.54

2-(Prop-2-yn-1-yloxy)ethanol 116. A mixture of ethylene glycol (3.49 mL, 62.5 mmol),
H2O (2.5 mL), and KOH (1.40 g, 25.1 mmol) was cooled to 0 OC. Then propargyl bromide (1.39
mL, 125 mmol) was added dropwise and slowly warmed to RT overnight. H2O was added to
reaction mixture to cause hydrolysis, stirred for 10 mins, and extracted with DCM (30 mL . 3).
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The combined organic layers were dried with NaSO4 and removed under reduced pressure. The
crude ether was purified with column chromatography to (silica, Hex: EtOAc 3:1 to 1:1, Rf = 0.35)
to give 116 in 42 % (2.58 g). 1H NMR (300 MHz, CDCl3) δH 4.15 (d, J = 2.4 Hz, 2H), 3.72-3.69
(m, 2H), 3.61-3.58 (m, 2H), 2.73 (m, 2H), 2.44 (t, J = 2.4,1H).

13

C NMR (75 MHz, CDCl3) δC

79.4, 74.61, 71.10, 61.35, 58.20. The spectroscopic data matched those previous published.55, 56
Ethyl (2E)-4-(2′-propynloxy)but-2-enoate 120. The same procedure was followed as 118
ethyl (2E)-hept-2-en-6-ynoate. The monoethyl ester 120 was obtained in 51% after column
chromatography (silica, Hex: EtOAc 35:1 to 28:1). 1H NMR (300 MHz, CDCl3) δH 6.93 (dt, J =
15.9, 4.6 Hz, 1H), 6.08 (dt, J = 15.9, 1.8 Hz, 1H), 4.24-4.18 (m, 6H), 2.46 (t, J = 2.4 Hz, 1H,), 1.28
(t, J = 7.2, 3H).

13

C NMR (75 MHz, CDCl3) δC 166.0, 143.1, 121.7, 79.0, 74.9, 68.0, 60.3, 57.8,

14.1. The NMR data was consistent with published literature data.50
(2E)-4-(2′-propynloxy)but-2-enoic acid 113. The same procedure was followed as the previous
acids 111-112 in 52%.

Propargyl maleic acid 123. Maleic anhydride 121 (1.0 g, 10 mmol) was added to propargyl
alcohol (10 mL) heated to 60 oC and stirred overnight. The reaction was cooled to RT and
propargyl alcohol was removed under reduced pressure and purified by column chromatography
to give 123 in 81% (1.25 g) (silica, Hex:EtOAc 8:1 to 3:1). 1H NMR (300 MHz, CDCl3) δ 9.4 (b,
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1H, 1H), 6.41 (d, J = 6.15 Hz, 1H), 6.36 (d, J = 6.15 Hz, 1H), 4.83 (d, J = 2.4 Hz, 1H), 2.56 (t, J
= 2.4 Hz, 2H).

13

C NMR (75 MHz, CDCl3) δC 167.8, 165.2, 131.6, 130.2, 76.3, 75.9, 53.23.

Propargyl fumaric acid 124. THF (10 mL), propargyl maleic acid 123 (0.95 g, 6.16 mmol),
and AlCl3 (200 mg) were in dry THF (20 mL) and heated to reflux (70 oC). The reaction mixture
was stirred at reflux overnight. Sat. NaHCO3 (25 mL) quenched the reaction, then the THF
removed under reduced pressure after cooling to RT. The aqueous layer was extracted with DCM
(2 . 30 mL), then acidified with conc. HCl (pH= 2-3). The acidic aqueous layer was extracted with
DCM (3 . 35 mL). The combined organic layers were dried with NaSO4, filtered and removed
under reduced pressure. The acid was purified with column chromatography (silica, Hex:EtOAc
8:1 to 3:1) to give the fumarate 77% (751 mg). 1H NMR (300 MHz, CDCl3) δH 10.0 (b, 1H), 6.99
(d, J = 15.9 Hz, 1H), 6.91 (d, J = 15.9, 1H), 4.83 (d, J = 2.4 Hz, 2H), 2.54 (t, J = 2.4 Hz, 1H). 13C
NMR (75 MHz, CDCl3) δC 169.7, 164.0, 134.6, 134.0, 76.8, 75.8, 53.12.

Monomethyl Fumarate 121. Maleic Anhydride (2 g, 20.3 mmol), EtOH (1.32 mL, 22.4
mmol), and AlCl3 (200 mg) were dissolved in 10 mL of dis tetrahydrofuran. The reaction mixture
was heated to reflux (75 oC) and stirred overnight. The mixture was cooled to RT and the THF
removed under reduced pressure. NaHCO3 (30 mL) was added the oil and extracted with DCM (2
.

40 mL). Next, the aqueous layer was acidified with concentrated HCl until pH 2-3 and extracted
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again with DCM (3 . 40 mL). The latter organic layers were combined, dried over Na2SO4, and
concentrated under reduced pressure to give white crystals 125 (79%, 2.35 g). 1 H NMR (400
MHz, CDCl3) δC 10.15 (b, 1H), 6.95 (d, J = 15.8 Hz, 1H), 6.85 (d, J = 15.8 Hz, 1H), 4.29 (q, J =
7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δC 170.1, 164.86, 115.2, 136.1,
132.7, 61.82, 14.30. The NMR data was consistent with published literature data.57, 58
(2E)-2-Butenoic acid, 4-[(1,1-dimethyl-tert-butyl-silyl)oxy]-, ethyl ester 127. BF3 . Me2S
in 1 M THF (7.34 mL, 32.0 mmol) was added dropwise at 0 oC to a solution of monoethyl furmate
125 (2.31 g, 16.0 mmol) in THF (25 mL). The solution was allowed gradually warm to room
temperature overnight. TLC showed the reaction was complete (4:1, Rf = 0.21). AcOH/H2O (1:1,
v:v, 2.5 mL) was added to the reaction mixture to quench the reaction. The THF was removed
under reduced pressure to give a residual slurry. Ice-cold saturated NaHCO3 was added to slurry
(20 mL) and stirred for 10 mins. Then the aqueous layer was extracted with EtOAc (3 . 30 mL).
The resulting organic layers were combined then washed with saturated NaHCO3 solution, dried
with NaSO4. Then, the organic layer was filtered and concentrated under reduced pressure to give
(E)-ethyl-4-hydroxy-2-butenoate 126. After drying, the oil was re-dissolved in Dis. DCM and
treated with DMAP (250 mg, 0.70 mmol) and TBSCl (4.86 g, 32.0 mmol). The mixture was
cooled to 0oC and Et3N (6.05 mL, mmol) was added while the reaction was slowed warmed to RT.
TLC (6:1 Hex: EtOAc, Rf = 0.81) showed the reaction was complete. The reaction mixture was
washed with H2O (25 mL) and BRINE (25 mL). The organic layer was dried with NaSO4 and
concentrated under reduced pressure. Column chromatography (silica gel, Hex:EtOAc 15:1) was
used to give the oil 127 (1.55 g 39% over two steps). 1H NMR (300 MHz, CDCl3) δH 7.00 (dt, J
=15.3, 3.2 Hz, 1H), 6.10 (dt, J =15.3, 2.0 Hz, 1H), 4.35 (dd, J = 3.2, 2.0 Hz, 2H), 4.20 (q, J = 7.4
Hz, 2H), 1.32 (t, J =7.4 Hz, 3H), 0.92 (s, 9H), 0.06 (s, 6H).
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13

C NMR (75 MHz, CDCl3) δC 166.8,

147.5, 119.8, 62.30, 132.7, 61.82, 14.30. The 1H NMR and 13C NMR were identical to literature
published data.59, 60

(2E)- 4-[[(1,1-dimethyl-tert-butyl)dimethylsilyl]oxy]-2-Butenoic acid 128. The ethyl ester
128 (115 mg, 4.1 mmol) was dissolved in MeOH (9 mL) and 0.5 M NaOH (aq.) (0.5 mL). The
reaction mixture was stirred at RT for 3 hrs and TLC (4:1 Hex:EtOAc Rf = 0.4) showed the reaction
was complete. Then, the MeOH was evaporated under reduced pressure. The residue was cooled
to 0oC, then acidified with 10% KHSO4 (aq). The aqueous layer was extracted with diethyl ether
(3X 25 mL). The organic layers were combined, dried with NaSO4, and concentrated under
reduced pressure to give 128 in 52%. 1H NMR (300 MHz, CDCl3) δH 7.14 (dt, J = 15.3, 3.2 Hz,
1H), 6.14 (dt, J =15.3, 2.0 Hz, 1H), 4.39 (m, 2H), 0.93 (s, 9H), 0.1 (s, 6H). 13C NMR (75 MHz,
CDCl3) δC 171.9, 150.3, 119.0, 62.2, 26.0, 18.4, -5.4. The NMR data was consistent with published
literature data.59, 61

3.12. Biology and Cytotoxicity Assays

3.12.1. Cell Culture

Two breast cancer cell lines MCF7 and MDA-MB-231 were maintained in a
DMEM/HIGH culture medium supplemented with 10% bovine calf serum (BCS) and 2 mM Lglutamine, so-called complete medium. Cell cultures were grown in monolayers in a humidified
atmosphere of 5% CO2 and 95% air at 37 °C. The culture medium was changed every 48−72 hrs.
Cell cultures were passaged once or twice a week using trypsin-EDTA (0.25%) to detach the cells
from their culture flasks/dishes.
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3.12.2. MTT Cytotoxicity Assay
The viable cells were counted before each experiment was done. The assays were
performed in triplicate. First, 100 μL of cell suspension at the density of 25,000 cells/mL was
seeded in a 96-well plate (2,500 cells/well), which was incubated at 37 °C in 5% CO2 for 24 hrs.
Ipomoeassin F, analog 86, and 87 were dissolved in DMSO (dimethyl sulfoxide) to make drug
stocks (10 mM). The stock solutions were diluted with the complete DMEM/HIGH medium to
make a series of gradient fresh working solutions right before each test. Then, the cells were
treated with 100 μL of the freshly made gradient working solution in the total volume of 200
μL/well for 72 hrs. After that, the media were discarded and 200 μL of the fresh complete medium
containing 10% of MTT stock solution (5 mg/mL) was added to each well. The plate was then
incubated at 37 °C in 5% CO2 atmosphere for another 3 hrs. Next, 180 μL of the medium was
discarded from each well. The formed formazan crystals were dissolved with 180 μL of DMSO.
Absorbance of formazan was detected by a microplate reader (BioTek Synergy H1) at 570 nm
with 650 nm as the reference wavelength. The percentage of viability compared to the negative
control (DMSO-treated cells) was determined. Activities of the synthesized ipomoeassin F, analog
86, and 87 were tested against breast cancer cell line MCF7 by the MTT cytotoxicity assay.
GraphPad Prism 6 software was used to make a plot of % viability versus sample concentration
and to calculate the concentration at which a compound exhibited 50% cytotoxicity (IC50).
3.12.3. AlamarBlue Cytotoxicity Assay
The viable cells were counted before each experiment was done. The assays were
performed in triplicates. First, 100 μL of cell suspension at the density of 25,000 cells/mL was
seeded in a 96-well plate (2,500 cells/well), which was incubated at 37 °C in 5% CO2 for 24 hrs.
Ipomoeassin F, analogs 86 and 87 were dissolved in DMSO (dimethyl sulfoxide) to make drug
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stocks (10 mM). The stock solutions were diluted with the complete DMEM/ HIGH medium to
make a series of gradient fresh working solutions right before each test. Subsequently, the cells
were treated with 100 μL of the freshly made gradient working solution in the total volume of 200
μL/well for 72 hrs. After that, the media were discarded and 200 μL of the fresh complete medium
containing 10% of AlamarBlue (resazurin) stock solution (3 mg/27.15 mL) was added to each
well. The plate was then incubated at 37 °C in 5% CO2 atmosphere for another 3 hrs. Next, 180
μL of the medium was discarded from each well. The formed formazan crystals were dissolved
with 180 μL of DMSO. Absorbance of formazan was detected by a microplate reader (BioTek
Synergy H1) at excitation 580 nm with emission 620 nm as the reference wavelength. The
percentage of viability compared to the negative control (DMSO-treated cells) was determined.
Activities of synthesized Ipomoeassin F 1, analogs 86, and 87 were tested against breast cancer
cell line MDA-MB-231 by the AlamarBlue cytotoxicity assay. GraphPad Prism 6 software was
used to make a plot of % viability versus sample concentration and to calculate the concentration
at which a compound exhibited 50% cytotoxicity (IC50).

Ipomoeassin F
93
96

Figure 3.1. IC50 curves of Ipomoeassin F and analogs 86-87 against the MDA-MB-231 cell line.
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Ipomoeassin F
93
96

Figure 3.2. IC50 curves of Ipomoeassin F and analogs 86-87 against the MCF-7 cell line.
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